



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>C12N 15/86, A61K 38/00, C07K 16/00, 14/03, A61K 39/00</b></p>	<p><b>A3</b></p>	<p>(11) International Publication Number: <b>WO 99/53047</b></p> <p>(43) International Publication Date: 21 October 1999 (21.10.99)</p>
<p>(21) International Application Number: PCT/US99/08220</p> <p>(22) International Filing Date: 15 April 1999 (15.04.99)</p> <p>(30) Priority Data: 60/081,882 15 April 1998 (15.04.98) US</p> <p>(71) Applicant (for all designated States except US): UNIVERSITY OF SASKATCHEWAN [CA/CA]; 120 Veterinary Road, Saskatoon, Saskatchewan S7N 5E3 (CA).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): REDDY, Police, Seshidhar [CA/US]; Apartment #1, 722 Clopper Road, Gaithersburg, MD 20878 (US). TIKOO, Suresh, Kumar [CA/CA]; 302 102 Edinburgh Place, Saskatoon, Saskatchewan S7H 5J7 (CA). BABIUK, Lorne, A. [CA/CA]; 245 East Place, Saskatoon, Saskatchewan S7J 2Y1 (CA).</p> <p>(74) Agents: BRENNAN, Sean, M. et al.; Morrison &amp; Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> <p>(88) Date of publication of the international search report: 13 January 2000 (13.01.00)</p>
<p>(54) Title: PORCINE ADENOVIRUS TYPE 3 GENOME</p> <p>(57) Abstract</p> <p>The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3) is provided. Methods for construction of infectious PAV genomes by homologous recombination in procaryotic cells are provided. Recombinant PAV viruses are obtained by transfection of mammalian cells with recombinant PAV genomes. The PAV-3 genome can be used as a vector for the expression of heterologous nucleotide sequences, for example, for the preparation and administration of subunit vaccines to swine or other mammals. In addition, PAV-3 vectors can be used for gene therapy and expression of heterologous polypeptides. PAV-3 genome sequences can also be used for diagnostic purposes, to detect the presence of PAV-3 DNA in a subject or biological sample.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/08220

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 A61K38/00 C07K16/00 C07K14/03 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	<p>WO 99 08706 A (HAMMOND JEFFREY MICHAEL ;JOHNSON MICHAEL ANTHONY (AU); COMMW SCIEN) 25 February 1999 (1999-02-25) abstract</p> <p>page 5, line 18 - line 23</p> <p>page 6, line 16 -page 7, line 3</p> <p>page 7, line 23 -page 8, line 18</p> <p>page 15, line 12 - line 16</p> <p>page 26, line 1 -page 23, line 30</p> <p>claims and figures</p> <p style="text-align: center;">— -/-</p>	1-13, 20-118

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

16 November 1999

Date of mailing of the international search report

03/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Panzica, G

## INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/US 99/08220

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	<p>REDDY P.S. ET AL.: "Development of porcine adenovirus-3 as an expression vector"</p> <p>JOURNAL OF GENERAL VIROLOGY, vol. 80, no. 3, March 1999 (1999-03), pages 563-570, XP002120921</p> <p>READING GB</p> <p>the whole document</p>	1-13, 20-118
X,P	<p>REDDY P.S. ET AL.: "Sequence and transcription map analysis of early region-1 of porcine adenovirus type-3"</p> <p>VIRUS RESEARCH, vol. 58, no. 1-2, November 1998 (1998-11), pages 97-106, XP002120922</p> <p>the whole document</p>	1-13, 20-118
X,P	<p>REDDY P.S. ET AL.: "Nucleotide sequence and transcription map of porcine adenovirus type-3"</p> <p>VIROLOGY, vol. 251, no. 2, 25 November 1998 (1998-11-25), pages 414-426, XP002120923</p> <p>ORLANDO US</p> <p>the whole document</p>	1-13, 30-33, 38-41, 43,44, 47-60, 64-78, 111,112
X,P	<p>DATABASE BIOSIS 'Online!</p> <p>BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US</p> <p>biosis no.: 199800510266, 1998</p> <p>PARK JONG-HYEON ET AL.: XP002122737</p> <p>abstract</p>	1-13, 20-118
X,P	<p>&amp; PARK J-H ET AL.: "Sequence analysis of the early region 1 B (EB1B) of porcine adenovirus type 3"</p> <p>RDA JOURNAL OF VETERINARY SCIENCE, vol. 40, no. 1, June 1998 (1998-06), pages 19-25,</p>	1-13, 20-118
X	<p>REDDY P.S. ET AL.: "Characterization of the early region 4 of porcine adenovirus type-3"</p> <p>VIRUS GENES, vol. 15, no. 1, 1997, pages 87-90, XP002120925</p> <p>the whole document</p>	1-13, 30-33, 38-41, 43,44, 47-60, 64-78, 111,112

-/-



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/08220

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>REDDY P.S. ET AL.: "Porcine adenoviruses types 1, 2 and 3 have short and simple early E-3 regions"  VIRUS RESEARCH,  vol. 43, no. 2, 1996, pages 99-109,  XP002120926</p> <p>the whole document</p>	<p>1-13,  30-33,  38-41,  43,44,  47-60,  64-78,  111,112</p>
X	<p>TUBOLY T. ET AL.: "Potential viral vectors for the stimulation of mucosal antibody responses against enteric viral antigens in pigs"  RESEARCH IN VETERINARY SCIENCE,  vol. 54, no. 3, 1993, pages 345-350,  XP002120927</p> <p>the whole document</p>	<p>1-13,  20-118</p>
X	<p>REDDY P.S. ET AL.: "Restriction endonuclease analysis and molecular cloning of porcine adenovirus type-3"  INTERVIROLOGY,  vol. 36, no. 3, 1993, pages 161-168,  XP002120928</p> <p>the whole document</p>	<p>1-13,  20-77,  111-118</p>
X	<p>REDDY P.S. ET AL.: "Sequence analysis of putative pVIII, E3 and fibre regions of porcine adenovirus type 3"  VIRUS RESEARCH,  vol. 36, no. 1, April 1995 (1995-04),  pages 97-106, XP002120929</p> <p>the whole document</p>	<p>1-13,  30-33,  38-41,  43,44,  47-60,  64-78,  111,112</p>
A	<p>KLEIBOEKER S.B. ET AL.: "Genomic cloning and restriction site mapping of a porcine adenovirus isolate: demonstration of genomic stability in porcine adenovirus"  ARCHIVES OF VIROLOGY,  vol. 133, no. 3-4, 1993, pages 357-368,  XP002120930</p>	<p>1-13,  30-33,  38-41,  43,44,  47-60,  64-78,  111,112</p>
X	<p>REDDY P.S. ET AL.: "Comparison of the inverted terminal repetition sequences from five porcine adenovirus serotypes"  VIROLOGY,  vol. 212, no. 1, 1995, pages 237-239,  XP002120931</p> <p>ORLANDO US</p> <p>the whole document</p>	<p>1-13,  30-33,  38-41,  43,44,  47-60,  64-78,  111,112</p>

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 08220

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

**Continuation of Box I.1**

Insofar as claims 50-53 57-59 68-74 may be intended as to be directed to a diagnostic method practised on the human/animal body, then objection arises under Rule 39.1.iv PCT (subject-matter under Art. 17.2.a.1), therefore the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 99-110 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/08220

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9908706 A	25-02-1999	AU 8720998 A	08-03-1999



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/53047</b> <b>(43) International Publication Date:</b> 21 October 1999 (21.10.99)
<b>(21) International Application Number:</b> PCT/US99/08220 <b>(22) International Filing Date:</b> 15 April 1999 (15.04.99) <b>(30) Priority Data:</b> 60/081,882      15 April 1998 (15.04.98)      US <b>(71) Applicant (for all designated States except US):</b> UNIVERSITY OF SASKATCHEWAN [CA/CA]; 120 Veterinary Road, Saskatoon, Saskatchewan S7N 5E3 (CA). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> REDDY, Police, Seshidhar [CA/US]; Apartment #1, 722 Clopper Road, Gaithersburg, MD 20878 (US). TIKOO, Suresh, Kumar [CA/CA]; 302 102 Edinburgh Place, Saskatoon, Saskatchewan S7H 5J7 (CA). BABIUK, Lorne, A. [CA/CA]; 245 East Place, Saskatoon, Saskatchewan S7J 2Y1 (CA). <b>(74) Agents:</b> BRENNAN, Sean, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> PORCINE ADENOVIRUS TYPE 3 GENOME  		
<b>(57) Abstract</b> <p>The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3) is provided. Methods for construction of infectious PAV genomes by homologous recombination in procaryotic cells are provided. Recombinant PAV viruses are obtained by transfection of mammalian cells with recombinant PAV genomes. The PAV-3 genome can be used as a vector for the expression of heterologous nucleotide sequences, for example, for the preparation and administration of subunit vaccines to swine or other mammals. In addition, PAV-3 vectors can be used for gene therapy and expression of heterologous polypeptides. PAV-3 genome sequences can also be used for diagnostic purposes, to detect the presence of PAV-3 DNA in a subject or biological sample.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

## PORCINE ADENOVIRUS TYPE 3 GENOME

### TECHNICAL FIELD

The present invention is in the field of recombinant mammalian viral  
10 vectors. More particularly, it concerns recombinant porcine adenovirus vectors  
for diagnostic and therapeutic purposes, such as vaccines and expression systems.

### BACKGROUND

Adenoviruses are double-stranded DNA viruses that have been isolated  
15 from a wide variety of avian and mammalian species, including swine. While the  
majority of adenovirus infections in swine are subclinical, porcine adenovirus  
(PAV) infection has been associated with encephalitis, pneumonia, kidney lesions  
and diarrhea. Derbyshire (1992) In: "Diseases of Swine" (ed. Leman *et al.*), 7th  
edition, Iowa State University Press, Ames, IA. pp. 225-227. Thus, there is a  
20 need for vaccines that will provide protection against PAV infection.

In addition to their potential ability to provide protection against PAV  
infection, PAVs could also be used as viral vaccine vectors, if insertion capacity  
can be determined, and appropriate insertion sites can be defined and  
characterized. It has been shown that PAV is capable of stimulating both humoral  
25 response and a mucosal antibody responses in the intestine of infected piglets.  
Tuboly *et al.* (1993) *Res. in Vet. Sci.* 54:345-350. Thus, recombinant PAV  
vaccine vectors would be especially useful, as they would be likely to be capable  
of providing both systemic and mucosal immunity to antigens encoded by native  
and/or recombinant PAV genomes.

30 Cross-neutralization studies have indicated the existence of at least five  
serotypes of PAV. Derbyshire *et al.* (1975) *J. Comp. Pathol.* 85:437-443; and

Hirahara *et al.* (1990) *Jpn. J. Vet. Sci.* 52:407-409. Previous studies of the PAV genome have included the determination of restriction maps for PAV Type 3 (PAV-3) and cloning of restriction fragments representing the complete genome of PAV-3. Reddy *et al.* (1993) *Intervirology* 36:161-168. In addition, restriction  
5 maps for PAV-1 and PAV-2 have been determined. Reddy *et al.* (1995b) *Arch. Virol.* 140:195-200.

Nucleotide sequences have been determined for segments of the genome of various PAV serotypes. Sequences of the E3, pVIII and fiber genes of PAV-3 were determined by Reddy *et al.* (1995a) *Virus Res.* 36:97-106. The E3, pVIII  
10 and fiber genes of PAV-1 and PAV-2 were sequenced by Reddy *et al.* (1996) *Virus Res.* 43:99-109; while the PAV-4 E3, pVIII and fiber gene sequences were determined by Kleiboeker (1994) *Virus Res.* 31:17-25. The PAV-4 fiber gene sequence was determined by Kleiboeker (1995b) *Virus Res.* 39:299-309. Inverted terminal repeat (ITR) sequences for all five PAV serotypes (PAV-1 through PAV-  
15 5) were determined by Reddy *et al.* (1995c) *Virology* 212:237-239. The PAV-3 penton sequence was determined by McCoy *et al.* (1996a) *Arch. Virol.* 141:1367-1375. The nucleotide sequence of the E1 region of PAV-4 was determined by Kleiboeker (1995a) *Virus Res.* 36:259-268. The sequence of the protease (23K) gene of PAV-3 was determined by McCoy *et al.* (1996b) *DNA Seq.* 6:251-254.  
20 The unpublished sequence of the PAV-3 hexon gene (and the 14 N-terminal codons of the 23K protease gene) has been deposited in the GenBank database under accession No. U34592. The unpublished sequence of the PAV-3 100K gene has been deposited in the GenBank database under accession No. U82628. The sequence of the PAV-3 E4 region has been determined by Reddy *et al.* (1997)  
25 *Virus Genes* 15:87-90.

Adenoviruses have proven to be effective vectors for the delivery and expression of foreign genes in a number of specific applications, and have a number of advantages as potential gene transfer and vaccine vectors. See Gerard  
30 *et al.* (1993) *Trends Cardiovasc. Med.* 3:171-177; Imler *et al.* (1995) *Hum. Gene Ther.* 6:711-721. The ability of these vectors to mediate the efficient expression



of candidate therapeutic or vaccine genes in a variety of cell types, including post mitotic cells, is considered an advantage over other gene transfer vectors. Adenoviral vectors are divided into helper-independent and helper-dependent groups based on the region of the adenoviral genome used for the insertion of transgenes. Helper-dependent vectors are usually made by deletion of E1 sequences and substitution of foreign DNA, and are produced in complementing human cell lines that constitutively express E1 proteins. Graham *et al.* (1977) *J. Gen. Virol.* 36:59-74; Fallaux *et al.* (1996) *Hum. Gene Ther.* 7:215-222; Fallaux *et al.* (1998) *Hum. Gene Ther.* 9:1909-1917. However, porcine adenoviruses do not replicate in human cell lines; hence these lines are unsuitable for the propagation of E1-deleted PAV vectors.

Though E1-deleted viruses do not replicate in cells that do not express E1 proteins, the viruses can express foreign proteins in these cells, provided the genes are placed under the control of a constitutive promoter. Xiang *et al.* (1996) *Virology* 219:220-227. Vaccination of animals with adenovirus recombinants containing inserts in the E1 region induced a systemic immune response and provided protection against subsequent challenge. Imler *et al.* (1995) *Hum. Gene Ther.* 6:711-721; Imler *et al.* (1996) *Gene Therap* 3:75-84.. This type of expression vector provides a significant safety profile to the vaccine as it eliminates the potential for dissemination of the vector within the vaccinee and therefore, the spread of the vector to nonvaccinated contacts or to the general environment. However, the currently used human adenovirus (HAV) based vectors are endemic in most populations, which provides an opportunity for recombination between the helper-dependent viral vectors and wild type viruses. To circumvent some of the problems associated with the use of human adenoviruses, non human adenoviruses have been explored as possible expression vectors. All vectors developed to date, except one (Klonjowski *et al.* (1997) *Hum. Gene Ther.* 8:2103-2115), contain an intact E1 region. Use of such vectors for gene therapy in humans and vaccination in animals is unsafe because they

have the ability to replicate in normal cells, and they retain the oncogenic potential of the E1 region.

Recombinant PAV genomes containing heterologous nucleotide sequences have not yet been described. Similarly, sites where insertion of heterologous sequence would not interfere with the ability of a PAV vector to stimulate an immune response against a determinant encoded by an inserted sequence have not been identified. Consequently, the development of effective recombinant PAV vectors for use in immunization, expression systems and gene therapy, awaits resolution of these issues. Similarly, there is a need for improved adenoviral vectors lacking E1 replication and oncogenic functions, for expression of transgenes in mammalian cells.

#### SUMMARY OF THE INVENTION

The present invention provides the complete nucleotide sequence of the porcine adenovirus type 3 (PAV-3) genome. Nucleic acid sequences that are substantially homologous to those comprising a PAV genome are also encompassed by the invention. Substantially homologous sequences include those capable of duplex and/or triplex formation with a nucleic acid comprising all or part of a PAV genome (or with its complement). As is known to those of skill in the art, duplex formation is influenced by hybridization conditions, particularly hybridization stringency. Factors affecting hybridization stringency are well-known to those of skill in the art. *See*, for example, Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual*; Hames *et al.* 1985) *Nucleic Acid Hybridisation: A Practical Approach*, IRL Press Ltd., Oxford. Accordingly, it is within the skill of the art to identify a sequence that is substantially homologous to a sequence from a PAV genome.

In addition, novel porcine adenovirus (PAV) expression vector systems comprising PAV genome sequences are disclosed herein. The PAV-3 sequence includes regions into which heterologous sequences can be inserted including, but not limited to, the E1, E3 and E4 regions, and the region between E4 and the right

end of the genome. The invention also provides non-essential regions which can be deleted to increase the capacity of a PAV vector for inserted heterologous sequences. These include, but are not limited to, the E3 and E4 regions, and the region between E4 and the right end of the genome. Essential regions, such as E1, can also be deleted, if virus bearing such deletions are propagated in helper cell lines supplying the deleted essential function. Thus, PAV genome sequences can be replaced by one or more foreign genes to generate recombinant PAV vectors expressing heterologous antigenic polypeptides (or antigenic fragments thereof) for the purposes of producing live recombinant virus, subunit vaccines, nucleic acid immunization, or other types of therapy. Multiple heterologous sequences can be inserted into the same, or different, locations in the genome, limited only by the capacity of the virus to accept heterologous sequences. This capacity can be expanded by deletion of viral sequences.

In addition, the invention provides PAV transcriptional and translational regulatory sequences which can be used for expression of heterologous genes that have been inserted into the vectors of the invention. Furthermore, the novel sequences of the present invention can be used for diagnostic purposes, to determine the presence of PAV antigens and/or PAV nucleic acids in a subject or biological sample.

In additional embodiments, the invention provides compositions providing immunity to PAV infection, through expression of antigenic PAV polypeptides. The invention also provides vectors comprising PAV genome sequences, including sequences encoding various PAV genes as well as PAV regulatory sequences, which are useful for controlling the expression of heterologous genes inserted into PAV vectors.

The invention provides defective recombinant PAV vectors that are deleted in their E1 region, as well as helper cell lines providing E1 function, in which such defective vectors can be propagated. Because these defective vectors replicate inefficiently in cells other than the helper cells, they are less likely to stimulate an immune response in a mammalian host. This makes them

particularly suitable for use as vaccine vectors. In addition, since the amount of nucleic acid that can be packaged into an adenovirus virion is limited, deletion of the E1 region expands the capacity of these defective vectors, enabling them to accept larger inserts of heterologous sequence. Additional deletions in other regions of the genome can be used to expand the capacity of these defective vectors still further.

The invention further provides methods for obtaining recombinant PAV vectors. In a preferred embodiment, heterologous nucleotide sequences are introduced, through recombinant DNA techniques, into a bacterial plasmid comprising a defined portion of the PAV genome. The recombinant plasmid, containing heterologous sequences flanked by PAV sequences, is introduced into a host cell in combination with a full-length PAV genome or a plasmid containing a full-length or nearly full-length PAV genome. Within the host cell, recombination between the plasmid and the PAV genome generates a recombinant PAV genome. Alternatively, recombinant PAV genomes can be constructed *in vitro*, using standard techniques in molecular biology and biotechnology.

The invention also provides methods for preparing live recombinant virus and subunit vaccines for inducing protective immune responses to an infectious organism in a mammalian subject. Protective immune responses include humoral (antibody) responses, cell-mediated responses, mucosal responses, or any combination of these. The methods involve insertion, into the porcine adenovirus genome, of heterologous nucleotide sequences encoding one or more protective antigenic determinants of a pathogen. The heterologous sequences are inserted in such a way as to come under the regulatory control of a PAV promoter, or the heterologous sequences are inserted in operative linkage to a eukaryotic transcriptional regulatory sequence. Translation of transcribed heterologous sequences can be controlled by PAV translational regulatory elements, or the heterologous sequence can include non-PAV sequences which regulate its translation.

In another aspect, the invention includes the use of recombinant porcine adenoviruses and recombinant PAV vectors for the expression of a nucleotide or amino acid sequence of interest in a cell system, such as, for example, production of antigen to be used in the preparation of antibodies, or production of antisense  
5 RNA.

The invention also includes an expression system comprising a porcine adenovirus expression vector wherein heterologous nucleotide sequences are inserted. The inserted heterologous sequences can comprise one or more regulatory elements for transcription and/or translation, or can be inserted so as to  
10 come under the control of PAV regulatory elements. Inserted regulatory elements can be those that are normally associated with the heterologous sequence, or a heterologous sequence can be juxtaposed to and placed in operative linkage with a regulatory element with which it is not normally associated, using standard recombinant DNA techniques. Heterologous sequences can be inserted into a  
15 full-length PAV genome, or into a PAV genome which has been deleted in one or more regions. A deletion in the PAV genome can be made to provide a site for insertion of a heterologous sequence, or simply to increase the capacity of the PAV vector to accommodate heterologous sequences inserted at another location.

The invention also provides recombinant PAV polypeptides including, but  
20 not limited to, those encoded by the following genes: E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K. Such recombinant PAV polypeptides are produced in any eukaryotic expression vector known in the art, into which is inserted a PAV nucleotide sequence according to the invention. Also provided are methods and compositions for recombinant production of  
25 heterologous polypeptides and RNAs in a PAV vector. Expression of heterologous polypeptides and RNAs in a PAV vector can be regulated by endogenous PAV regulatory sequences, or by non-PAV sequences. Non-PAV regulatory sequences can be those which normally regulate the heterologous sequence, or they can be sequences that are not normally associated with the  
30 heterologous sequence in a regulatory capacity.

Thus, in one embodiment, the invention includes an expression system in which one or more regions of the PAV genome are deleted and replaced with heterologous sequences. In another embodiment, the invention includes a PAV expression system in which heterologous sequences are introduced into the PAV genome without the removal of any PAV sequences. Intergenic regions of the PAV genome comprising regulatory sequences are useful in the practice of the invention for controlling the expression of homologous and heterologous sequences.

The invention also includes recombinant vector systems comprising two or more nucleic acid molecules. In one embodiment, the vector system comprises two plasmids, the first containing a full-length or nearly full-length PAV genome and the second containing a segment of the PAV genome, such as the left end (including the E1 region) or the right end (including the E3 and/or E4 regions). Introduction of heterologous nucleotide sequences into the second plasmid, followed by co-transfection of both plasmids into a suitable host cell, will allow homologous recombination between the two plasmids to generate a viral genome containing inserted heterologous sequences. In another embodiment, the vector system comprises a full-length or nearly full-length PAV genome and a plasmid containing a segment of the PAV genome. Insertion of heterologous sequences into the plasmid, followed by co-transfection and homologous recombination, will generate recombinant PAV genomes as above.

Additional aspects of the invention provide a recombinant PAV comprising a heterologous sequence wherein the heterologous sequence encodes an antigenic determinant of a disease-causing organism; and a recombinant PAV comprising a heterologous sequence wherein the heterologous sequence encodes a foreign gene or fragment thereof. In further embodiments, the invention provides pharmaceutical compositions comprising recombinant PAV for producing an immune response in a mammalian host, the recombinant PAV comprising a heterologous nucleotide sequence encoding a protective determinant of a pathogenic organism. The heterologous sequence is expressed in quantities

sufficient for induction of a protective immune response, either through operative linkage to one or more non-PAV regulatory sequences, or through control by endogenous PAV regulatory sequences. The protective immune response can be humoral, cell-mediated and/or mucosal.

5           The recombinant PAV vectors of the invention will also allow the expression of various therapeutic polypeptides in a wide range of mammalian hosts and are thus useful in the practices of nucleic acid immunization and gene therapy. Exemplary hosts include, but are not limited to, human, equine, bovine, porcine, ovine, caprine, avian, and murine. Those of skill in the art are aware of  
10 various therapeutic polypeptides which can be usefully expressed in mammalian hosts. Such therapeutic polypeptides include, but are not limited to, coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane  
15 conductance regulator (CFTR) and immunogenic polypeptides.

          The invention also provides diagnostic methods and compositions for the detection of PAV nucleic acids and proteins in a cell or biological sample. The PAV nucleotide sequences disclosed herein can be used as hybridization probes to detect PAV nucleic acids. In addition, the PAV nucleotide sequences disclosed  
20 herein encode PAV polypeptides, which can be used for the production of antibodies reactive with various PAV antigens. Such antibodies can be used to detect PAV antigens by immunoassay. Alternatively, PAV polypeptides themselves can be used in competitive immunoassays to detect the presence of PAV antigens in a cell or biological sample. PAV polypeptides can be produced  
25 by the PAV vectors of the invention, or can be produced in any mammalian expression vector known in the art.

#### BRIEF DESCRIPTION OF THE DRAWINGS

          Figure 1 shows the complete nucleotide sequence of the PAV-3 genome  
30 (SEQ ID NO: 1).

**Figure 2** shows the transcriptional map of the PAV-3 genome derived from alignment of the sequences of cDNA clones with the genomic sequence, and nuclease protection mapping of viral transcripts. The PAV-3 genome is represented by the thick horizontal line, with the numbers below the line representing PAV-3 map units (*i.e.*, percentage of genome length from the left end). Rightward-reading transcription units are depicted above the line and leftward-reading transcription units are shown below the line.

**Figure 3** shows immunoprecipitation of E1A and E1B proteins from various cell lines.

10        In **Figure 3A**, proteins in cell lysates were separated by gel electrophoresis, and analyzed by immunoblotting using the DP11 monoclonal antibody, which recognizes the human adenovirus E1A protein. Lane 1: 293 cells (human cells transformed by HAV-5, which express adenovirus E1A and E1B); Lane 2: Fetal porcine retinal cells; Lane 3: VIDO R1 cells; Lane 4: 293 cells.

15        In **Figure 3B**, proteins in cell lysates were separated by gel electrophoresis, and analyzed by immunoblotting using the DP17 monoclonal antibody, which recognizes the human adenovirus E1B protein. Lane 1: human 293 cells; Lane 2: Fetal porcine retinal cells; Lane 3: VIDO R1 cells; Lane 4: 293 cells.

**Figure 4** shows a map of the plasmid pPAV-101.

20        **Figure 5** shows a map of the plasmid pPAV-102.

**Figure 6** shows a map of the plasmid pPAV-300.

**Figure 7** shows proteins labeled after infection of VIDO R1 cells with a recombinant PAV containing the PRV gp50 gene inserted in the E3 region. Labeled proteins were separated by gel electrophoresis; an autoradiogram of the gel is shown. Lane 1: Molecular weight markers of 30K, 46K, 69K and 96K, in order of increasing molecular weight. Lane 2: Mock-infected cells, 12 hours post-infection. Lane 3: PAV-3-infected cells, 12 hours post-infection. Lane 4: cells infected with a recombinant PAV containing the PRV gp50 gene, 12 hours post-infection. Lane 5: cells infected with a recombinant PAV containing the PRV

25



gp50 gene, 16 hours post-infection. Lane 6: cells infected with a recombinant PAV containing the PRV gp50 gene, 24 hours post-infection.

Figure 8 provides a schematic diagram of the construction of an E1- and E3-deleted PAV vector with a green fluorescent protein gene insertion.

5

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides the complete nucleotide sequence and transcriptional map of the porcine adenovirus type 3 (PAV-3) genome. The sequence comprises a linear, double-stranded DNA molecule of about 34,094 base pairs, as shown in Figure 1 (SEQ ID NO: 1). Previously-determined partial sequences can be aligned with the complete genomic sequence as shown in Table 1.

10

**Table 1. Alignment of published PAV-3 sequences**

GenBank Accession No.	PAV Gene(s) included within sequence	Reference	Genome coordinates
L43077	ITR	Reddy et al., 1995c	1-144
U24432	penton	McCoy et al., 1996a	13556-15283
U34592	hexon; N-terminal 14 codons of 23K (protease) gene	unpublished	19036-21896
U33016	protease (23K)	McCoy et al., 1996b	21897-22676
U82628	100K	unpublished	24056-26572
U10433	E3, pVIII, fiber	Reddy et al., 1995a	27089-31148
L43363	E4	Reddy et al., 1997	31064-34094

15

Knowledge of the PAV genome sequence is useful for both therapeutic and diagnostic procedures. Regions suitable for insertion and regulated expression of heterologous sequences have been identified. These regions include, but are not limited to the E1, E3 and E4 regions, and the region between the E4 region and the right end of the genome. A heterologous nucleotide

sequence, with respect to the PAV vectors of the invention, is one which is not normally associated with PAV sequences as part of the PAV genome.

Heterologous nucleotide sequences include synthetic sequences. Regions encoding immunogenic PAV polypeptides, for use in immunodiagnostic

5 procedures, have also been identified and are disclosed herein. These include the regions encoding the following PAV proteins: E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, 33K, pVIII, hexon and fiber (see Table 2). Regions essential for viral replication, such as E1 and E2A, can be deleted to provide attenuated strains for use as vaccines. Nonessential regions,  
10 such as parts of the E3 and E4 regions, can be deleted to provide insertion sites, or to provide additional capacity for insertion at a site other than the deleted region. Deletions of viral sequences can be obtained by any method known in the art, including but not limited to restriction enzyme digestion and ligation, oligonucleotide-mediated deletion mutagenesis, and the like.

15 The practice of the present invention employs, unless otherwise indicated, conventional microbiology, immunology, virology, molecular biology, and recombinant DNA techniques which are within the skill of the art. These techniques are fully explained in the literature. See, e.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual* (1982); *DNA Cloning: A Practical Approach*, vols. I & II (D. Glover, ed.); *Oligonucleotide Synthesis* (N. Gait, ed.  
20 (1984)); *Nucleic Acid Hybridization* (B. Hames & S. Higgins, eds. (1985)); *Transcription and Translation* (B. Hames & S. Higgins, eds. (1984)); *Animal Cell Culture* (R. Freshney, ed. (1986)); Perbal, *A Practical Guide to Molecular Cloning* (1984); Ausubel, et al., *Current Protocols In Molecular Biology*, John  
25 Wiley & Sons (1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996); and Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2<sup>nd</sup> Edition); vols. I, II & III (1989).

### Nucleotide Sequence, Genome Organization, and Transcription Map of Porcine Adenovirus Type 3 (PAV-3).

The complete nucleotide sequence of PAV-3 genome is 34,094 base pairs (bp) in length and has a base composition of 31.3% G, 32.5% C, 18.3% A, and 17.9% T. Thus, the sequence of the PAV-3 genome has a G+C content of 63.8%, which is unusually high when compared with the G+C content of many other animal adenoviruses. The genome termini share inverted terminal repeats (ITR) of 144 bp. Reddy *et al.*, 1995c, *supra*. The organization of the genome as determined by analysis of open reading frames (ORFs), nuclease protection mapping, and sequencing of cDNA clones, is summarized in Table 2 and Figure 2.

One important feature of PAV-3 genome is the presence of a short virion associated (VA) RNA gene between the splice acceptor sites of the precursor terminal protein (pTP) and 52 kDa protein genes (Figure 2). Expression of VA genes increases the kinetics of viral replication; thereby providing the potential for higher yields of recombinant gene products using the PAV vectors of the invention. The locations of the signature sequences present upstream and downstream of VA RNA genes indicate the VA RNA gene of PAV-3 is about 126 nucleotides (nt) in length. This is somewhat shorter than most VA RNAs, whose lengths are  $163 \pm 14$  nts, however shorter VA RNAs have also been reported in HAV-10 and CELO virus. Ma *et al.* (1996) *J. Virol.* 70:5083-5099; and Chiocca *et al.* (1996) *J. Virol.* 70:2939-2949. The VA RNA genes were not found in the genomes of BAV-3, CAV-1, and OAV. Reddy *et al.* (1998) *J. Virol.* 72:1394-1402; Morrison *et al.* (1997) *J. Gen. Virol.* 78:873-878; and Vrati *et al.* (1996) *Virology* 220:186-199.

In PAV-3 the major late transcript initiates at 17.7 map units (m.u.: an adenovirus map unit is 1% of genome length, starting from the left end of the genome). There are six 3'-coterminal families of late mRNAs, denoted L1 to L6 (see Figure 2). All mRNAs produced from the major late promoter (MLP) contain a tripartite leader sequence (TPL). The first portion of the TPL lies next

to the MLP and is 61 nts long. The second portion lies within the gene coding for pol and is 68 nt in length. The third portion is 99 nts long and is located within the gene coding for pTP. Thus the TPL of PAV-3 is 228 nt long and is derived from three exons located at 17.7, 20.9, and 28.1 m.u.

- 5           The MLP and TPL sequences can be used for expression of a heterologous sequence in a recombinant PAV vector or in any other adenoviral expression system.

Table 2: Transcriptional and Translational Features of the PAV-3 Genome

Region	Gene	Transcription start site	ATG	Splice donor site	Splice acceptor site	Poly(A) signal	Poly(A) addition site
E1A	229R	heterogeneous	533			1286	1307
	214R		533	1043	1140	1286	1307
E1B	202R	1382	1461			4085	4110, 4112
	474R	1382	1829			4085	4110, 4112
pIX	Pix	3377	3394			4085	4110, 4112
E2A	DBP	17011c	24041c	26949c, 24714c	24793c, 24051c	22560c	22536c
E2B	pTP	17011c	13638c	24949c, 24714c	24793c, 13772c	4075c	4053c
	pol	17011c	13638c	24949c, 24714c	24793†c, 13772†c	4075c	4053c
IVa2	IVa2	5867c	5711c	5699c	5441c	4075c	4053c
E3		27473				28765	28793
E4		33730c				31189c	31170c
L1	52K	6064	10629	9684	10606	13601	13627
	IIIa	6064	11719	9684	11715	13601	13627
L2	pIII	6064	13662	9684	13662	15698*	15735
	pVII	6064	15170	9684	15139	15698*	15735
L3	pV	6064	15819	9684	15793	18992	19013
	pX	6064	17783	9684	17776	18992	19013
	pVI	6064	18076	9684	18063	18992	19013
	Hexon	6064	19097	9684	19096	22544	22567
L4	Protease	6064	21934	9684	21931†	22544	22567
	100k	6064	24056	9684	24056	28765	28793
L5	33K	6064	26181	9684	26130	28765	29793
	pVIII	6064	27089	9684	26792	28765	28793
L6	Fiber	6064	28939	9684	28910	31143	31164

## Notes:

\* TTGTTT is present as a polyadenylation signal instead of AATAA

† The splice acceptor sites for the *pol* and protease genes were determined based on consensus splice acceptor sequences "c" refers to sequences on the complementary (leftward-reading) strand of the PAV genome.

### Construction of recombinant PAV vectors

In one embodiment of the invention, a recombinant PAV vector is constructed by *in vivo* recombination between a plasmid and a PAV genome. Generally, heterologous sequences are inserted into a plasmid vector containing a portion of the PAV genome, which may or may not possess one or more deletions of PAV sequences. The heterologous sequences are inserted into the PAV insert portion of the plasmid vector, such that the heterologous sequences are flanked by PAV sequences that are adjacent on the PAV genome. The PAV sequences serve as "guide sequences," to direct insertion of the heterologous sequences to a particular site in the PAV genome; the insertion site being defined by the genomic location of the guide sequences.

The vector is generally a bacterial plasmid, allowing multiple copies of the cloned sequence to be produced. In one embodiment, the plasmid is co-transfected, into an appropriate host cell, with a PAV genome comprising a full-length or nearly full-length PAV genomic sequence. The PAV genome can be isolated from PAV virions, or can comprise a PAV genome that has been inserted into a plasmid, using standard techniques of molecular biology and biotechnology. Construction of a plasmid containing a PAV genome is described in Example 2, *infra*. Nearly full-length PAV genomic sequences can be deleted in regions such as E1, E3, E4 and the region between E4 and the right end of the genome, but will retain sequences required for replication and packaging. PAV genomes can be deleted in essential regions if the essential function can be supplied by a helper cell line.

Insertion of the cloned heterologous sequences into a viral genome occurs by *in vivo* recombination between a plasmid vector (containing heterologous sequences flanked by PAV guide sequences) and a PAV genome following co-transfection into a suitable host cell. The PAV genome contains inverted terminal repeat (ITR) sequences required for initiation of viral DNA replication (Reddy *et al.* (1995c), *supra*), and sequences involved in packaging of replicated viral genomes. Adenovirus packaging signals generally lie between the left ITR and

the E1A promoter. Incorporation of the cloned heterologous sequences into the PAV genome thus places the heterologous sequences into a DNA molecule containing viral replication and packaging signals, allowing generation of multiple copies of a recombinant PAV genome that can be packaged into infectious viral particles. Alternatively, incorporation of the cloned heterologous sequences into a PAV genome places these sequences into a DNA molecule that can be replicated and packaged in an appropriate helper cell line. Multiple copies of a single sequence can be inserted to improve yield of the heterologous gene product, or multiple heterologous sequences can be inserted so that the recombinant virus is capable of expressing more than one heterologous gene product. The heterologous sequences can contain additions, deletions and/or substitutions to enhance the expression and/or immunological effect of the expressed gene product(s).

Attachment of guide sequences to a heterologous sequence can also be accomplished by ligation *in vitro*. In this case, a nucleic acid comprising a heterologous sequence flanked by PAV guide sequences can be co-introduced into a host cell along with a PAV genome, and recombination can occur to generate a recombinant PAV vector. Introduction of nucleic acids into cells can be achieved by any method known in the art, including, but not limited to, microinjection, transfection, electroporation, CaPO<sub>4</sub> precipitation, DEAE-dextran, liposomes, particle bombardment, *etc.*

In one embodiment of the invention, a recombinant PAV expression cassette can be obtained by cleaving a wild-type PAV genome with an appropriate restriction enzyme to produce a PAV restriction fragment representing, for example, the left end or the right end of the genome comprising E1 or E3 gene region sequences, respectively. The PAV restriction fragment can be inserted into a cloning vehicle, such as a plasmid, and thereafter at least one heterologous sequence (which may or may not encode a foreign protein) can be inserted into the E1 or E3 region with or without an operatively-linked eukaryotic transcriptional regulatory sequence. The recombinant expression cassette is

contacted with a PAV genome and, through homologous recombination or other conventional genetic engineering methods, the desired recombinant is obtained. In the case wherein the expression cassette comprises the E1 region or some other essential region, recombination between the expression cassette and a PAV  
5 genome can occur within an appropriate helper cell line such as, for example, an E1-transformed cell line. Restriction fragments of the PAV genome other than those comprising the E1 or E3 regions are also useful in the practice of the invention and can be inserted into a cloning vehicle such that heterologous sequences can be inserted into the PAV sequences. These DNA constructs can  
10 then undergo recombination *in vitro* or *in vivo*, with a PAV genome either before or after transformation or transfection of an appropriate host cell.

The invention also includes an expression system comprising a porcine adenovirus expression vector wherein a heterologous nucleotide sequence, e.g. DNA, replaces part or all of the E3 region, part or all of the E1 region, part or all  
15 of the E2 region, part or all of the E4 region, part or all of the late region and/or part or all of the regions occupied by the pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K genes. The expression system can be used wherein the foreign nucleotide sequences, e.g. DNA, are optionally in operative linkage with a eukaryotic transcriptional regulatory sequence. PAV expression  
20 vectors can also comprise inverted terminal repeat (ITR) sequences and packaging sequences.

The PAV E1A, E1B, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K genes are essential for viral replication. Therefore, PAV  
vectors comprising deletions in any of these genes, or which lack functions  
25 encoded by any of these genes, are grown in an appropriate complementing cell line (*i.e.*, a helper cell line). Most, if not all, of the open reading frames in the E3 and E4 regions of PAV-3 are non-essential for viral replication and, therefore, deletions in these regions can be constructed for insertion or to increase vector capacity, without necessitating the use of a helper cell line for growth of the viral  
30 vector.



In another embodiment, the invention provides a method for constructing a full-length clone of a PAV genome by homologous recombination *in vivo*. In this embodiment, two or more plasmid clones, containing overlapping segments of the PAV genome and together covering the entire genome, are introduced into an appropriate bacterial host cell. Approximately 30 base pairs of overlap is required for homologous recombination in *E. coli*. Chartier *et al.* (1996) *J. Virol.* 70:4805-4810. Through *in vivo* homologous recombination, the PAV genome segments are joined to form a full-length PAV genome. In a further embodiment, a recombinant plasmid containing left-end sequences and right-end sequences of the PAV genome, separated by a unique restriction site, is constructed. This plasmid is digested with the restriction enzyme recognizing the unique restriction site, to generate a unit-length linear plasmid, which is introduced into a cell together with a full-length PAV genome. Homologous recombination within the cell will result in production of a recombinant plasmid containing a full-length PAV genome. Recombinant plasmids will also generally contain sequences specifying replication in a host cell and one or more selective markers, such as, for example, antibiotic resistance.

Suitable host cells include any cell that will support recombination between a PAV genome and a plasmid containing PAV sequences, or between two or more plasmids, each containing PAV sequences. Recombination is generally performed in procaryotic cells, such as *E. coli*, while transfection of a plasmid containing a viral genome, to generate virus particles, is conducted in eukaryotic cells, preferably mammalian cells, most preferably porcine cell cultures. The growth of bacterial cell cultures, as well as culture and maintenance of eukaryotic cells and mammalian cell lines are procedures which are well-known to those of skill in the art.

In one embodiment of the invention, a defective recombinant PAV vector is used for expression of heterologous sequences. The defective vector will be deleted in all or part of the E1 region. Construction of a deletion in the E1 region of PAV is described in Example 3, *infra*. Heterologous sequences can be inserted

so as to replace the deleted E1 region, and/or can be inserted at other sites in the PAV genome, preferably E3, E4 and/or the region between E4 and the right end of the genome. Defective vectors with E1 deletions are grown in helper cell lines, which provide E1 function.

5           Accordingly, in one embodiment of the invention, a number of recombinant helper cell lines are produced according to the present invention by constructing an expression cassette comprising an adenoviral E1 region and transforming host cells therewith to provide complementing cell lines or cultures providing E1 functions. The terms "complementing cell," "complementing cell  
10   line," "helper cell" and "helper cell line" are used interchangeably herein to denote a cell line that provides a viral function that is deficient in a deleted PAV, preferably E1 function. These recombinant complementing cell lines are capable of allowing a defective recombinant PAV, having a deleted E1 gene region, wherein the deleted sequences are optionally replaced by heterologous nucleotide  
15   sequences, to replicate and express one or more foreign genes or fragments thereof encoded by the heterologous nucleotide sequences. PAV vectors with E1 deletions, wherein heterologous sequences are inserted in regions other than E1, can also be propagated in these complementing cell lines, and will express the heterologous sequences if they are inserted downstream of a PAV promoter or are  
20   inserted in operative linkage with a eukaryotic regulatory sequence. Preferred helper cell lines include VIDO R1 cells, as described in Example 1, *infra*. Briefly, the VIDO R1 cell line is a porcine retinal cell line that has been transfected with DNA from the human adenovirus type 5 (HAV-5) E1 region, and which supports the growth of PAV E1A deletions and HAV-5 E1 deletions.

25           Transformation of porcine cells with either PAV or HAV has not been reported due to the fact that exposure of permissive or semi-permissive cells to adenovirus normally leads to lysis of infected cells. Graham *et al.*, *supra*. The approach used in the present study to create a PAV E1-complementing cell line employing the E1 region of HAV-5 is novel as E1A proteins of HAV-5 have been  
30   shown for the first time to complement PAV-3 E1 mutants. There are several

reasons that the E1 region of HAV-5 was used for transformation of porcine embryonic retinal cells. The E1 region of HAV-5 was shown to transform human retina cells very efficiently. Fallaux *et al.* (1998) *supra*. In contrast to the E1 region of PAV-3, the E1 region of HAV-5 has been thoroughly characterized and the monoclonal antibodies against the E1 proteins are readily available from commercial sources. In addition, the E1A region of HAV-5 was shown to complement the E1A functions of several non-human adenoviruses. Ball *et al.* (1988) *J. Virol.* 62:3947-3957; Zheng *et al.* (1994) *Virus Res.* 31:163-186.

More generally, defective recombinant PAV vectors, lacking one or more essential functions encoded by the PAV genome, can be propagated in appropriate complementing cell lines, wherein a particular complementing cell line provides a function or functions that is (are) lacking in a particular defective recombinant PAV vector. Complementing cell lines can provide viral functions through, for example, co-infection with a helper virus, or by integrating or otherwise maintaining in stable form a fragment of a viral genome encoding a particular viral function.

In another embodiment of the invention, E1 function (or the function of any other viral region which may be mutated or deleted in any particular viral vector) can be supplied (to provide a complementing cell line) by co-infection of cells with a virus which expresses the function that the vector lacks.

#### **PAV expression systems**

In one embodiment, the present invention identifies and provides means of deleting regions of the PAV genome, to provide sites into which heterologous or homologous nucleotide sequences encoding foreign genes or fragments thereof can be inserted to generate porcine adenovirus recombinants. In preferred embodiments, deletions are made in part or all of the nucleotide sequences of the PAV E1, E3, or E4 regions and/or the region between E4 and the right end of genome. E1 deletion is described in Example 3; E3 deletion and insertion of heterologous sequence in the E3 region are described in Example 4 and 5; and

insertion of a heterologous sequence between the E4 region and the right end of the PAV genome, as well as expression of the inserted sequence, is described in Example 6, *infra*.

In another embodiment, the invention identifies and provides additional regions of the PAV genome (and fragments thereof) suitable for insertion of heterologous or homologous nucleotide sequences encoding foreign genes or fragments thereof to generate PAV recombinants. These regions include nucleotides 145-13,555; 15,284-19,035; 22,677-24,055; 26,573-27,088; and 31,149-34,094 and comprise the E2 region, the late region, and genes encoding the pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K proteins. These regions of the PAV genome can be used, among other things, for insertion of foreign sequences, for provision of DNA control sequences including transcriptional and translational regulatory sequences, or for diagnostic purposes to detect the presence, in a biological sample, of viral nucleic acids and/or proteins encoded by these regions. Example 7, *infra*, describes procedures for constructing insertions in these regions.

One or more heterologous sequences can be inserted into one or more regions of the PAV genome to generate a recombinant PAV vector, limited only by the insertion capacity of the PAV genome and ability of the recombinant PAV vector to express the inserted heterologous sequences. In general, adenovirus genomes can accept inserts of approximately 5% of genome length and remain capable of being packaged into virus particles. The insertion capacity can be increased by deletion of non-essential regions and/or deletion of essential regions whose function is provided by a helper cell line.

In one embodiment of the invention, insertion can be achieved by constructing a plasmid containing the region of the PAV genome into which insertion is desired. The plasmid is then digested with a restriction enzyme having a recognition sequence in the PAV portion of the plasmid, and a heterologous sequence is inserted at the site of restriction digestion. The plasmid, containing a portion of the PAV genome with an inserted heterologous sequence,

in co-transformed, along with a plasmid (such as pPAV-200) containing a full-length PAV genome, into a bacterial cell (such as, for example, *E. coli*), wherein homologous recombination between the plasmids generates a full-length PAV genome containing inserted heterologous sequences.

5           Deletion of PAV sequences, to provide a site for insertion of heterologous sequences or to provide additional capacity for insertion at a different site, can be accomplished by methods well-known to those of skill in the art. For example, for PAV sequences cloned in a plasmid, digestion with one or more restriction enzymes (with at least one recognition sequence in the PAV insert) followed by  
10 ligation will, in some cases, result in deletion of sequences between the restriction enzyme recognition sites. Alternatively, digestion at a single restriction enzyme recognition site within the PAV insert, followed by exonuclease treatment, followed by ligation will result in deletion of PAV sequences adjacent to the restriction site. A plasmid containing one or more portions of the PAV genome  
15 with one or more deletions, constructed as described above, can be co-transfected into a bacterial cell along with a plasmid containing a full-length PAV genome to generate, by homologous recombination, a plasmid containing a PAV genome with a deletion at a specific site. PAV virions containing the deletion can then be obtained by transfection of mammalian cells (such as ST or VIDO R1 cells) with  
20 the plasmid containing a PAV genome with a deletion at a specific site.

          Expression of an inserted sequence in a recombinant PAV vector will depend on the insertion site. Accordingly, preferred insertion sites are adjacent to and downstream (in the transcriptional sense) of PAV promoters. The transcriptional map of PAV, as disclosed herein, provides the locations of PAV  
25 promoters. Locations of restriction enzyme recognition sequences downstream of PAV promoters, for use as insertion sites, can be easily determined by one of skill in the art from the PAV nucleotide sequence provided herein. Alternatively, various *in vitro* techniques can be used for insertion of a restriction enzyme recognition sequence at a particular site, or for insertion of heterologous  
30 sequences at a site that does not contain a restriction enzyme recognition

sequence. Such methods include, but are not limited to, oligonucleotide-mediated heteroduplex formation for insertion of one or more restriction enzyme recognition sequences (*see*, for example, Zoller *et al.* (1982) *Nucleic Acids Res.* 10:6487-6500; Brennan *et al.* (1990) *Roux's Arch. Dev. Biol.* 199:89-96; and Kunkel *et al.* (1987) *Meth. Enzymology* 154:367-382) and PCR-mediated methods for insertion of longer sequences. *See*, for example, Zheng *et al.* (1994) *Virus Research* 31:163-186.

It is also possible to obtain expression of a heterologous sequence inserted at a site that is not downstream from a PAV promoter, if the heterologous sequence additionally comprises transcriptional regulatory sequences that are active in eukaryotic cells. Such transcriptional regulatory sequences can include cellular promoters such as, for example, the bovine hsp70 promoter and viral promoters such as, for example, herpesvirus, adenovirus and papovavirus promoters and DNA copies of retroviral long terminal repeat (LTR) sequences.

In another embodiment, homologous recombination in a procaryotic cell can be used to generate a cloned PAV genome; and the cloned PAV-3 genome can be propagated as a plasmid. Infectious virus can be obtained by transfection of mammalian cells with the cloned PAV genome rescued from plasmid-containing cells. Example 2, *infra* describes construction of an infectious plasmid containing a PAV-3 genome.

The invention provides PAV regulatory sequences which can be used to regulate the expression of heterologous genes. A regulatory sequence can be, for example, a transcriptional regulatory sequence, a promoter, an enhancer, an upstream regulatory domain, a splicing signal, a polyadenylation signal, a transcriptional termination sequence, a translational regulatory sequence, a ribosome binding site and a translational termination sequence.

#### **Therapeutic genes and polypeptides**

The PAV vectors of the invention can be used for the expression of therapeutic polypeptides in applications such as *in vitro* polypeptide production,

vaccine production, nucleic acid immunization and gene therapy, for example. Therapeutic polypeptides comprise any polypeptide sequence with therapeutic and/or diagnostic value and include, but are not limited to, coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell  
5 receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator (CFTR) and immunogenic polypeptides.

In a preferred embodiment, PAV vectors will contain heterologous sequences encoding protective determinants of various pathogens of swine, for  
10 use in subunit vaccines and nucleic acid immunization. Representative swine pathogen antigens include, but are not limited to, pseudorabies virus (PRV) gp50; transmissible gastroenteritis virus (TGEV) S gene; porcine rotavirus VP7 and VP8 genes; genes of porcine respiratory and reproductive syndrome virus (PRRS), in particular ORF 5; genes of porcine epidemic diarrhea virus; genes of  
15 hog cholera virus, and genes of porcine parvovirus.

Various foreign genes or nucleotide sequences or coding sequences (prokaryotic, and eukaryotic) can be inserted into a PAV vector, in accordance with the present invention, particularly to provide protection against a wide range of diseases. Many such genes are already known in the art; the problem  
20 heretofore having been to provide a safe, convenient and effective vaccine vector for the genes or sequences.

A heterologous (*i.e.*, foreign) nucleotide sequence can consist of one or more gene(s) of interest, and preferably of therapeutic interest. In the context of the present invention, a gene of interest can code either for an antisense RNA, a  
25 ribozyme or for an mRNA which will then be translated into a protein of interest. A gene of interest can be of genomic type, of complementary DNA (cDNA) type or of mixed type (minigene, in which at least one intron is deleted). It can code for a mature protein, a precursor of a mature protein, in particular a precursor intended to be secreted and accordingly comprising a signal peptide, a chimeric  
30 protein originating from the fusion of sequences of diverse origins, or a mutant of

a natural protein displaying improved or modified biological properties. Such a mutant can be obtained by deletion, substitution and/or addition of one or more nucleotide(s) of the gene coding for the natural protein, or any other type of change in the sequence encoding the natural protein, such as, for example, transposition or inversion.

A gene of interest can be placed under the control of regulatory sequences suitable for its expression in a host cell. Suitable regulatory sequences are understood to mean the set of elements needed for transcription of a gene into RNA (ribozyme, antisense RNA or mRNA), for processing of RNA, and for the translation of an mRNA into protein. Among the elements needed for transcription, the promoter assumes special importance. It can be a constitutive promoter or a regulatable promoter, and can be isolated from any gene of eukaryotic, prokaryotic or viral origin, and even adenoviral origin. Alternatively, it can be the natural promoter of the gene of interest. Generally speaking, a promoter used in the present invention can be chosen to contain cell-specific regulatory sequences, or modified to contain such sequences. For example, a gene of interest for use in the present invention is placed under the control of an immunoglobulin gene promoter when it is desired to target its expression to lymphocytic host cells. There may also be mentioned the HSV-1 TK (herpesvirus type 1 thymidine kinase) gene promoter, the adenoviral MLP (major late promoter), in particular of human adenovirus type 2, the RSV (Rous Sarcoma Virus) LTR (long terminal repeat), the CMV (Cytomegalovirus) early promoter, and the PGK (phosphoglycerate kinase) gene promoter, for example, permitting expression in a large number of cell types.

Alternatively, targeting of a recombinant PAV vector to a particular cell type can be achieved by constructing recombinant hexon and/or fiber genes. The protein products of these genes are involved in host cell recognition; therefore, the genes can be modified to contain peptide sequences that will allow the virus to recognize alternative host cells.



Among genes of interest which are useful in the context of the present invention, there may be mentioned:

- genes coding for cytokines such as interferons and interleukins;
- genes encoding lymphokines;
- 5       - genes coding for membrane receptors such as the receptors recognized by pathogenic organisms (viruses, bacteria or parasites), preferably by the HIV virus (human immunodeficiency virus);
- genes coding for coagulation factors such as factor VIII and factor IX;
- genes coding for dystrophins;
- 10       - genes coding for insulin;
- genes coding for proteins participating directly or indirectly in cellular ion channels, such as the CFTR (cystic fibrosis transmembrane conductance regulator) protein;
- genes coding for antisense RNAs, or proteins capable of inhibiting the
- 15       activity of a protein produced by a pathogenic gene which is present in the genome of a pathogenic organism, or proteins (or genes encoding them) capable of inhibiting the activity of a cellular gene whose expression is deregulated, for example an oncogene;
- genes coding for a protein inhibiting an enzyme activity, such as  $\alpha_1$ -
- 20       antitrypsin or a viral protease inhibitor, for example;
- genes coding for variants of pathogenic proteins which have been mutated so as to impair their biological function, such as, for example, trans-dominant variants of the *tat* protein of the HIV virus which are capable of competing with the natural protein for binding to the target sequence, thereby
- 25       preventing the activation of HIV;
- genes coding for antigenic epitopes in order to increase the host cell's immunity;
- genes coding for major histocompatibility complex classes I and II proteins, as well as the genes coding for the proteins which are inducers of these
- 30       genes;

- genes coding for antibodies;
- genes coding for immunotoxins;
- genes encoding toxins;
- genes encoding growth factors or growth hormones;
- 5 - genes encoding cell receptors and their ligands;
- genes encoding tumor suppressors;
- genes coding for cellular enzymes or those produced by pathogenic

organisms; and

- suicide genes. The HSV-1 TK suicide gene may be mentioned as an
- 10 example. This viral TK enzyme displays markedly greater affinity compared to the cellular TK enzyme for certain nucleoside analogues (such as acyclovir or gancyclovir). It converts them to monophosphorylated molecules, which can themselves be converted by cellular enzymes to nucleotide precursors, which are toxic. These nucleotide analogues can be incorporated into replicating DNA
- 15 molecules, hence incorporation occurs chiefly in the DNA of dividing cells. This incorporation can result in specific destruction of dividing cells such as cancer cells.

This list is not restrictive, and any other gene of interest can be used in the context of the present invention. In some cases the gene for a particular antigen

20 can contain a large number of introns or can be from an RNA virus, in these cases a complementary DNA copy (cDNA) can be used. It is also possible that only fragments of nucleotide sequences of genes can be used (where these are sufficient to generate a protective immune response or a specific biological effect) rather than the complete sequence as found in the wild-type organism. Where

25 available, synthetic genes or fragments thereof can also be used. However, the present invention can be used with a wide variety of genes, fragments and the like, and is not limited to those set out above.

Recombinant PAV vectors can be used to express antigens for provision of, for example, subunit vaccines. Antigens used in the present invention can be

30 either native or recombinant antigenic polypeptides or fragments. They can be

partial sequences, full-length sequences, or even fusions (e.g., having appropriate leader sequences for the recombinant host, or with an additional antigen sequence for another pathogen). The preferred antigenic polypeptide to be expressed by the virus systems of the present invention contain full-length (or near full-length) sequences encoding antigens. Alternatively, shorter sequences that are antigenic (i.e., encode one or more epitopes) can be used. The shorter sequence can encode a "neutralizing epitope," which is defined as an epitope capable of eliciting antibodies that neutralize virus infectivity in an *in vitro* assay. Preferably the peptide should encode a "protective epitope" that is capable of raising in the host a "protective immune response," i.e., a humoral (*i.e.* antibody-mediated), cell-mediated, and/or mucosal immune response that protects an immunized host from infection.

The antigens used in the present invention, particularly when comprised of short oligopeptides, can be conjugated to a vaccine carrier. Vaccine carriers are well known in the art: for example, bovine serum albumin (BSA), human serum albumin (HSA) and keyhole limpet hemocyanin (KLH). A preferred carrier protein, rotavirus VP6, is disclosed in EPO Pub. No. 0259149, the disclosure of which is incorporated by reference herein.

Genes for desired antigens or coding sequences thereof which can be inserted include those of organisms which cause disease in mammals, particularly porcine pathogens such as pseudorabies virus (PRV), transmissible gastroenteritis virus (TGEV), porcine rotavirus, porcine respiratory and reproductive syndrome virus (PRRS), porcine epidemic diarrhea virus (PEDV), hog cholera virus (HCV), porcine parvovirus and the like. Genes encoding antigens of human pathogens are also useful in the practice of the invention.

### **Therapeutic applications**

With the recombinant viruses of the present invention, it is possible to provide protection against a wide variety of diseases affecting swine, cattle, humans and other mammals. Any of the recombinant antigenic determinants or

recombinant live viruses of the invention can be formulated and used in substantially the same manner as described for the antigenic determinant vaccines or live vaccine vectors.

The present invention also includes pharmaceutical compositions  
5 comprising a therapeutically effective amount of a recombinant vector, recombinant virus or recombinant protein, prepared according to the methods of the invention, in combination with a pharmaceutically acceptable vehicle and/or an adjuvant. Such a pharmaceutical composition can be prepared and dosages determined according to techniques that are well-known in the art. The  
10 pharmaceutical compositions of the invention can be administered by any known administration route including, but not limited to, systemically (for example, intravenously, intratracheally, intraperitoneally, intranasally, parenterally, enterically, intramuscularly, subcutaneously, intratumorally or intracranially) or by aerosolization or intrapulmonary instillation. Administration can take place in  
15 a single dose or in doses repeated one or more times after certain time intervals. The appropriate administration route and dosage will vary in accordance with the situation (for example, the individual being treated, the disorder to be treated or the gene or polypeptide of interest), but can be determined by one of skill in the art.

20 The vaccines of the invention carrying foreign genes or fragments can be orally administered in a suitable oral carrier, such as in an enteric-coated dosage form. Oral formulations include such normally-employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like. Oral vaccine  
25 compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, containing from about 10% to about 95% of the active ingredient, preferably about 25% to about 70%. An oral vaccine may be preferable to raise mucosal immunity (which plays an important role in protection against pathogens infecting the gastrointestinal tract)  
30 in combination with systemic immunity.

In addition, the vaccine can be formulated into a suppository. For suppositories, the vaccine composition will include traditional binders and carriers, such as polyalkaline glycols or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w), preferably about 1% to about 2%.

Protocols for administering to animals the vaccine composition(s) of the present invention are within the skill of the art in view of the present disclosure. Those skilled in the art will select a concentration of the vaccine composition in a dose effective to elicit antibody, cell-mediated and/or mucosal immune responses to the antigenic fragment. Within wide limits, the dosage is not believed to be critical. Typically, the vaccine composition is administered in a manner which will deliver between about 1 to about 1,000 micrograms of the subunit antigen in a convenient volume of vehicle, e.g., about 1-10 ml. Preferably, the dosage in a single immunization will deliver from about 1 to about 500 micrograms of subunit antigen, more preferably about 5-10 to about 100-200 micrograms (e.g., 5-200 micrograms).

The timing of administration may also be important. For example, a primary inoculation preferably may be followed by subsequent booster inoculations, for example, several weeks to several months after the initial immunization, if needed. To insure sustained high levels of protection against disease, it may be helpful to readminister booster immunizations at regular intervals, for example once every several years. Alternatively, an initial dose may be administered orally followed by later inoculations, or vice versa. Preferred vaccination protocols can be established through routine vaccination protocol experiments.

The dosage for all routes of administration of *in vivo* recombinant virus vaccine depends on various factors including, the size of patient, nature of infection against which protection is needed, carrier and the like and can readily be determined by those of skill in the art. By way of non-limiting example, a dosage of between approximately  $10^3$  pfu and  $10^8$  pfu can be used. As with *in*

*vitro* subunit vaccines, additional dosages can be given as determined by the clinical factors involved.

A problem that has beset the use of adenovirus vectors for immunization and gene therapy in humans is the rapid development of an immunological response (or indeed in some cases existing immunity) to human adenoviruses (HAVs). Recombinant PAV vectors are likely to be less immunogenic in humans and, for this and other reasons, will be useful either as a substitute for HAV vectors or in combination with HAV vectors. For example, an initial immunization with a HAV vector can be followed by booster immunizations using PAV vectors; alternatively, initial immunization with a recombinant PAV vector can be followed by booster immunizations with HAV and/or PAV vectors.

The presence of low levels of helper-independent vectors in the batches of helper-dependent human adenoviruses that are grown in complementing human cell lines has been reported. Fallaux *et al.* (1998) *supra*. This occurs as a result of recombination events between the viral DNA and the integrated adenoviral sequences present in the complementing cell line. Hehir *et al.* (1996) *J. Virol.* 70:8459-8467. This type of contamination constitutes a safety risk, which could result in the replication and spread of the virus. Complete elimination of helper-dependent adenoviruses in the batches of helper-dependent vectors can be achieved using two approaches. The first is by developing new helper cell lines and matched vectors that do not share any common sequences. Fallaux *et al.* (1998) *supra*. The second approach is to take advantage of possible cross-complementation between two distantly related adenoviruses such as HAV-5 and PAV-3. VIDO R1 cells contain the E1 coding sequences of HAV-5. Although there is no significant homology between the E1 regions of HAV-5 and PAV-3 at the nucleotide sequence level, the proteins produced from the region can complement each others' function(s). Thus, the problem of helper-independent vector generation by homologous recombination is eliminated when VIDO R1 cells are used for the propagation of recombinant PAV-3.

The invention also encompasses a method of treatment, according to which a therapeutically effective amount of a PAV vector, recombinant PAV, or host cell of the invention is administered to a mammalian subject requiring treatment. The finding that PAV-3 was effective in entering canine, sheep and bovine cells in which it does not replicate or replicates poorly is an important observation. *See Example 8, infra.* This may have implications in designing PAV-3 vectors for vaccination in these and other animal species.

### PAV Expression Systems

Recombinant PAV vectors can be used for regulated expression of foreign polypeptides encoded by heterologous nucleotide sequences. Standard conditions of cell culture, such as are known to those of skill in the art, will allow maximal expression of recombinant polypeptides. They can be used, in addition, for regulated expression of RNAs encoded by heterologous nucleotide sequences, as in, for example, antisense applications and expression of ribozymes.

When the heterologous sequences encode an antigenic polypeptide, PAV vectors comprising insertions of heterologous nucleotide sequences can be used to provide large quantities of antigen which are useful, in turn, for the preparation of antibodies. Methods for preparation of antibodies are well-known to those of skill in the art. Briefly, an animal (such as a rabbit) is given an initial subcutaneous injection of antigen plus Freund's complete adjuvant. One to two subsequent injections of antigen plus Freund's incomplete adjuvant are given at approximately 3 week intervals. Approximately 10 days after the final injection, serum is collected and tested for the presence of specific antibody by ELISA, Western Blot, immunoprecipitation, or any other immunological assay known to one of skill in the art.

Adenovirus E1 gene products transactivate many cellular genes; therefore, cell lines which constitutively express E1 proteins can express cellular polypeptides at a higher levels than other cell lines. The recombinant mammalian, particularly porcine, cell lines of the invention can be used to prepare and isolate

polypeptides, including those such as (a) proteins associated with adenovirus E1A proteins: *e.g.* p300, retinoblastoma (Rb) protein, cyclins, kinases and the like; (b) proteins associated with adenovirus E1B protein: *e.g.* p53 and the like; growth factors, such as epidermal growth factor (EGF), transforming growth factor (TGF) and the like; (d) receptors such as epidermal growth factor receptor (EGF-R), fibroblast growth factor receptor (FGF-R), tumor necrosis factor receptor (TNF-R), insulin-like growth factor receptor (IGF-R), major histocompatibility complex class I receptor and the like; (e) proteins encoded by proto-oncogenes such as protein kinases (tyrosine-specific protein kinases and protein kinases specific for serine or threonine), p21 proteins (guanine nucleotide-binding proteins with GTPase activity) and the like; (f) other cellular proteins such as actins, collagens, fibronectins, integrins, phosphoproteins, proteoglycans, histones and the like, and (g) proteins involved in regulation of transcription such as TATA-box-binding protein (TBP), TBP-associated factors (TAFs), Sp1 binding protein and the like.

15

### Gene Therapy

The invention also includes a method for providing gene therapy to a mammal, such as a porcine, human or other mammal in need thereof, to control a gene deficiency. In one embodiment, the method comprises administering to said mammal a live recombinant porcine adenovirus containing a heterologous nucleotide sequence encoding a non-defective form of said gene under conditions wherein the recombinant virus vector genome is incorporated into said mammalian genome or is maintained independently and extrachromosomally to provide expression of the required gene in the target organ or tissue. These kinds of techniques are currently being used by those of skill in the art to replace a defective gene or portion thereof. Examples of foreign genes, heterologous nucleotide sequences, or portions thereof that can be incorporated for use in gene therapy include, but are not limited to, cystic fibrosis transmembrane conductance regulator gene, human minidystrophin gene, alpha-1-antitrypsin gene and the like.

25



In particular, the practice of the present invention in regard to gene therapy in humans is intended for the prevention or treatment of diseases including, but not limited to, genetic diseases (for example, hemophilia, thalassemias, emphysema, Gaucher's disease, cystic fibrosis, Duchenne muscular dystrophy, 5 Duchenne's or Becker's myopathy, *etc.*), cancers, viral diseases (for example, AIDS, herpesvirus infection, cytomegalovirus infection and papillomavirus infection) and the like. For the purposes of the present invention, the vectors, cells and viral particles prepared by the methods of the invention may be introduced into a subject either *ex vivo*, (*i.e.*, in a cell or cells removed from the 10 patient) or directly *in vivo* into the body to be treated. Preferably, the host cell is a human cell and, more preferably, is a lung, fibroblast, muscle, liver or lymphocytic cell or a cell of the hematopoietic lineage.

#### Diagnostic applications

15 The PAV genome, or any subregion of the PAV genome, is suitable for use as a nucleic acid probe, to test for the presence of PAV nucleic acid in a subject or a biological sample. The presence of viral nucleic acids can be detected by techniques known to one of skill in the art including, but not limited to, hybridization assays, polymerase chain reaction, and other types of amplification 20 reactions. Suitable labels and hybridization techniques are well-known to those of skill in the art. See, for example, Kessler (ed.), *Nonradioactive Labeling and Detection of Biomolecules*, Springer-Verlag, Berlin, 1992; Kricka (ed.) *Nonisotopic DNA Probe Techniques*, Academic Press, San Diego, 1992; Howard (ed.) *Methods in Nonradioactive Detection*, Appleton & Lange, Norwalk, 1993; 25 Ausubel *et al.*, *supra*; and Sambrook *et al.*, *supra*. Diagnostic kits comprising the nucleotide sequences of the invention can also contain reagents for cell disruption and nucleic acid purification, as well as buffers and solvents for the formation, selection and detection of hybrids.

Regions of the PAV genome can be inserted into any expression vector 30 known in the art and expressed to provide, for example, vaccine formulations,

protein for immunization, *etc.* The amino acid sequence of any PAV protein can be determined by one of skill in the art from the nucleotide sequences disclosed herein. PAV proteins can be used for diagnostic purposes, for example, to detect the presence of PAV antigens. Methods for detection of proteins are well-known to those of skill in the art and include, but are not limited to, various types of direct and competitive immunoassays, ELISA, Western blotting, enzymatic assay, immunohistochemistry, *etc.* See, for example, Harlow & Lane (eds.): Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York, 1988. Diagnostic kits comprising PAV polypeptides or amino acid sequences can also comprise reagents for protein isolation and for the formation, isolation, purification and/or detection of immune complexes.

## EXAMPLES

### **METHODS**

#### **15 Virus and viral DNA.**

The 6618 strain of PAV-3 was propagated in the swine testis (ST) cell line and in E1-transformed porcine retinal cells (VIDO R1, see below). Porcine embryonic retinal cells were obtained from the eyeballs of piglets delivered by caesarian section two weeks before the parturition date. Uninfected cells were grown in MEM supplemented with 10% fetal bovine serum (FBS). MEM with 2% FBS was used for maintenance of infected cells. Viral DNA was extracted either from infected cell monolayers by the method of Hirt (1967) *J. Mol. Biol.* 26:365-369, or from purified virions as described by Graham *et al.* (1991) in "Methods in Molecular Biology" Vol. 7, Gene transfer and expression protocols, ed. E.J. Murray, Humana Press, Clifton, NJ, pp. 109-128.

#### **Plasmids and genomic DNA sequencing.**

Selected restriction enzyme fragments of PAV-3 DNA were cloned into pGEM-3Z and pGEM-7Zf(+) plasmids (Promega). Nucleotide sequences were determined on both strands of the genome by the dideoxy chain-termination

method using Sequenase<sup>®</sup> enzyme (U.S. Biochemicals) and the dye-terminator method with an Applied Biosystems (Foster City, CA) DNA sequencer.

#### **cDNA library.**

5        A cDNA library was generated from polyadenylated RNA extracted from PAV-3 infected ST cells at 12 h and 24 h post infection. Double stranded cDNAs were made with reagents from Stratagene and cloned into Lambda ZAP vector. Plaques which hybridized to specific restriction enzyme fragments of PAV-3 DNA were plaque purified twice. Plasmids containing cDNAs were excised from  
10      the Lambda ZAP vector according to the manufacturer's protocol. The resulting plasmid clones were characterized by restriction endonuclease analysis and by sequencing of both ends of the cDNA insert with T3- and T7-specific primers. Selected clones were sequenced with internal primers. cDNA sequences were aligned with genomic sequences to determine the transcription map.

15

#### **Viral transcript mapping by nuclease protection**

Transcript mapping was conducted according to the method of Berk *et al.* (1977) *Cell* 12:721-732.

#### **20        Example 1: Development of an E1-complementing helper cell line (VIDO R1)**

Primary cultures of porcine embryonic retina cells were transfected with 10 µg of plasmid pTG 4671 (Transgene, Strasbourg, France) by the calcium phosphate technique. The pTG 4671 plasmid contains the entire E1A and E1B  
25      sequences (nts 505-4034) of HAV-5, along with the puromycin acetyltransferase gene as a selectable marker. In this plasmid, the E1 region is under the control of the constitutive promoter from the mouse phosphoglycerate kinase gene, and the puromycin acetyltransferase gene is controlled by the constitutive SV40 early promoter. Transformed cells were selected by three passages in medium  
30      containing 7 µg/ml puromycin, identified based on change in their morphology

from single foci (*i.e.*, loss of contact inhibition), and subjected to single cell cloning. The established cell line was first tested for its ability to support the growth of E1 deletion mutants of HAV-5. Subsequently the cell line was further investigated for the presence of E1 sequences in the genome by PCR, expression of the E1A and E1B proteins by Western blot, and doubling time under cell culture conditions. E1 sequences were detected, and production of E1A and E1B proteins was demonstrated by immunoprecipitation (Figure 3). Doubling time was shorter, when compared to that of the parent cell line. Example 3, *infra*, shows that this cell line is capable of complementing a PAV E1A deletion mutant.

10 To assess the stability of E1 expression, VIDO R1 cells were cultured through more than 50 passages (split 1:3 twice weekly) and tested for their ability to support the replication of E1-deleted HAV-5. Expression of the E1A and E1B proteins at regular intervals was also monitored by Western blot. The results indicated that the VIDO R1 line retained the ability to support the growth of  
15 E1-deleted virus and expressed similar levels of E1 proteins during more than 50 passages in culture. Therefore, VIDO R1 can be considered to be an established cell line.

#### **Example 2: Construction of a full-length infectious clone of PAV-3.**

20 A plasmid clone containing a full-length copy of the PAV-3 genome (pPAV-200) was generated by first constructing a plasmid containing left- and right-end sequences of PAV-3, with the PAV-3 sequences bordered by *PacI* sites and separated by a *PstI* restriction site (pPAV-100), then allowing recombination between *PstI*-digested pPAV-100 and an intact PAV-3 genome. Left- and right-  
25 end sequences for insertion into pPAV-100 were produced by PCR amplification, as follows.

The plasmid p3SB (Reddy *et al.*, 1993, *Intervirology* 36:161-168), containing the left end of PAV-3 genome (position 1-8870) was used for amplification of the first 433 bp of the PAV-3 genome by PCR. Amplification  
30 primers were oligonucleotides 1

(5'-GCGGATCCTTAATTAAACATCATCAATAATATACCGCACACTTTT-3')

(SEQ ID NO.: 2) and 2

(5'-CACCTGCAGATACACCCACACACGTCATCTCG-3') (SEQ ID NO.:

3). In the sequences shown here, adenoviral sequences are shown in bold and  
 5 engineered restriction enzyme sites are italicized.

For amplification of sequences at the right end of the PAV-3 genome, the  
 plasmid p3SA (Reddy *et al.*, 1993, *supra*) was used. This plasmid was used as  
 template in PCR for amplification of the terminal 573 bp of the genome using  
 oligonucleotide 1 (above) and oligonucleotide 3

10 (5'-CACCTGCAGCCTCCTGAGTGTGAAGAGTGTCC-3') (SEQ ID NO.:

4). The primers were designed based on the nucleotide sequence information  
 described elsewhere (Reddy *et al.*, 1995c, *supra*; and Reddy *et al.*, 1997, *supra*).

For construction of pPAV-100, the PCR product obtained with  
 oligonucleotides 1 and 2 was digested with *Bam*HI and *Pst*I restriction enzymes  
 15 and the PCR product obtained using primers 1 and 3 was digested with *Pst*I and  
*Pac*I enzymes. Modified bacterial plasmid pPolyIIsn14 was digested with *Bam*HI  
 and *Pac*I enzymes. This plasmid was used based on its suitability for homologous  
 recombination in *E. coli*. The two PCR products described above were cloned  
 into pPolyIIsn14 by three way ligation to generate the plasmid pPAV-100 which  
 20 carries both termini of PAV-3, separated by a *Pst*I site and bordered by *Pac*I  
 restriction enzyme sites.

Plasmid pPAV-200, which contains a full length PAV-3 genome, was  
 generated by co-transformation of *E. coli* BJ 5183 *recBC sbcBC* (Hanahan, 1983,  
*J. Mol. Biol.* **166**:557-580) with *Pst*I-linearized pPAV-100 and the genomic DNA  
 25 of PAV-3. Extensive restriction enzyme analysis of pPAV-200 indicated that it  
 had the structure expected of a full-length PAV-3 insert, and that no unexpected  
 rearrangements had occurred during recombination in *E. coli*.

The infectivity of pPAV-200 was demonstrated by lipofectin transfection  
 (Life Technologies, Gaithersburg, MD) of ST cells following *Pac*I enzyme  
 30 digestion of the plasmid to release the viral genome from the plasmid. Viral

plaques were evident 7 days following transfection, and titers were equivalent to, or higher than, those obtained after infection with wild-type PAV. The plaques were amplified and the viral DNA was extracted and analyzed by restriction enzyme digestion. The viral DNA obtained by cleavage of pPAV-200 with *PacI* contained an extra 3 bases at each end; but these extra bases did not substantially reduce the infectivity of the PAV genome excised from pPAV-200. In addition, the bacterial-derived genomes lacked the 55-kDa terminal protein that is covalently linked to the 5' ends of adenoviral DNAs and which enhances infectivity of viral DNA.

### Example 3: Generation of E1 deletion mutants of PAV-3.

A plasmid (pPAV-101) containing the left (nucleotides 1-2,130) and the right (nucleotides 32,660-34,094) terminal *NcoI* fragments of the PAV-3 genome was constructed by digesting pPAV-200 with the enzyme *NcoI* (which has no recognition sites in the vector backbone, but many sites in the PAV insert), gel-purifying the appropriate fragment and self-ligating the ends. *See* Figure 4. The E1A sequences of pPAV-101, between nucleotides 407 and 1270 (PAV genome numbering), were deleted by digestion of pPAV-101 with *NotI* (recognition site at nucleotide 407) and *AseI* (recognition site at 1270), generation of blunt ends, and insertion of a double-stranded oligonucleotide encoding a *XbaI* restriction site to create a plasmid, pPAV-102, containing PAV left- and right-end sequences, separated by a *NcoI* site, with a deletion of the E1A region and a *XbaI* site at the site of the deletion. *See* Figure 5. Plasmid pPAV-201, containing a full-length PAV-3 genome minus E1A sequences, was created by co-transformation of *E. coli* BJ 5183 with *NcoI* linearized pPAV-102 and genomic PAV-3 DNA. The resulting construct, when transfected into VIDO R1 cells following digestion with *PacI* restriction enzyme, produced a virus that had a deletion in the E1 region. In similar fashion, construction of a virus with deletions in E1 and E3 was accomplished by transformation of BJ 5183 cells with *NcoI* linearized pPAV-102 and genomic PAV-3 DNA containing an E3 deletion. These

EIA deletion mutants did not grow on either ST (swine testis) cells or fetal porcine retina cells and could only be grown in the VIDO R1 cell line.

**Example 4: Generation of E3 inserts and deletion mutants.**

5 To systematically examine the extent of the E3 region that could be deleted, a E3 transfer vector was constructed. The vector (pPAV-301) contained a PAV-3 segment from nucleotides 26,716 to 31,064 with a green fluorescent protein (GFP) gene inserted into the *Sna*BI site (located at nucleotide 28,702) in the same orientation as E3. The GFP gene was obtained from the plasmid pGreen  
10 Lantern-1™ (Life Technologies), by *Not*I digestion followed by purification of a 732-nucleotide fragment. Similarly, another construct was made with GFP cloned into the *Sac*I site located at nucleotide 27,789. *Kpn*I-*Bam*HI fragments encompassing the modified E3 regions were then isolated from these E3 transfer vectors and recombined in *E. coli* with pPAV-200 that had been linearized at  
15 nucleotide position 28,702 by *Sna*BI digestion. Virus were obtained with a construct that had the GFP gene cloned into the *Sna*BI site.

To delete the non-essential portion of E3 from the transfer vector, a PCR approach was used. In this approach, the region of the PAV genome between nucleotides 27,402 and 28,112 was amplified using the following primers:

20 5'-GACTGACGCCGGCATGCAAT-3' SEQ ID NO: 5

5'-CGGATCCTGACGCTACGAGCGGTTGTA-3' SEQ ID NO: 6

In a second PCR reaction, the portion of the PAV genome between nucleotides 28,709 and 29,859 was amplified using the following two primers:

5'-CGGATCCATACGTACAGATGAAGTAGC-3' SEQ ID NO: 7

25 5'- TCTGACTGAAGCCGACCTGC-3' SEQ ID NO: 8

In the oligonucleotides designated SEQ ID NO: 6 and SEQ ID NO: 7, a *Bam*HI recognition sequence is indicated by underlining. The template for amplification was a *Kpn*I-*Bam*HI fragment encompassing nucleotides 26,716-31,063 of the PAV genome, inserted into the plasmid pGEM3Z (Promega), and  
30 *Pfu* polymerase (Stratagene) was used for amplification. The first PCR product

(product of amplification with SEQ ID NO: 5 and SEQ ID NO: 6) was digested with *Bam*HI and gel-purified. The second PCR product (product of amplification with SEQ ID NO: 7 and SEQ ID NO: 8) was digested with *Bam*HI and *Spe*I and gel-purified. They were inserted into *Sma*I/*Spe*I-digested pBlueScript II SK(+) (Stratagene) in a three-way ligation reaction to generate pPAV-300. See Figure 6. pPAV-300 contains the portion of the PAV-3 genome extending from nucleotides 27,402 to 29,859, with 594 base pairs (bp) between nucleotides 28,113 and 28,707 deleted from the E3 region. A virus with such a deletion was constructed as follows. A *Sph*I-*Spe*I fragment from pPAV-300, containing part of the pVIII gene, a deleted E3 region, and part of the fiber gene was isolated (see Figure 6). This fragment was co-transfected, with *Sna*BI-digested pPAV-200 (which contains a full-length PAV-3 genome) into *E. coli*. Homologous recombination generated a plasmid, pFPAV-300, containing a full-length PAV genome with a deletion in the E3 region. pFPAV-300 was digested with *Pac*I and transfected into VIDO R1 cells (Example 1) to generate recombinant virus with a deletion in the E3 region of the genome.

**Example 5: Construction of a PAV recombinant with an insertion of the PRV gp50 gene in the PAV E3 region and expression of the inserted gene**

To construct a recombinant PAV expressing pseudorabies virus (PRV) gp50, the PRV gp50 gene was inserted at the *Sna*BI site of pPAV-300 to create plasmid pPAV-300-gp50. A *Sph*I-*Spe*I fragment from pPAV-300-gp50, containing part of the pVII gene, a deleted E3 region with the PRV gp50 gene inserted, and part of the fiber gene, was purified and co-transfected, along with *Sna*BI-digested pFPAV-300 (E3-deleted) into *E. coli*. In the bacterial cell, homologous recombination generated pFPAV-300-gp50, a plasmid containing a PAV genome with the PRV gp50 gene replacing a deleted E3 region. Recombinant virus particles were obtained as described in Example 4.

Expression of the inserted PRV gp50 was tested after infection of VIDO R1 cells with the recombinant virus, by <sup>35</sup>S labeling of infected cells (continuous



label), followed by immunoprecipitation with an anti-gp50 monoclonal antibody and gel electrophoresis of the immunoprecipitate. Figure 7 shows that large amounts of gp50 are present by 12 hours after infection, and expression of gp50 persists up to 24 hours after infection.

5

**Example 6: Expression of the Chloramphenicol acetyltransferase gene from a region that lies between the promoter of the E4 region and the right ITR.**

The right terminal fragment of the PAV genome (encompassing  
10 nucleotides 31,054-34,094) was obtained by *Xho*I digestion of pPAV-200 and cloned between the *Xho*I and *Not*I sites of pPolyIIsn14. A Chloramphenicol acetyltransferase (CAT) gene expression cassette, in which the CAT gene was flanked by the SV40 early promoter and the SV40 polyadenylation signal, was inserted, in both orientations, into a unique *Hpa*I site located between the E4  
15 region promoter and the right ITR, to generate plasmids pPAV-400A and pPAV-400B. The modified terminal fragments were transferred into a plasmid containing a full-length PAV-3 genome by homologous recombination in *E coli* between the isolated terminal fragments and *Hpa*I-digested pPAV-200. Recombinant viruses expressing CAT were obtained following transfection of  
20 VIDO R1 cells with the plasmids. PAV-CAT2 contained the CAT gene cassette in a leftward transcriptional orientation (*i.e.*, the same orientation as E4 region transcription), while, in PAV-CAT6, the CAT gene cassette was in the rightward transcriptional orientation.

These recombinant viruses were tested for expression of CAT, after  
25 infection of VIDO R1 cells, using a CAT Enzyme Assay System from Promega, following the instructions provided by the supplier. *See*, Cullen (1987) *Meth. Enzymology* 43:737; and Gorman *et al.*, (1982) *Mol. Cell. Biol.* 2:1044. The results are shown in Table 3.

30

**Table 3: CAT activity expressed by recombinant PAV viruses**

Sample	<sup>3</sup> H cpm
Mock-infected	458
CAT positive control*	199,962
PAV-CAT2	153,444
PAV-CAT6	63,386

\* - the positive control sample contained 0.1 Units of purified CAT.

These results show that recombinant PAV viruses, containing an inserted  
5 gene, are viable and are capable of expressing the inserted gene.

**Example 7: Construction of replication defective PAV-3 expressing  
GFP**

A 2.3 kb fragment containing the CMV immediate early promoter, the  
10 green fluorescent protein (GFP) gene and the bovine growth hormone poly(A)  
signal was isolated by digesting pQBI 25 (Quantum Biotechnology) with *Bgl*II  
and *Dra*III followed by filling the ends with T4 DNA polymerase. This fragment  
was inserted into the *Srf*I site of pPAV-102 in both orientations to generate  
pPAV-102GFP (Figure 8). This plasmid, digested with *Pac*I and *Sma*I enzymes,  
15 and the fragment containing part of the E1 sequence and the GFP gene was gel  
purified. This fragment and the *Srf*I digested pFPAV-201 were used to transform  
*E. coli* BJ 5183 to generate the full-length clone containing GFP in the E1 region  
(pFPAV-201-GFP) by homologous recombination. The recombinant virus,  
PAV3delE1E3.GFP was generated following transfection of VIDO R1 cells with  
20 *Pac*I restricted pFPAV-201-GFP that had the GFP transcription unit in the  
opposite orientation to the E1. A similar virus with the GFP in the same  
orientation as E1 could not be rescued from transfected cells. Presence of the  
GFP gene in the viral genome was confirmed by restriction enzyme analysis. The  
recombinant virus replicated in VIDO R1 cells two logs less efficiently than the  
25 wild type PAV-3.

**Example 8: Virus entry and replication of PAV-3 in human and animal cells.**

To initially characterize the host species restriction of PAV *in vitro*, monolayers of 11 cell types from 6 different mammalian species were infected with wild type PAV-3 or PAV3del.E1E3.GFP. ST, VIDO R1 (porcine), 293, A549 (human), MDBK, VIDO R2 (bovine), C3HA (mouse), COS, VERO (monkey), sheep skin fibroblasts or cotton rat lung cells were incubated with 1 pfu/cell of wild type PAV-3 or helper-dependent PAV-3 expressing GFP. The cells infected with wild type PAV were harvested at 2 h and 3 days post-infection, subjected to two cycles of freeze-thaw, and virus titers were determined on VIDO R1 cells. Cells that were infected with the recombinant virus expressing GFP were observed with the aid of a fluorescent microscope for green fluorescence.

A ten-fold increase in virus titers in Vero and COS cells, and a hundred-fold increase in cotton rat lung fibroblasts and VIDO R2 cells, was noticed. No increase in the virus titers was observed with 293, A549, MDBK, sheep skin fibroblasts, dog kidney and C3HA cells. All of these cell types showed bright green fluorescence when infected with PAV3delE1E3.GFP except human cells, which showed a weak fluorescence. In addition, low levels of GFP expression were achieved in human cells with recombinant PAV-3. These observations suggest that virus entry into human cells is limited and/or the human cells are non-permissive for the replication of the virus. These results also demonstrated that GFP was expressed by the PAV-3 vector in cells which are semi-permissive (VERO, COS, Cotton rat lung fibroblasts and VIDO R2), or non-permissive (Sheep skin fibroblasts, MDBK and human cells) for virus replication.

25

**Example 9: Insertions in the regions of the PAV-3 genome defined by nucleotides 145-13,555; 15,284-19,035; 22,677-24,055; 26,573-27,088; and 31,149-34,094**

Insertions are made by art-recognized techniques including, but not limited to, restriction digestion, nuclease digestion, ligation, kinase and phosphatase

30

treatment, DNA polymerase treatment, reverse transcriptase treatment, and chemical oligonucleotide synthesis. Heterologous nucleic acid sequences of interest are cloned into plasmid vectors containing portions of the PAV genome (which may or may not contain deletions of PAV sequences) such that the foreign  
5 sequences are flanked by sequences having substantial homology to a region of the PAV genome into which insertion is to be directed. Substantial homology refers to homology sufficient to support homologous recombination. These constructs are then introduced into host cells that are co-transfected with PAV-3 DNA or a cloned PAV genome. During infection, homologous recombination  
10 between these constructs and PAV genomes will occur to generate recombinant PAV genome-containing plasmids. Recombinant virus are obtained by transfecting the recombinant PAV genome-containing plasmids into a suitable mammalian host cell line. If the insertion occurs in an essential region of the PAV genome, the recombinant PAV virus is propagated in a helper cell line  
15 which supplies the viral function that was lost due to the insertion.

### Deposit of Biological Materials

The following materials were deposited and are maintained with the Veterinary Infectious Disease Organization (VIDO), Saskatoon, Saskatchewan, Canada.

- 5           The nucleotide sequences of the deposited materials are incorporated by reference herein, as well as the sequences of the polypeptides encoded thereby. In the event of any discrepancy between a sequence expressly disclosed herein and a deposited sequence, the deposited sequence is controlling.

10	<u>Material</u>	<u>Internal Accession No.</u>	<u>Deposit Date</u>
	<b>Recombinant plasmids</b>		
	pPAV-101	VIDO 98-1	April 10, 1998
	pPAV-102	VIDO 98-2	April 10, 1998
	pPAV-200	VIDO 98-3	April 10, 1998
15	pPAV-300	VIDO 98-4	April 10, 1998
	pPAV-400A	VIDO 98-5	April 10, 1998
	pPAV-400B	VIDO 98-6	April 10, 1998
	<b>Recombinant cell lines</b>		
20	Porcine embryonic retinal cells transformed with HAV-5 E1 sequences:		
	VIDO R1	VIDOO 98C-1	April 10 1998

- 25           While the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent to those skilled in the art that various changes and modifications may be practiced without departing from the spirit of the invention. Therefore the foregoing descriptions and examples should not be construed as limiting the scope of the invention.

30

CLAIMS

What is claimed is:

1. A nucleotide sequence that is substantially homologous to the genome of porcine adenovirus type 3 (PAV-3), or a fragment thereof.
- 5        2. A nucleotide sequence that is substantially homologous to a portion of the genome of porcine adenovirus type 3, said portion selected from the group consisting of nucleotides 145-13,555; 15,284-19,035; 22,677-24,055; 26,5732-27,088; and 31,149-34,094 of the PAV-3 genome, or a fragment thereof.
- 10       3. A nucleotide sequence that is substantially homologous to a PAV-3 gene or fragment thereof, wherein the gene is selected from the group consisting of E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K.
- 15       4. A nucleotide sequence according to claim 3 comprising a PAV-3 coding sequence from a region of the PAV-3 genome selected from the group consisting of E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K, and fragments thereof.
5. A nucleotide sequence that is substantially homologous to the nucleotide sequence of claim 4.
- 20       6. A nucleotide sequence comprising an intergenic region of the PAV-3 genome.
7. A nucleotide sequence that is substantially homologous to the nucleotide sequence of claim 6.
8. A nucleotide sequence encoding a PAV-3 regulatory sequence.
- 25       9. The nucleotide sequence of claim 8, wherein the regulatory sequence is selected from the group consisting of a transcriptional regulatory sequence, a promoter, an enhancer, an upstream regulatory domain, a splicing signal, a polyadenylation signal, a transcriptional termination sequence, a translational regulatory sequence, a ribosome binding site and a translational termination sequence.
- 30       10. A vector comprising the nucleotide sequence of claim 1.

11. A vector comprising the nucleotide sequence of claim 2.
12. A vector comprising the nucleotide sequence of claim 3.
13. A vector comprising the nucleotide sequence of claim 8.
14. A defective recombinant PAV vector, comprising ITR sequences,  
5 packaging sequences, and at least one heterologous nucleotide sequence, wherein  
the PAV vector lacks E1 function.
15. A defective recombinant PAV vector according to claim 14,  
wherein the vector is deleted in the E1 region.
16. A defective recombinant PAV vector according to claim 15,  
10 wherein the vector is additionally deleted in a region selected from the group  
consisting of E2, E3, E4, L1, L2, L3, L4, L5, L6 and the region between E4 and  
the right end of the genome.
17. A defective recombinant PAV vector according to claim 16,  
wherein the vector is additionally deleted in more than one region selected from  
15 the group consisting of E2, E3, E4, L1, L2, L3, L4, L5, L6 and the region between  
E4 and the right end of the genome.
18. A defective recombinant PAV vector according to claim 14,  
wherein the heterologous nucleotide sequence encodes a therapeutic polypeptide.
19. A defective recombinant PAV vector according to claim 18,  
20 wherein the therapeutic polypeptide is selected from the group consisting of  
coagulation factors, growth hormones, cytokines, lymphokines, tumor-  
suppressing polypeptides, cell receptors, ligands for cell receptors, protease  
inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis  
transmembrane conductance regulator (CFTR) and immunogenic polypeptides.
20. A recombinant PAV vector comprising a PAV genome and at least  
25 one heterologous nucleotide sequence, wherein the heterologous sequence is  
inserted in a region selected from the group consisting of the E1 region, the E3  
region, the E4 region and the region between E4 and the right end of the genome.
21. The recombinant PAV vector of claim 20, comprising two or more  
30 heterologous nucleotide sequences.

22. The recombinant PAV vector of claim 21, wherein the two or more heterologous nucleotide sequences are inserted at different sites.

23. The recombinant PAV vector of claim 20, wherein the heterologous nucleotide sequence encodes a therapeutic polypeptide.

5        24. The recombinant PAV vector of claim 23, wherein the therapeutic polypeptide is selected from the group consisting of coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator  
10 (CFTR) and immunogenic polypeptides.

25. A method for obtaining a recombinant PAV comprising a heterologous nucleotide sequence inserted into an insertion site, the method comprising the steps of:

- 15                    (a) providing a PAV genome;
- (b) providing a heterologous nucleotide sequence;
- (c) linking the heterologous nucleotide sequence to guide sequences, the guide sequences being substantially homologous to PAV sequences flanking the insertion site, such that guide sequences are present at both ends of the heterologous sequence;
- 20                    (d) introducing the construct from step (c) into a cell together with the PAV genome;
- (e) allowing homologous recombination to occur between the two sequences from step (d) to generate a recombinant PAV genome;
- (f) purifying the recombinant PAV genome;
- 25                    (g) inserting the recombinant PAV genome into a mammalian cell;
- (h) culturing the mammalian cell under conditions wherein the recombinant PAV genome is replicated and packaged; and
- (i) collecting the recombinant PAV from the cell or the culture  
30 medium.



26. The method according to claim 25 wherein the insertion site is located in a region of the PAV genome selected from the group consisting of the E1 region, the E3 region, the E4 region and the region between E4 and the right end of the genome.

5        27. The method according to claim 26 wherein the PAV genome is deleted in a region selected from the group consisting of the E1 region, the E3 region, the E4 region and the region between E4 and the right end of the genome.

28. A method for producing a recombinant PAV that comprises introducing the PAV vector of claim 14 into an appropriate helper cell line and  
10 recovering virus from the infected cells.

29. The method according to claim 28 wherein the helper cell line provides E1 function.

30. A host cell comprising the vector of claim 10.

31. A host cell comprising the vector of claim 11.

15        32. A host cell comprising the vector of claim 12.

33. A host cell comprising the vector of claim 13.

34. A host cell comprising the vector of claim 14.

35. A host cell comprising the vector of claim 20.

36. A recombinant porcine cell line comprising an adenovirus E1 gene  
20 region, said recombinant cell line thereby providing E1 function and allowing replication of a PAV vector having a deletion in the E1 region.

37. A method for producing a recombinant PAV, the method comprising:

(a) introducing, into the cell line of claim 36, a vector  
25 comprising ITR sequences, PAV packaging sequences, and at least one heterologous nucleotide sequence, wherein the vector is deleted in the E1 region and the vector is additionally deleted in one or more regions selected from the group consisting of the E2 region, the E3 region, the E4 region, and the region between E4 and the right end of the genome;

(b) culturing the cell line under conditions whereby virus replication and packaging occurs; and

(c) recovering virus from the infected cells.

38. A method for producing a recombinant PAV polypeptide, the  
5 method comprising:

(a) providing a population of host cells according to claim 31;

and

(b) growing said population of cells under conditions whereby  
the PAV polypeptide is expressed.

10 39. A method for producing a recombinant PAV polypeptide, the  
method comprising:

(a) providing a population of host cells according to claim 32;

and

(b) growing said population of cells under conditions whereby  
15 the PAV polypeptide is expressed.

40. A method for producing a recombinant polypeptide, the method  
comprising:

(a) providing a population of host cells according to claim 33,

and

20 (b) growing said population of cells under conditions whereby  
the polypeptide is expressed.

41. A method for producing a recombinant polypeptide, the method  
comprising:

(a) providing a population of host cells according to claim 34,

25 and

(b) growing said population of cells under conditions whereby  
the polypeptide is expressed.

42. A method for producing a recombinant polypeptide, the method comprising:

(a) providing a population of host cells according to claim 35,

and

5 (b) growing said population of cells under conditions whereby the polypeptide is expressed.

43. A PAV polypeptide encoded by the nucleotide sequence of claim 2.

44. A PAV polypeptide encoded by the nucleotide sequence of  
10 claim 3.

45. A PAV polypeptide produced by the method of claim 38.

46. A PAV polypeptide produced by the method of claim 39.

47. A recombinant polypeptide produced by the method of claim 40.

48. A recombinant polypeptide produced by the method of claim 41.

15 49. A recombinant polypeptide produced by the method of claim 42.

50. A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

(a) providing a biological sample; and

(b) subjecting the sample to hybridization using a labeled probe  
20 comprising at least ten continuous nucleotides of the sequence according to claim 1.

51. A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

(a) providing a biological sample; and

25 (b) subjecting the sample to hybridization using a labeled probe comprising at least ten continuous nucleotides of the sequence according to claim 3.

52. A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to a polymerase chain reaction using primers comprising at least ten continuous nucleotides of the sequence according to claim 1.

53. A method for detecting the presence of PAV nucleotide sequences in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to a polymerase chain reaction using primers comprising at least ten continuous nucleotides of the sequence according to claim 3.

54. A kit for detecting the presence of PAV nucleotide sequences in a biological sample comprising one or more probes, said probes comprising at least ten continuous nucleotides of the sequence according to claim 1.

55. A kit for detecting the presence of PAV nucleotide sequences in a biological sample comprising one or more probes, said probes comprising at least ten continuous nucleotides of the sequence according to claim 3.

56. A method for detecting the presence of PAV antibodies in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the polypeptide of claim 43.

57. A method for detecting the presence of PAV antibodies in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the polypeptide of claim 44.

58. A method for detecting the presence of PAV antibodies in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the

5 polypeptide of claim 45.

59. A method for detecting the presence of PAV antibodies in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the

10 polypeptide of claim 46.

60. A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 43.

61. A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 44.

15 62. A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 45.

63. A kit for detecting the presence of PAV antibodies in a biological sample comprising one or more polypeptides according to claim 46.

64. A method for obtaining antibodies to PAV, the method comprising:

- 20 (a) providing a PAV polypeptide according to claim 43;
- (b) immunizing a mammalian host with the polypeptide; and
- (c) collecting antibody from the immunized host.

65. A method for obtaining antibodies to PAV, the method comprising:

- 25 (a) providing a PAV polypeptide according to claim 44;
- (b) immunizing a mammalian host with the polypeptide; and
- (c) collecting antibody from the immunized host.

66. A method for obtaining antibodies to PAV, the method comprising:

- 30 (a) providing a PAV polypeptide according to claim 45;
- (b) immunizing a mammalian host with the polypeptide; and
- (c) collecting antibody from the immunized host.

67. A method for obtaining antibodies to PAV, the method comprising:
- (a) providing a PAV polypeptide according to claim 46;
  - (b) immunizing a mammalian host with the polypeptide; and
  - (c) collecting antibody from the immunized host.
- 5        68. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:
- (a) providing a biological sample; and
  - (b) subjecting the sample to immunoassay using an antibody according to claim 64.
- 10       69. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:
- (a) providing a biological sample; and
  - (b) subjecting the sample to immunoassay using an antibody according to claim 65.
- 15       70. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:
- (a) providing a biological sample; and
  - (b) subjecting the sample to immunoassay using an antibody according to claim 66.
- 20       71. A method for detecting the presence of a PAV antigen in a biological sample, the method comprising:
- (a) providing a biological sample; and
  - (b) subjecting the sample to immunoassay using an antibody according to claim 67.
- 25       72. A method for detecting the presence of an antigen in a biological sample comprising:
- (a) providing a biological sample; and
  - (b) subjecting the sample to immunoassay using the polypeptide of claim 47.

73. A method for detecting the presence of an antigen in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the

5 polypeptide of claim 48.

74. A method for detecting the presence of an antigen in a biological sample comprising:

- (a) providing a biological sample; and
- (b) subjecting the sample to immunoassay using the

10 polypeptide of claim 49.

75. A kit for detecting the presence of an antigen in a biological sample comprising one or more polypeptides according to claim 47.

76. A kit for detecting the presence of an antigen in a biological sample comprising one or more polypeptides according to claim 48.

15 77. A kit for detecting the presence of an antigen in a biological sample comprising one or more polypeptides according to claim 49.

78. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a nucleotide sequence according to claim 2.

20 79. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a nucleotide sequence according to claim 3.

80. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide  
25 according to claim 43.

81. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 44.

82. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 45.

5 83. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 46.

84. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 47.

10 85. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 48.

86. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a polypeptide according to claim 49.

15 87. A pharmaceutical composition comprising the defective recombinant PAV vector of claim 14.

88. A pharmaceutical composition capable of inducing an immune response in a mammalian subject, said composition comprising a defective recombinant PAV vector according to claim 87, wherein the vector encodes an immunogenic polypeptide.

89. A pharmaceutical composition comprising the vector of claim 10.

90. A pharmaceutical composition comprising the vector of claim 11.

91. A pharmaceutical composition comprising the vector of claim 12.

25 92. A pharmaceutical composition comprising the vector of claim 13.

93. A pharmaceutical composition comprising the vector of claim 20.

94. A pharmaceutical composition comprising a recombinant PAV obtained according to the method of claim 25.

95. A pharmaceutical composition comprising a recombinant PAV obtained according to the method of claim 37.



96. A pharmaceutical composition comprising the host cell of claim 30.
97. A pharmaceutical composition comprising the host cell of claim 31.
- 5 98. A pharmaceutical composition comprising the host cell of claim 33.
99. A method for eliciting an immune response in a mammalian host to protect against an infection comprising administering a pharmaceutical composition comprising a recombinant PAV vector capable of expressing a protective antigen.
- 10 100. A method of gene therapy in a mammalian host comprising administering to the host the vector of claim 11.
101. A method of gene therapy in a mammalian host comprising administering to the host the vector of claim 13.
- 15 102. A method of gene therapy in a mammalian host comprising administering to the host the defective recombinant PAV vector of claim 14.
103. A method of gene therapy in a mammalian host comprising administering to the host the recombinant PAV vector of claim 20.
104. A method of gene therapy in a mammalian host comprising administering to the host a recombinant PAV vector obtained according to the method of claim 25.
- 20 105. A method of gene therapy in a mammalian host comprising administering to the host a recombinant PAV obtained according to the method of claim 37.
- 25 106. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 31.
107. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 32.
108. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 33.
- 30

109. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 34.

110. A method of gene therapy in a mammalian subject comprising administering to the subject the host cell of claim 35.

5 111. An antibody that specifically binds the polypeptide of claim 43.

112. An antibody that specifically binds the polypeptide of claim 44.

113. An antibody that specifically binds the polypeptide of claim 45.

114. An antibody that specifically binds the polypeptide of claim 46.

10 115. A composition comprising a full-length genomic clone of a PAV genome.

116. The composition of claim 115 wherein the PAV genome is the genome of PAV-3.

117. A method for obtaining a full-length genomic clone of a PAV genome, the method comprising:

15 (a) providing two or more cloned segments of the PAV genome, wherein the cloned segments of the PAV genome, taken together, represent the entire PAV genome;

(b) introducing the two or more cloned segments of the PAV genome into a cell;

20 (c) allowing homologous recombination to occur within the cell between the two or more cloned segments of the PAV genome to generate a full-length PAV genome; and

(d) purifying the full-length PAV genome from the cell.

118. A full-length PAV genome produced by the method of claim 117.

1 / 14

CATCATCAATAATATACCGCACACTTTTATTGCCCTTTTGTGGCGTGGTGATTGGCGGAGAGGGT  
TGGGGGCGGCGGGCGGTGATTGGTGGAGAGGGGTGTGACGTAGCGTGGGAACGTGACGTGCGGTGG  
GAAAATGACGTGTGATGACGTCCCGTGGGAACGGGTCAAAGTCCAAGGGGAAGGGGTGGAGCCCTG  
GGGCGGTCTCCGCGGGGCGGGGCCGAGCGGCGGAAATCCCCGCACAGGTGGAGAGTACCGCGGA  
TTTTGTGCCCTCTGGACCGGACCTTCGCCCTCCGGTGTGGCACTTCGCGACACACGTCCGCGGCC  
CGGTATTCCCCACCTGACGACGGTGACACCACTCACCTGAGCGGGGTGTCCTTCGCGCTGAGAGGT  
CCGCGGCGGCGCGCCGAGATGACGTGTGTGGGTGTATTTTTTCCCTCAGTGTATATAGTCCGCGC  
AGCGCCCCGAGAGTCACTACTCTTGAGTCCGAAGGGAGTAGAGTTTTCTCTCAGCGGAACAGACCT  
CGACATGGCGAACAGACTTCACCTGGACTGGGACGGAAACCCCGAGGTGGTGCCGGTGCTGGAATG  
GGACCCGGTGGATGCGCGACCCCTCTCCGGGGGATGAGGGCTTCTGTGAGCCGTGCTGGGAGAG  
TCTGGTGCATGGACTGCCGACGAGTGCTGGACAGTGTGGACGAGGTGGAGGTGATTGTGACTGA  
GGGGGTGAGTCAGAGGACAGTGGTGGGAGTGCCGCTGGTGACTCAGGTGGCTCTCAGGGGGTCTT  
TGAGATGGACCCCCAGAAGAGGGGGACAGTAATGAGGAGGATATCAGCGCGGTGGCTCGCGAGGT  
GCTGTCTGAACGGCTGATGTGGTGTGAGGACCCACTTGCGCCACCCCTCCGTTTGTGTGGA  
CTGCCCCGAGGTACCTGGTGTGAACGCCGCTCTGTGATTACCATCGCTTCACTCCAAGGACCC  
CAATCTGAAGTGCAGTCTGTGCTACATGAGGATGCATGCCTTGTCTGTATGGTGAGTGTTTTTG  
GACATTTGTGGGATTATGTGGAAGGAAAGGAAAGTGCTTGTAAAGAAATCTCATGTGCTATTTCC  
CATTTTTTGTCTTTTTAGAAAGCTGTTTCTCCAGCACCTCACAGGTCCGGTTCGCCGGGACTTGGAG  
ACCTGCCAGGACGCAAGAGGAAGTACTGCTATGACTCATGCAGCGAACACCTTTGGACCTGTCTA  
TGAAGCGCCCCCGCGATTAATCATTAACTCAATAAACAGCATGTGATGATGACTGATTGTCTGTG  
TCTCTGCCTATATATACCCCTTGTGGTTTGCAGGGAAGGGATGTGGTGAAGTATTTCTCAGCA  
TCATCATCGCTCTGCTTTTTTCTACTGCAGGCTATTTCTTGCTAGCTCGCTGTCCCTTTTTCTTTT  
CTGTGGGCATGGACTATCAACTTCTGGCCAAGCTTACTAACGTGAACCTACCTTAGGAAGGTGATAG  
TACAGGGGTCTCAGAACTGCCCTTGGTGGAAAGAGTTTTTTCGGACAGGTTTATCAAGGTAGTAG  
CAGAGGCGAGGAGCAGTACGGGCAAGAGTTGATTGAGATTTTTGTGGAGGTGAGAGGGGCTTTG  
GTCCTGAGTTCTCTCGGGAAGGGGACTGTACGAAGAGGCCGTTCTGAAAGAGTTGGATTTACAGCA  
CCTTGGGACGCACCGTAGCTAGTGTGGCTCTGGTCTGCTTCATTTTTGAGAAGCTTCAGAAGCACA  
GCGGGTGGACTGACGAGGGTATTTAAGTCTTCTGGTGCCGCACTATGTTCCCTGCTGGAGGCGC  
GAATGATGGCGGAGCAGGTGCGGCAGGGGCTGTGCATCATCAGGATGCCGAGCGCGGAGCGGGAGA  
TGCTGTTGCCAGTGGGTCTCCGGCAGTGGCAGCGGGGCCGGGATGCGGGACCAGGTGGTGCCCA  
AGCGCCCCGCGGAGCAGGAAGAGGAGGAGGAGGACGAGGATGGGATGGAAGCGAGCGGGCGCAGGC  
TCGAAGGGCCGGATCTGGTTTAGATCGCCGCCGGCCCGGGGAGCGGTGGAGAGGGGAGCGGGGA  
GGAGGCGGGGGGGTCTTCCATGGTTAGCTATCAGCAGGTGCTTTCTGAGTATCTGGAGAGTCTCT  
GGAGATGCATGAGCGCTACAGCTTTGAGCAGATTAGGCCCTATATGCTTCAGCCGGGGGATGATCT  
GGGGGAGATGATAGCCAGCACGCCAAGGTGGAGTTGCAGCCGGGCACGGTGTACGAGCTGAGGCG  
CCCGATCACCATCCGCAGCATGTGTTACATCATCGGGAACGGGGCCAAGATCAAGATTCCGGGGAA  
TTACACGGAGTACATCAACATAGAGCCGCGTAACCACATGTGTTCCATTGCGGGCATGTGGTCCGT  
GACTATCACGGATGTGGTTTTTGATCGGGAGCTACCGGCCCGGGGTGCTGATTTTAGCCAACAC  
GCACTTCATCCTGCACGGCTGCAACTTCTGGGCTTTCTGGGCTCGGTAATAACGGCGAACGCCGG  
GGGGGTGGTGCGGGGATGCTACTTTTTCGCCTGCTACAAGGCGCTGGACCACCGGGGGCGGCTGTG  
GCTGACGGTGAACGAGAACACGTTTGAAAGTGTGTGTACGCGGTGGTCTCTGCGGGCGGTGCGAG  
GATCAAGTACAACCTCCCTGTCCACCTTCTGCTTCTGCACATGAGCTATACGGGCAAGATAGT  
GGGGAACAGCATCATGAGCCCTTACACGTTACGCGACGACCCCTACGTGGACCTGGTGTGCTGCCA  
GAGCGGGATGGTGATGCCCCGTGAGCAGGTGCACATCGCTCCCTCGTCTCGCCTGCCCTACCCTGA  
GTTCCGCAAGAATGTGCTCCTCCGACGACCATGTTTGTGGGCGGCCGCTGGGCAGCTTCAGCCC  
CAGCCGCTGCTCCTACAGCTACAGCTCCCTGGTGGTGGACGAGCAGTCTACCGGGGTCTGAGTGT  
GACCTGCTGCTTCGATCAGACCTGTGAGATGTACAAGCTGCTGCAGTGTACGGAGGCGGACGAGAT  
GGAGACGGATACCTCTCAGCAGTACGCCTGCCTGTGCGGGGACAATCACCCTGGCCGACGGTGGC  
GCAGATGAAAGTGACAGACGCGCTGCGGGCCCCCGGTCCCTGGTGAGCTGCAACTGGGGGGAGTT  
CAGCGATGACGATGACTGAGGATGAGTACCCCTCCCTCCTCTTGCAGGTACGTGGCCCCGCC  
AGTGGGATGGGCTTTGGATGGGGGAGGGGTGTTCCCTATAAAAGGGGATGGGGGTGGAGGATGC  
AGCCCCACGGGGAAGCTTGTGTGGAGGATGTCTCCGAGGTGAGATCCGACCTGCTTCATTTCA

**FIG. 1-1**

SUBSTITUTE SHEET (Rule 26)

2 / 14

GCTCGTCTTCCACGCTGGGCCGCGTGCCTCAGGGAGTGGCCGGGACGAATGTGAACGGCGGAGTG  
GTGGGCGCCCTGCCCAGAGCGGGGTGCTGGCCTACTCCCGCTTCGTTTCCAGCAGCAACAGCAGCAG  
CCGGGGACGGCGGCGACGGGGTCTGTGTTCCGGGCGGTGTTTCCATCGGTGGATCTGAGCGCGGAG  
GTGGGCATGATGCGGCAGGCGCTGGCGGAGCTGCGGCAGCAGCTGCAGGAGCTGCGGGAGGTGGTG  
GAGATACAGCTGCGGGCCACGGCCTCGGAGGCGGCCAGGAGGAAGAGGAGGAGGAGATTGTGGTG  
GACGAGGAGGTGGCGCCCGCGCTGGAGCGAACACCATGGAAGAGGAGGAGGATGAGATGGTCCTG  
ACGATGACTGTGGTGGGGGACCTGAGCCTGCTGGAGTGGAAGCCAGCCGCCACCACCACCACC  
CCGAGAGAGCACCCTGCGGTGCCCTGCTACTACCACTACCCCGAAGCGGCTCAGCTACGGCGCGAGC  
AAGAGGAGCGGTCCATGCGCGGAGGACAACCTGACGCGGACTGTGGGGGGAAGAAGGGGGAGGAGGA  
AAGAAGACCATGGAGACGGGTGTTTGTCTTTTCCAGCCCACTTTATTGAGAATAATAATAAAGC  
TTATGGATGTTTGAACGATAATAGCGTGTCCAGCGTTCTCTGTCTTGCAGGGTCTTGTGTATCTT  
CTCGAGGCACCGGTAGACCTGGTGTGGACGTTGAAATACATGGGCATGACTCCCTCGGCGGGGTG  
CAGGTAAAGCCACTGGAGGGCTGGGTGCGGGGGGAGGTGCAGTAGATGATCCAGTCATAGGCGTT  
CTGGTTGCGGTGGTGGTTGAAAATGTCCTTGAGGAGCAGGCTGATGGCGGTGGGCAGACCCTTGGT  
GTAGGCATTGATGAACCGGTTGACCTGGGCGGGCTGCATGAGGGGGGACATGATGTGGTACTTGGC  
CTGGATCTTGAGGTTGGAGATGTTGCCGCTCTGGTCGCGGCGGGGGTTCATGTTGTGGAGGACGAC  
GAGGACGGCGTAGCCGTTGCAGCGGGGAAGCGGGCGTGCAGCTTGAGGGGAAGGCGTGGAAGAA  
CTTGCGGACCCCTTGTGTCCGCCGAGGTCTCCATGCATCTGTCGAGGACGATGGCGATGGGTCC  
GCGGGCGGGCGGCGCGGGCGAAGACGTTGCGTGAGTCAGTGACATCATAGTTGTGCTCCTGCATGAG  
GTCTTGGTAGCTCATGCGGACAAAGTCTGGCATGAGGTTGGCGGTCTGGGGGATTAGGGTGTGGTC  
CGGACCGCTGCGGTAGTTGCCCTCGCAGATCTGGGTCTCCAGGCGACTACCTCCTGCGGGGGGAT  
CATGTCCACCTGCGGGGTGATGAAGAAAACAGTCTCCGGCGGGGGGAGAGGAGTTGGGAGGAGAT  
GAGGTTGCGGAGCAGCTGGGACTTGCCGGAGCCGTTGGGACCGTAGATGACAGCGATGACTGGCTG  
GACCTGGTAGTTGAGGGAGCGGCAGGTGCCAGCCGGGTGAGGAAGGGCATGCAGGCGTTGAGGGT  
GTCGCGCAGGTTGCGGTTCTCTTGACGAGGTCTGCAGGAGGTGTCGGCCTCCAGGGAGAGGAG  
GTGGGAGAGGGAGGCGAAGGCCTTGAGGGGCTTGAGGCCCTCGGCGTAGGGCATGTCTGCAGGGC  
CTGGTGGAGCACGCGCATGCGCTCCAGAGCTCGGTTACATGTCCACGGTATCGTCTCCAGCAG  
GTCTGGTTGTTTCTCGGGTTGGGGTTGCTGCGTGAGTACGGAACGAGGCGGTGGGCGTCGAGCGGG  
TGGAGGGTCCGGTCTTCCAGGGCCGGAGGGCCCGCTGAGGGTGGTCTCGGTGACGGTGAAGGGG  
GCGGTCTGGGGCTGCTCGGTGGCCAGGGTCTCTTGAGGCTGAGGCGGCTGGTGTGAAGGTGGCG  
CTTCCGAGCTGCGCGTCTGTTAGGTAGCACTGGCGGAGGAGGTATAGGAGAGGTGTTGGGTGGCA  
TGGCCCTTGCGCGCGGAGCTTGCCGGGGCCCGGTGCCCGCAAGCATCGCAAACGGTGTGCGCGAGG  
GCGTAGAGCTTGCGGCGGAGCAGGACCGTCTCGGAGCTGTGGGCGTCTGCGGCGAGCGCTCGCAC  
TGGGTCTCGCACTCGACCAGCCAGGTGAGCTGGGGGTTCTGGGGATCGAAGACGAGGGGGCCCCG  
TTCCGCTTGAGGCGGTGTTTACCTTTGGTCTCCATGAGCTCGCGTCCGGCGCGGGTGAGGAAGAGG  
CTGTGCGGTGTCCCGTAGACGAGCGCAGGGGCCGGTCCGGCATGGGGGTGCCGCGGTCTGCGCG  
TAGAGGATGAGGGCCCACTCGGAGATGAAGGCACGCGCCAGGCGAGGACGAAGCTGGCGACCTGC  
GAGGGGTAGCGGTGCTTGGGCACTAATGGCGAGGCGCTGCTCGAGCGTGTGGAGACAGAGGTCTCG  
TCGTCCGCGTCCAGGAAGTGGATTGGTCCGAGTGGTAGTCCACGTGACCGGCTTGCGGGTCCGGG  
GGTATAAAAGGCGCGGGCCGGGGTGGCTGGCCGTGAGTTGCTTCGAGGCCTCGTCACCGGAGTCC  
GCGTCTCCGGCGTCTCGCGCTGCGGCTGCATCTGTGGTCCCGGAGTCTTCAGGTGGGTACGCTACG  
ACAAAGTCCGGGGTGACCTCAGCGCTGAGGTTGTCTGTTTCTATGAAGGCGGAGGAGCGGACGGAG  
AGGTGCGCGCGGGCGATGGCTTCGGTGGTGCGGGCGTCCATCTGGCTGGCGAAGACCACTTCTTA  
TTGTGAGGCGGTGTGGCGAAACTGCCGTAGAGGGCGTTGGAGAGAAGCTTGCGGATGCTGCGGAGC  
GTTTGGTTTCTGTCCCGGTGCGGCTTTTCTTGGCAGCGATGTTGAGCTGCACGTAGTCTCGGGCG  
AGGCAGCGCCACTCGGGGAAGATGCTGTTGCGCTCGTCCGGCAGGAGGCGCACGGCCAGCCACGG  
TTGTGGAGGGTGACCACGTCCACGGAGGTGGCTACCTCGCCGCGGAGGGGCTCGTTGGTCCAGCAG  
AGGCGGCGCCCTTGCGGGAGCAGTAGGGGGGAGGACGTCCAGCTGGTCTCGTGGGGGGGTGCG  
GCGTCGATGGTGAAGAGGGCGGGCAGGAGGTCCGGGTGGAAGTAGCTGAGGGGCTCGGGGCCGTGCG  
AGGCGGTCTGCGAGCGGCGGGCGGCGAGGGCGGCTCGAAGGGGTTGAGGGGTTGGCCGGCGGGG  
AAGGGGTGGGTGAGGGCGCTGGCATAACATGCCGAGATGTATAGACGTAGAGGGGCTCCCGCAGG  
AGGCCGATGAAGTTGGGGTAGCAGCGGCGCGCGCAGGCTCTTCGCGGACGTAGTCATACAGCTC  
GTGGGAGGGCGGAGGAGGTTCCGGCAGGTGCGGCGGCTGGGGCCGGTGGCGCGTAGAGGAGC  
TGCTTGAAGATGGCGTGGGAGTTGGAGCTGATGGTGGGCTCTGGAAGACATTGAAGGCGGCGTG  
GGAAGGCCGCGCTGCGTGTGGACGAAGGCGGCTAGGACTCTTGACGCTTGCAGGACGAGCGGGCG  
GTGACGACGACGTCTGGGCGCAGTAGCGCAGGTTGGCTGGACGATGTGTAAGCGTCCCCCTGG

**FIG. 1-2**

SUBSTITUTE SHEET (Rule 26)

3 / 14

CTCTCCTTCTTCCACAGGTCCTTGTGAGGAGGTA CTCTGATCGCTGTCCCAGTACTTGGCGTGT  
GGGAAGCCGTCCTGATCGCGTAAGTAGTCCCCGTCGCGTAGAACTCGTTCACGGCATCGTAGGGG  
CAGTGTCCCTTGTCCACGGCCAGCTCGTAGGCCGCGCGGCCTTGCGGAGGCTGGTGTGCGTGAGG  
GCGAAGGTGTCCCGGACCATGAAC TTGACGTACTGGTGCTGGGGGTCCTCGGGGGCCATGACGCC  
TCCTCCAGTCCGCGTAGTCGCGGCGCGGGCGGAAGGCGGGGTGGGCAGGTTGAAGCTGATGTCA  
TTGAAGAGGATGCGGCCGTTGCGCGGCATGAAGGTGCGGGTGACCAGGAAGGAGGGGGGACCTCG  
CGGCGGTGGGCGAGCACCTGCGCGGCCAGGACGATCTCATCGAAGCCGAGATGTTGTGGCCACG  
ATGTAGACCTCCAGGAAGAGGGGCGGCCGCGCAGGCGGCGCGCGCAGCTGGGCATAGGCCAGG  
GGGTCTCGGGGTGCTCCGGCAGGCCGGGGCCCCGCTCTGCGCCAGCTCGGCGAGGTCTGGGTTG  
TGGGCCAGCAGGTGCTGCCAGAGGGTGTGCGTGAGGCGGGCCTGCAGGGCGTGCCGAGGGCCTTG  
AAGGCGCGGCCGATGGCGCGCTTCTGCGGGCAGAGCATGTAGAAGGTGTGGGCTCGGGCTCCAGC  
GCTGCAGGCGGGCTCTGGACGGCCACCACCTGCGAGCGGCGTCCAGCAGCTCCTCGTCCCCCGAG  
AGGTGGAAGACCAAGGAAGAGGCGGCGGGTGCCTCGGGGAGCCGATGGGGCGGAAGGCGATGGTC  
AGGT CATAGGTGAGGAAGAGGCGGCGGGTGCCTCGGGGAGCCGATGGGGCGGAAGGCGATGGTC  
TGCCACCAGTCGGCCGTCTGGCGCTGAACGTGGTGAAGTAGAAGTCCCGGCGGCGCACGGAGCAG  
GTGTGGGCGGTCTGGAAGATGCGGCCGCGAGTGCTCGCACTTCTGGGCCTCCTGGATGCTCTTGATG  
AGGTGGCAGCGGCCCTGGGTGAAGAGCAGGCGGAGGGGGAAGGGGAGGCGGGGCGGCGGGCCCTCG  
GGCGGGGGGTCCCAGCGCACGTGGTGACGGTGGTGTGCTGGCGGGTGACCACCTGGACGAAGGTG  
GGCCCGGCGGCGCGGGCCAGCTCCACCGCGGTCTGGGGGGTAGCCTGCAGGAGGTGGGGGGCGGG  
CGCAGGAGGTGCAGCTGGAAGAGGTTGGCCAGGGCGCTGTCCAGTGGCGGTGGTAGGTGATGCTC  
CAGCTCTCCCCGTCTGGGTGGTGCCCTGGAGGCGGAGGGTGGCGCGGCGCTCGAGCAGGAGCCCC  
CGCGTGCCGGCTCCGCGGCCTCGGCGGCGGCGGCGGCTCTCAGGCGGGCAGCTGGGCCAGGGCA  
CGGGCGCGTTGAGCTCGGGCAGCGGAGGTGGTGCAGCGCAGACGCGAGGCGTGGGCGATGACGC  
GGCGGTGATGTTCTGGATCTGCGGGTTCGCGAGAAGACCACGGGCCCGGTGACTCGGAACCTGA  
AAGAGAGTTCCACGGAATCAATGTCCGCATCGTGGGTGGCCACCTGGCGCAGGATCTCGGACACGT  
CCCCGTGTTTTCTCGCGGTAGGCGATGTCTGCATGAACGTCTCGAGCTCGTCTCGTCCAGGTCCC  
CGTGCCCGGCGCGCTCCACGGTGGCGGCCAGGTGCAGCGTGATGCGGTTTCATGATGGCCACCAGGG  
CGTTCTCTCCGTTCTCGTTCCACACGCGACTGTAGACCAGCTGGCCGTTCGGCGTCCCGCGCGCA  
TGACTACCTGGGCCAGGTGAGCGCCACCAGGCGGTTGAAGGGCGCCTGCAGGCGCAGGGCGTGGT  
GCAGGTAGTTGAGGTGGTGGCGATGTGCTCGCAGAGGAAGAAGTTATGACCCAGCGGCGCAGGG  
TCAGCTCGTTGATGTGCGCCAGGTCTCGAGGCGCTGCATGACCCGGTAGAACTCGGGGGCGAAGC  
GAAAAA ACTCGTGCTGGCGGGCCGAGACCGTGAGCTCCTCTTCCAGGGCGGCGATGGCCTCGGCCA  
CCGCTGCGGCACCTCCTCCTTAAGGAGGGCGGGGCGTGCTGGGTCCGGCCACCGCCGCTCTT  
CTTCTCTTCTCCCTCCAGGGTGGCATCTCCTCGTCTTCTTCTTCTGCTGCTGCTGCCCTCCGCGG  
GGACGGGGGCGCAGGCGGGGACGGCGCGCGCAAGGGCAGCCGGTCCACGAAGCGCTCGATGA  
CCTCGCCCCGCGATGCGGCGCATGGTCTCGGTGACGGCGCGGCCGCCCTCCCGGGGCGCAGCTCGA  
AGGCGCCCCGCGCAGCGCGGTGCCGCTGCAGAGGGCAGGCTGAGCGCACTGATGATGCAGCGTG  
TCAACTCTCTCGTAGGTACCTCCTGCTGTTGCAGCGCTTCGGCAA ACTCGCGCACCTGCTCTTCGG  
ACCGGGCGAAGCGTTCGACGAAGGCGTCTAGCCAGCAACAGTCGCAAGGTAAGTTGAGCGCGGTGT  
GCGTCGGGAGCCGGAGGTGCCGGCTGACGAGGAAGTGAAGTAGGCCGTCTTGAGCTGCCGGATGG  
CGCGCAGGAGGGTGAGGTCTTTGCGGCGGCGCGCTGCAGGCGGATGCGGTTCGGCCATGCCCCAGG  
CCTCCTGCTGGCAGCGGCCGATGTCTTGAGCTGCTCCTGCAGCAGATGTGCCACGGGCAGTCCC  
GGTCGGCGTCCAGGTGGGTGCGACCGTAGCCCGCAGGGGCGCAGCAGCGCCAGGTTCGGCCACCA  
CGCGCTCGGCCAGGATGGCCTGCTGCATGCGTGCAGGGAGTCTGAGAAGTCATCCAGGTCCAGGA  
ACCGGTGGTAGGCGCCGTTGATGGTGTAGGAGCAGTTGCCAGCACGGACAGTTGACCACCT  
GGTAGTGGGGCTGGATGACCTCGGTGTAGCGCAGTCGACTGTAGGCGCGCGTGTCAAAGATGTAAT  
CGTTGCAGAGGCGCAGCAGGTGCTGGTAGCCACGAGCAGGTGGGGCGGAGGGTAGAGGTAGAGGG  
GCCAGTGTTCCGTGGCCGTTGGCGGGGGAGAGGTTTCATGAGCATGAGGCGGTGGTAGCGGTAGA  
TGAAGCGGGACATCCAGGCGATGCCGACGGCGGAGACGGAGGCGCGGGTCCACTGGTGGGCGCGGT  
TCCAAATGTTGCGCACCGGGCGGAAGAGCTCCACGGTGTAAATGGATTGCCCCGTGAGGCGGGCGC  
AGTCGAGGGCGCTCTGTCAAAAAGAACCGGTGTGGTTGGTTGGTGTGTGGTAGCGATCTATCTTT  
CTTTGTGATCTTGGTAGTGAAGCCTGCCAGGCTCCAGCAGGGGGCGTCCGCCGTCTTCTCTCTT  
CCCTATCTGGAGGTGTGCTCTGTTCTCTTTTTTATTTTCATGTAGCCATGCATCCCGTCTGCGGC  
AGATGAAGCCGCGCGCGCGGCGCCCTGGGCGCGGAGGGGCGACGCGCTCTCGGTGCGCCCTCGCCGT  
CGGTGACGCGGCGCGCGAGGAGGGGAGGGCTGGCGCGGCTGTGCGGCGCGGCGGCCCCCGAGC  
GGCACCACGGGTGACGCTCAAGCGAGAGGCCATGGAGGCCTATGTGCCGAGGCAGAATGCGTTCC

**FIG. 1-3**

SUBSTITUTE SHEET (Rule 26)

4 / 14

GCGAGCGACCGGGGGAGGAGGGGGAGGAGATGAGGGACCTGCGGTTCCGCGCGGGGCGGGAGATGC  
AGCTGGACCGGGAGCGAGTGCTCCAGCCCGAGGACTTTGAGGGGCGCGTGGAGGAGGCGGGGGAG  
TGAGCGCGCGCGGGCCACATGAGCGCGGCCAGCCTGGCCAGGCCTACGAGCAGACGGTACGCG  
AGGAGGTCAACTTCCAAAAGACCTTCAACAACAACGTGCGCACCCCTGGTGAGCCGGGACGAGGTGA  
CCATGGGACTGATGCACCTGTGGGACTTTGTGGAGGCCTTCTGCGACACCCCGGTCCCGCGCGC  
TGACCGCGCAGCTGCTGCTGATCGCGCAGCACTGCCGGGACGAGGGCATGGTGAAGGAGGCGCTGC  
TGAGCCTGGGCGCGCCCGAGAGCCGCTGGCTGGTGGACCTGGTGAACCTGCTCCAGACCATTGTGG  
TGCAGGAGCGGTCCATGAGCCTGAGCGAGAAGGTGGCGGCCATCAACTACTCGGTGGCGACCCTGG  
CCAAGCACTACGCGCGCAAGATCTCCACCTTCTACATGCGCGCGGTGGTGAAGCTGCTGGTGTGG  
CCGACAACCTGGGCATGTACCGCAACAAGCGGCTGGAGCGCGTGGTCAGCACCTCGCGGCGGCGCG  
AGCTCAATGACAAGGAAGCTCATGTTTGGCCTCCGCCGGGCGCTGGCCGGGAGGGCGAGGAGGAC  
CTGGAGGAGGAGGAGGACCTGGAGGAGGCGGAGGAGGAGGAGCTGGAAGAGGAGGAGTTCCGTTCC  
CCGGGGACCGCGCGCGTGGAGTGGCAGTCCCCGCTGACTGCGAGCGATGAGGGTGTGTGTACTG  
ATGGCAACCATCCCCCTTTTAACAACAACAGCAGCATGGCGGCGAGCTCTGAAGCTGGGGCGGCG  
GCGGCGGGGGGTGAGCGCGGCCCTCCCTGGCGCCCGAGCGGGCGACGCGGATGCAGGCGCTGCCCTCC  
CTGGACGAGCCTTGGGAGCAGGCTCTGCGGCGCATCATGGCGCTGACGGCCGACGGGTCTCGGCGC  
TTCGCGAGCCAGCCCCTGGCCAACCGCATCGGGGCCATCCTGGAGGCGGTGGTGCCTCCGCGCACG  
AACCCGACGCACGAGAAGGTGCTGACCGTGGTGAACGCGCTGCTGGAGACCTCGGCCATCCGCCCG  
GACGAGGCCGGCATGGTGTACGATGCGCTGCTGGAGCGGGTCTCCCCGTACAACAGCGGCAACGTG  
CAGACCAACCTGGACCGGCTGTCCAGGACGTGCGGCGAGGTGATCGCCAGCGCGAGCGCTCGAGC  
GCCAACAACCTGGGCGAGCCTGGCCGCGCTGAATGCCTTCATCGCCTCGCTGCCCGCAACGGTGGAG  
CGGGGCCAGGAGAGCTACCTGGGGTTCCTCAGCGCGCTGCGGCTGCTGGTGAGCGAGGTGCCGCGAG  
ACGGAGGTGTTCCGCTCGGGGCCGCACACCTTCTGCGAGCGCGCGCGGAACGGTTCCAAGACGGTG  
AACCTCAACCAGGCCATGGAGAACCTGCGGCCCTGTGGGGGCTGCAGGCCCCGCTGGGGAGCGC  
GGGCAGGTGTCTCCCTGCTGACGCCAACACCCGGCTGCTGCTGCTCCTGGTGGCTCCCTTCGCG  
GAGGAGATGAACGTGAGCCGGAGCTCCTACATTGGGCACCTGCTGACACTCTACCAGGAGACGCTG  
GCCAATTGCGATGTGGACGAGCGCACGTACCAGGAGATCACCAGCGTCAGCCGGGCGTTGGGCGAC  
GAGGACGACGCGGCGCGGCTGCAGGCCACCCTCAACTTCTTCTGACCAACCGGCAGCGCGGCTG  
CCGGCGGCGTATGCCCTGACCGCCGAGGAGGAGCGCATCCTGCGCTACGTGCAGCAGGCGGTGAGC  
CTGTACCTGATGCAGGACGGGGCGACGGCCACGGGCGCCCTGGACGAGGCCAGCCGCAACCTGGAG  
CCCAGCTTCTACGCGGCGCACCGGGACTTCATCAACCGCCTGATGGACTACTTCCATCGCGCGGCC  
GCGGTGGCGCCCAACTACTTTATGAATGCCGTCTGAACCCCGCTGGCTGCCCTCGGAGGGCTTC  
TTCACCGCGTGTATGACTTCCCGAGCAGGAGGAGGGGAGGAGCGGCCCTGGGACGCCTTTGAC  
AGCGACGAGGAGGGCGCCTCATGCTGCGGTCCGCGAGCCTCCTCAGAGCCCTCCTCCTTACC  
CCCCGCCCCCTGACCGAGGAGCCGCTCGCGGCCCTCCACCCCGGCCCTCTCGCGCGTCCCGTCC  
CGGGCATCCTCCTGCTCTCTGCGCTCTGCGGAAAGCGGGAGGAGGGGACTCGCTCGCCTAC  
TCGCGGCGCACGCCACCTATGGCTCTCGCTGGGGCTCGCGCGCTCCAGCCTGGCCAGCGGCGCC  
GACAGCCTGGAGTGGGACGCGCTGCTGGCCCTCCCAAGGATGTGAACGAGCACCCAGGCGCGCC  
GCCGGCGCGCGCGCGCCTCCCGCTCCTCCCTGGAGGAGGACATCGACGCCATCAGCAGCCGG  
CTGTTACCTGGCGCACGCGCGCCAGGAGATGGGCTGCCCGTGGCCAGCTTCTCCCGCGCCAC  
CAGCCGCGCCCCGGGGCCCTCGAAGACGACGAGGAGGAGGAAGACTGGCGCCAGGACCGGTTCTTT  
CGCTTCGAAGCGCCCCGAGGAAAACCCCTTCCGCCACATCGCCCCAAGGGGCTGTAATGCAAAAAA  
GCAAAATAAAAAACCCCTCCCGGTCCAACCTACCACGGCCATGGTTGTCTTGTGTCCTCAGAG  
TGAGGAGGATGATGCCAGCAGCGCGCGCGGAGCGCTCGCCTCCGCGCTCCTACGAGAGTGTGG  
TGGGGTCTTCGCTCAGGAGCCTCTTTATGTGCCGCGCGGTACCTGGGCCCCACCGAGGGGCGGA  
ACAGCATCCGTTATTACAGCTCCCGCGCTCTACGATACCACAAAGATCTATCTGATCGATAACA  
AGTCGGCGGATATCGCCAGTCTGAACTACCAAAACAACCACAGTGACTTCTCACCAGCGTGGTGC  
AGAACAGCGACTTCACGCCCATGGAGGCGAGCAGCAGACCATCAACCTGGATGAGCGCTCGCGCT  
GGGGCGGGGAGTTTAAGAGCATTCTGACCACCAACATCCCCAACGTGACCCAGTACATGTTACGA  
ACAGCTTCCGGGTGCGCCTGATGAGCGCGCGGATAAAGAGACAAATGCCCCACCTACGAGTGGT  
TCACCCTGACCCTGCCCGAGGGCAACTTCTCGGACATCGCGGTATCGACCTGATGAACAACGCGA  
TCGTGGAGAACTACCTGGCGGTGGGGCGGACGAGGGGGTCAAGGAGGAGGACATCGGGGTGAAGA  
TCGACACGCGCAACTTCCGCCCTGGGCTATGACCCGGAGACCAAGCTGGTCTATGCCCGGAGCTACA  
CCAACATGGCCTTTCACCCGACGTGGTGTGCTGCCACCGGGCTGCGCCATCGACTTCACCTTCTCCC  
GCCTAAACAACCTGCTGGGCATCCGCAAGCGCTACCCCTACCAGGAGGGCTTCATGCTGACCTACG  
AGGACCTGGCGGGGGGCAACATCCCCGCGCTGCTGGACCTACCACCTATGATCAGGAGAACTCCA

**FIG. 1-4**

SUBSTITUTE SHEET (Rule 26)

GCACCATCAAGCCCTGAAGCAGGACAGCAAGGGTCGACGCTACCACGTGGGCGAGGACCCCGGAGG  
CGGGGACACCTTACCTACTACCGCAGCTGGTACCTGGCCTACAACCTACGGGGACCCGGCCACGG  
GCACCGCCTCCAGACGCTGCTGGTCTCCCCGGACGTAACCTGCGGAGTGAGCAGGTCTACTGGA  
GCCTGCCGGACCTGATGCAGGACCCGGTGACCTTCCGGCCAGCCAGACGCCGAGCAACTACCCGG  
TGGTAGCCACGGAGCTACTGCCGCTGCGCTCCCGGGCTTCTACAACACCCAGGCCGTGTACTCCC  
AGCTCCTGCAGCAGGCCACCAACAACACCCTGGTCTTTAACCGCTTCCCGGAGAACCAGATCCTCC  
TGCGCCCGCCAGAGTCCACCATCACCTCCATCAGCGAGAACGTGCCCTCGCTGACGGACCACGGCA  
CGCTGCCGCTGCGTAACAGCATCCCCGGGGTGACGCGGTAACCGTCACCGACGCGCGCGCCGCG  
TGTGTCCCTATGTGTACAAGAGTCTCGGGGTGGTGACCCGAGGGTGCTCAGCAGCCGAACCTTCT  
AACCAGACAGCCCTACCCGTACAGGGGAGACAGAGAAAGACAGCCAGCCGCCCATGGCCATCCT  
CGTCTCGCCAGCAACAACCTTTGGCTGGGACTGGGGCTGCGCTCCATGTACGGGGGCGCCCGCG  
CCTGTCCCGGATCACCCCGTATCGTCCGACGCCACTACCGGGCCAACCTGGGCCAGTCTGAAGGG  
ACGCGTGGCCCCCAGCACCATAGCGACAACGGATGACCTGTGGCCGACGTGGTCAACGCGATCGC  
CGGCGCCACCCGCGCGCGCGCCCATCGTCGACGTGCGAGGGCCGCGCGCTCTCCTCCGTGGC  
CGTACCGGGGACCCGGTGCCGATGTGGTCAACGCGGTGGAGGCGGTAGCCCGCGCGCGCGCGCG  
GCGGCGCGCTTCTTCGCGCATGCAGACCACGGGGGACCCCGTGGCGGATGTGGTGGCGGCGGTGGA  
AGCGGTGGCGCGCGGAGGCGGAGCACCCGGCGGCGGCGCAGGCGCTCCGCGCCGGCCATCCTGGG  
GGTGCGCGCAGCCGCGCCTCCGCAAACGCACCTCGTCTGAGATTTTTGTGTTTTGTTTTTTCT  
GCCTCCCGTGGGTGAACAAGTCCATCCATCCATCCAACATCCGTGGCTGCTGTGCTTTGTCTTT  
CTTTGCGTTGCGCCCCAGTTGAGCCGGCACCAGCGCTCGGCCATGGCCATCTCGCGCCGCTGA  
AAAAGGAGCTGCTGCAGGCGTTGGCGCCGAGGTGTACGGGGCGCTAAGAAGGAGGAGAAGGACG  
TCAAAGAGGAGTCAAAGCTGACCTTAAACCGGTGAAGAAGCGGCGCAAGGCCAAGCGGGGGTTGA  
GCGACAGCGAGTCAAGGTGCTGGTCTGGGCACGCGCCCCAGGCGCGCTGGACGGGGCGGCGCGTGC  
GCGCCACCTACCGCCCGGTGCCAGCCTCGCCTACGTCCCGGTCTTCGGAGGTGAGCGCCACCA  
AGCGCTCTGCGGACGAGTTGTATGCGGACACGGACATCCTGCAGCAGGCGTCCAGCGCCTGAACG  
AATTTGCTTATGGCAAGAGAGCCCGGCGGCAGCGGCGGGCCCGCCCTCGCCGACCCCGCGTCCC  
GCGGCCGACCACCAAGCGCTCTTATGACGAGGTGCTGGCAGACAGTGACATCCTGCAGCAACTTG  
GATCCGGGGACCGCTCCAATGAGTTCTCCTATGGCAAGCGGTGCTGCTGGGGGAGTCAGGAGACA  
CCGTCCCGGCTGTGGCCGTCCCGCTGGAGGAAGGCAGGAACCACACACCCAGCCTGCAGCGCTCA  
CCGAGCCCATGCCCTGGTGTCCCTTCGCACGCGCGTCAAGCGCGGGCGCCGCGGACGAGCCCA  
CCGCTCACTGGTCCCCACCGTGCAAGTCTGCCCCCAAGCGTCTGTCAGGAGGTGGTGGTGG  
AGCCGCCCCGCTCCAGCACCACGCGCCCTAGCCCCGCGCGGTCCAGCCGGCGCATCATTCTGG  
CTCCGCGCGCGGCGCGGCGCCCGCCAGCCGCTGCTGGCGCGCGCAGCTCAGCGCGGCGCGCGCTGG  
AGCGGCGCGCGCGCGCGCTGCTGGTCCCTGCCACCGGACACGGAGGACGACCTGGTGGAGATGGCAGAGG  
CTGTGCGCGCGCGCGGAGGTGCTGCCAGCCTCCCGTCTCCATCATGCCGCCACCGCCACGGAGG  
TGGCCCTGCCCCGTACAGACCCCACTGCCGCGCGTGCGGTGGCCAAGAGCTCCCTGACCCCCGCGC  
TCCGCGCGCTGATGGGCACCGAGCGGGTGCCGTTCCAGTCTTGAGGCGCCCCCTGGTGGCCATGC  
CCGTGCTCCGGGCCACCACCGCCCGTGCCGAGCCCCCGCGCGCGTGCCCCGACGGGCGGTGCGGG  
ACATCCCGGCCAGGCAGCCCCGCACGGTATCCCTGCCCGTGCTCACGGAGCCCCGGCCCGGCCACCG  
CGGTGCGCTCCGTGCGCGCGGCAGCCCAAGTCTGCAGGCGCCCCCGCCGCGACCGGCCACCGTCT  
CCGTGGGGGTGGGCACCGAGCCGGTGGTGCAGTCCATCAGGTCAGCGGTCAAAGCGCCTGACCA  
AGCACCATCGGGGTGCAGACCATCGAGTCAACGTGCCACCGTCCGCACTGTACAGCTGGGCACC  
AACAGCCCCCGGTGAGGAGCGCCTCGTGGGCTCCAGACCGCTCCCGAGACCCGCTCCAGGGG  
GTGACAGGTGGCTTTGCAACGACGCTGCTAGCCACCGCACACCCAGGCAGGTGCGGCTGACGGCGG  
TGGTGGCCCCCACCOCGCGCGCCCGGTGGTTCCGTTGGCCCGCGCGCCCGCGGCGTTCCGGTGCC  
TCCCCAGCCCCCTCCAGCCCCGCGCGCGCGCTGCGCTCGCGCCCCAGAGCGCTCGGCGTGC  
CCGCGGTACCCCGGTGGCGGTGGCAGCGCGCGCGCGCGCGCAGCGGCGGTCCCCGCGCTCGGTGC  
CGAGGCGGCCCCATCGTGCTGCCCGGGTGCGCTATCATCCAGTCAGGCCATGGCTCCACCGCCC  
AACCGGTATCTGGCGTTGATTTATTTTTGGAGACCTGACTGTGTTGTGTTCTTTAAATTTTTTAT  
CCTCCTCCTCCTCTGCTGAAGCCAGACGATGCTGACCTACCGGTTGCGGCTGCCCGTGCGGATGCG  
GAGACCGAGACTCCGCGGTGGGTTCGCGGTGGCGCTCGGCGCAGCGCGCGGCGGCGGTACCG  
CCGGGGGCGGATGAGGGGTGGCATCCTGCCGCGCTGGTGCCCATCATCGGCGCATCATCTGGGG  
CATCCCCGGCATCGCTCGGTGGCATGAGTGTAGACAAACGCAATTAACGGCGCTGCTGTGTATG  
TGTGCTTTCATGTGCTTCTTCTTCTTCTGTTCCCAACGGAACAGCAGCACCCTCTCCATGGAGGAC  
CTAAGCTTTTTCCGCGTTGGCTCCACGCTTTGGCACGCGCGCGGTGATGGGCACTGGAGCGAAATC  
GGCACGAGTCAGATGAACGGCGGCGCGCTCAGCTGGAGCAATATCTGGAGCGGCTGAAGAGCTTT

**FIG. 1-5**

**SUBSTITUTE SHEET (Rule 26)**



6 / 14

GGTAGTTCTCTGGCCTCCACGGCCAACAAGGCTTGAACAGCGGGACGGTGACGAGCGTGCGCAAC  
AAGTTGAAGGATGCCGACGTGCAGGGGAAGATAGGTGAGGTCATTGCCTCCGGGGTCCACGGTGCC  
CTGGACGTGGCCAACCAAGGCGCTCTCCACGCGGTGGACCGCGGTGCAACAGCAGCAGCTGCGGC  
AGCAGCAGCTCCTCCGCCAGCAGCAACAGATGGGCCTCGTGGAACCTCCTATGAGATGGAGA  
CAGACGAGCTGCCCTCCTCCCCCGAGGACCTCTTGCTCCTCCTCCTCCGCGCCTGCCTCGG  
CCACTCCCGCGCGCCAATCCCGCGGGACGTCCCGCCAAGCGCCCGCGCCGAGGATCATCA  
TCCGCTCCGACGAGCCCCCTCCCTATGAAGAGCTGTATCCCGACAAGGCCGGGATCCCCGCCACCT  
TGGAGCTGCGTCCCGAGACCAAACCTGCCCGCGGTGGCCACAATAAGATGCGCCCCCGCGCCGC  
TCACCACCACCACCTCCTCCGCTGCCGCGCGCGCCCCCGCCCCGGCCCCCGCGGCTCCTGTGCGTC  
GGCGTCCGGCCGCGGCTCCGGCCGCGGCTCCGGCGAGTTCCAAAGGCCCCCAGGTGGGGGTCCGC  
GCGCGCGGGTGGCAAACAACCTCAACACCATTGTGGGACTGGGTGTCCGCACATGCAAGCGCGCT  
CGTTGTTACTGAGAGAGACAGCATGGAGAAACAACATGTCTGGATTCAAATAAAGACAGCCTAT  
TCTTCCACGGTGCTCCGCGCTGTGTTATTTTCAACGGGCTGTTTCTTTTGCATCTCTGTGCCATC  
GCGCCACGGGGAATTCGCGAGGATGGCGACGCCGTGATGATGCCGAGTGGTCTATATGCACAT  
CTCCGGGCGAGGACGCGTCCGAGTACCTGTCTCCGGGCTGGTGCACTTCTCCAGGCGACGGAGAC  
CTACTTTAACCTGAACAACAAGTTTAGGAACCCACCGTCGCGCCACCCACGATGTGACGACGGA  
GCGCTCGCAGCGGCTGCAGCTGCGCTTCGTCCCGTGGACAAGGAGGACACTCAGTACACATACAA  
GACCCGCTTCCAGCTGGCGGTGGGCGACAACCGCGTGTGGACATGGCGAGCACCTTCTTTGACAT  
CCGGGGAACGCTGGACCGGGGACCCTCCTTCAAACCGTACTCGGGCACCGCGTACAACATCATGGC  
TCCCAAGAGCGCTCCCAACAACCTGTCAATATCTAGACCCTAAAGGTGAAACTGAGGCTGGCAAAGT  
TAATACCATTGCTCAAGCAAGTTTTGTGGGTCTATTGATGAAACCACGGGAGACATTAAATATAC  
AGAAGAAGAAGACGAAGAGACCACCATCGATCCTTTGTATGAGCCCCAACCCAGCTTGGTCCAAG  
CTCGTGGTCAGACAATATACCTTCTGCGACTAGCGGAGCTGGAAGAGTTCTCAAACAGACCACACC  
GCGTCAACCTTGTACGGTCTTATGCCTCTCCGACAAATATTACGGTGGGCAAACGAAGGATGA  
CAAGGTTACACCATTTGACTTTACAAACAATCCCGCCACCGAAGCCGAAGCACTCGAAGAAAATGG  
ATTAAAGCCAAATGTCACCTTATACTCAGAGGATGTTGACCTAAAAGCACCAGATACTCATCTGGT  
CTATGCTGTGAATCAAACCCAGGAATTCGCTCAATATGGACTTGGACAACAGGCCGCTCCAAACAG  
GGCCAATTACATCGGCTTCAGGGACAACCTTATCGGGCTGTTGTACTACAACAGCAATGGCAACCA  
GGGCATGCTAGCCGGTCAGGCCTCTCAGCTCAACGCGGTGGTTCGACCTGCAGGACAGGAATCACCG  
AACTAGCTACCAGCTCTTCTCGATAGCCTCTATGACAGGTGAGGTACTTTAGCCTGTGGAACCA  
GGCCATCGATTCTTATGACAAGGATGTGCGTGTGCTGGAAAACAATGGCGTGGAGGACGAGATGCC  
CAACTTTTGCTTTCCCATCGGCGCCATCGAGACCAACATGACATTTACACAGCTCAAAAAGAGTGA  
GAATGGTGGCTCAAGAGCCACAACCTGGACAAGGAGAATGGGGATGATGGCGGAAACGGAGCGGA  
GCACTACCTGGGCATCGGCAACCTCAACGCCATGGAGATCAATCTCACGGCCAACCTCTGGCGCAG  
CTTCTCTACAGCAACGTGGCGCTGTACCTGCCTGACAAGTACAAGTTTTCCCGCCCAACGTCCC  
CATCGACCCCAACACGCACTCCTATGACTACATCAACAAGCGCTGCCCTCAACAACCTCATTTGA  
TACCTTTGTCAACATCGGGGCGCGCTGGTCCCCGGATGTCATGGACAACGTCAACCCCTTCAACCA  
CCACCGCAACTACGGCTGCGCTACCGCTCCCAGCTCCTGGGCAACGGCGCTACTGCAAGTTCCA  
CATCCAGGTGCCGCAAAAGTTCTTTGCCCTCAAGAGCCTGCTGCTCCTGCCGGGGGCGACCTACAC  
CTACGAGTGGTCTTCCGCAAGGACGTCAACATGATCCTCCAGTCCACGCTGGGCAACGACCTCCG  
CGCGGACGGGGCCAAATCAACATCGAGAGCGTCAACCTCTACGCCAGCTTCTTTCCCATGGCCCA  
CAACACCGCCTCCACCCTGGAGGCCATGCTGCGCAACGACACCAACAACCAACCTTTATTGACTT  
CCTCTCCTCCGCCAACATGCTCTACCCCATCCGGCCCAACGTCAACCAACCTTGCCCATCTCCATTCC  
CAGCCGCAACTGGGCGGCTTCCGCGGCTGGAGCTTACGCGGCTGAAGCACAACGAGACCCCCGC  
CCTGGGCTCGCCCTTCGACCCCTACTTTACCTACTCGGGCTCCATCCCCCTACCTGGACGGGACCTT  
CTACCTGGGCGCACACCTTCCGCGCATCAGCATCCAGTTCGACTCCTCCGTGGCCTGGCCGGGCAA  
TGACCGCCTGCTCACTCCCAACGAGTTCGAGGTCAAGCGCACCGTGGACGGGGAGGGCTACACGGT  
GGCCAGACCAACATGACCAAGACTGGTTTCTGGTGCAGATGCTCGCCCACTACAACATCGGCTA  
CCAGGGATACCACCTGCCAGAGGGCTACCGCGACCGCACCTACTCCTTCTGCGCAACTTTGAGCC  
CATGTGCCGCCAGGTGCCCGACTACGCCAACCACAAAGATGAGTACCTGGAGGTGCCACCACCAA  
CCAGTTCAACAGCAGCGGCTTTGTATCCGCGGCTTACCGCGGGCATGCGCGAGGGGACCCATA  
CCCCGCCAACTGGCCCTACCGCTCATCGGCGAAGACGCCGTGCAGACCGTGACCCAGCGCAAGTT  
CCTCTGCGACCGCACGCTCTGGCGCATCCCCCTTCTCCTCAACTTCATGTCCATGGGCACCTTCAC  
CGACCTGGGCGCAGAACCTCCTTACGCCAACCTCGGCCACGCCCTCGACATGACCTTCGAGGTGCA  
CGCCATGGATGAACCCACCTCTTGTATGTTCTGTTGAGGTCTTTGACGTCTGCGGCGTGACCA  
CGCGCACCGAGGCGTCACTCGAGGCGCTTACCTGCGCACGCCCTTCTCCGCGGGAACGCCACCAC

**FIG. 1-6**

SUBSTITUTE SHEET (Rule 26)



7 / 14

CTAAGGCGGAGCCGCGCAGGCATGGGACGACCCGAGGACGAGCTCCGAGCCATGGCGCGGACCTC  
CAGCTGCCCCGCTTCCTGGGCACCTTTGACAAGTCCTTCCCGGGCTTCTTGCAAGAGTCCCAGCGC  
TGCTGCGCCATCGTCAACACGGCCGCCCCGCCACACCGGAGGCCGCACTGGCTGGCCGTGCGCTGG  
GAGCCCGCTCGCGCACCTTCTACTTCTTTGACCCCTTCGGCTTCTCCGACCGGGAGCTCGCCAG  
GTCTATGACTTTGAGTACCAGCGCTGCTGCGCAAGAGCGCCATCCAGAGCACCCCGGACCGCTGC  
CTCACGCTCGTCAAGAGCACCCAGAGCGTGCAGGGACCGCACAGCGCCGCTGCGGACTCTTCTGC  
CTCCTCTTCTCGCCGCTTTGCCCCGTACCCCGACAGCCCCATGGCCTACAATCCCGTCATGGAC  
CTGGTGGAGGGCGTGGACAACGAGCGGCTCTTCGACGCGGACGTCCAGCCCATCTTCCGCGCCAAC  
CAGGAGGCCTGCTACGCGTTCCTCGCTCGCCACTCCGCTACTTCCGCGCCACCGCCACGCCATC  
ATGGAACAGACACACCTGCACAAAGCGCTCGATATGCAATAAAGGCTTTTATTGTAAGTCAAAAA  
GGCCTCTTTTATCCTCCGTCGCTGGGGGTGTATGTAGATGGGGGACTAGGTGAACCCGGACCCG  
CCGTCGGCTCCCCCTCCATCCCCCTCTTCTCAAACAGGCTCTCATCGTCTGCTCCGTTCCACG  
GGGAAGATGGTGTCTGCACCTGGAACCTGGGGCCCCCACTTGAACCTCGGGCACCCTCAGTGGAGGC  
CGCGTCTGCATCAGGGCGGCCACATCTGTTTGGTCACTGCAGGGCCAGCATCACATCGGGGGCG  
CTGATCTTGAAATCACAATTCTTCTGGGGGTGCGCGCGGACCCGCGGTACACCGGGTTGTAGCAC  
TGGAACACCAGCACCGCGGGGTGGGTACGCTGGCCAGAATCTTGGGGTCTTCCACCAGCTGGGGG  
TTCAGCGCCGCGGACCCGCTCAGCGCGAAGGGGTGATCTTGCAGGTCTGCCGGCCAGCAGGGGC  
ACCTGGCGGCAGCCCCAGCCGAGTGCACACCAGCGGCATCAGCAGGTGCGTCTCCGCGTTGCC  
ATCCGGGGGTAGCAGGCCTTCTGGAAGCCTTGAGCTGCTCGAAGGCCTGCTGCGCCTTGGAGCCC  
TCCGAGTAGAAGAGGCCGAGGACCGCGCGGAGAAGGTGTTGGGGGCGGACCCACGTCGTGGCTG  
CAACACATGGCCCCGTCGTTGCGCAGCTGCACCAGTTCGCGGCCAGCGGTTGGTGGTGATCTTG  
GCGCGCTCGGGGGTCTCGCGCAGGGCGCGCTGCCGCTTCTCGTGTGAGATCCATCTCCACCAGC  
TGCTCCTTGTGATCATGGGCAGCCCGTGCAGGAGTGCAGCCCCCTCCGAGCCGCTGCGGTGCTGC  
CAGATCAGCACCCCGAGGGGTTCCACTCGGGCGTCTTCAAGCCCGCGCCTTACCACAAAGTCC  
AGCAGGAAGCGGGCCATCACTGTGAGCAGGCTCTTTGCGTGTGTAAGGTGAGTGGCAGCTGATC  
TTGCGCTCGTTTCAAGCAGGCTTGGGCCCCGCGCGGAAGCACTCCAGGGTGTGCGCTCCGGCAGC  
AGCGTCAGGCCCTTGACATCCACCTTCAAGGGGACCAGCATCTGCACAGCCAGATCCATGGCCCCG  
TGCCACTTCTGCTCCTGAGCATCCAGCTGCAGCAGCGGCGGGCCACCGCCGGGCTCGGGGTCAAC  
GGGCGCGGGGGCGGGCCCCCTCCTCTTCTTCCCCATCTTCCGCTTCTCCTCGCGGGCGCGCG  
GTCGCGCTGCGCTCTCTTCAAGCTCGTCTCCTCCTCGCTGACCAGGGGTGACAGGGGTGCGCG  
CGCTTCCGCGCTCCTGACGGGCGGAGAGGCCGCGCGCTTGGCGCCTCCCCCGCGCGGCTGGGG  
GTCGCGACAGGAGCGTCTTCAACATCAGACCCCCCTTCCCCGCTGTATAGTCAGACACGTCC  
GAATAGCGGCACTCATTTTGTCTCCCTAGATGGAAGACCAGCACAGCGCAGCCAGTGAAGTGGG  
GTCCTCCGCGGCCCCGACCTTCCGCGGCCACACCGCCGCCACCTCCGCCCAGCTCACCGCCACC  
TTCATGTCAGCAGCGGACAGCAGGAGCCACCGAAACCGATGACGCGGAGGACACCTGCTCCTCGTC  
CTCCTCGTCTTCCGCTCAGCGAGTGTCTGCTCTCGCGCTGGAAGACAGAGCTCCGAGGACTC  
GGCGGACACGGTGTCTCCCTCCGAGCCCCGCGGGACGAGGAGGAGCAGGAGGAGGACTCGCCCCGA  
CCGCTACATGGACGCGGACGTGCTGCAGCGCCACCTGCTGCGCCAGAGTACCATCCTGCGCCAGGT  
CCTGCAGGAGGCCGCCCGCGCGAGCCGCGGAGGCCGCGGAGGCGCCCTCGGTGGCGGAGCTCAG  
CCGCGCCTGGAAGCGGCCCTCTTCTCCCCGCCACGCGCGCGCGGCCAGGAGAACGGAACCTG  
CGCCCCGACCCCCGCTCAACTTCTACCCGCTTCTATGCTGCCCGAGGCCCTGGCCACCTACCT  
CCTCTTCTTCCACAACCAAAAGATCCCCGTGAGTGCAGCGCCCAACCGCCACGAGCCGACGCGCA  
CTGGCGGCTGCCAGTGGGACCCCTTACCTGACTATCCAACCACCGACGAGGTTTACAAGATCTT  
TGAGGGCCTGGGGGACGAGGAGCGGCGCTGCGCCAACCAGGACCTGAAAGAGCGCGACAGCGTGT  
AGTCGAGCTCAAGCTGGACAACCCCCGCTGGCGGTGGTCAAGCAGTGCATCGCCGTACCCACTT  
CGCCTACCCGGCCCTGGCGCTGCCACCAAGGTATGAGCACGCTCATGCAGACCCTGCTGGTGGC  
CCGCGCGAGCCCACTCCCCGACGAGGGCGAGACGCCCTCGAGGACCTCCTGGTGGTCAGCGACGA  
GCAGCTGGCCCGCTGGATGCACACCTCGGACCCCAAGGTCTGGAGGAGCGGCGCAAGACCGTCAC  
CGCCGCTGCATGGTCAAGGTGCAGTCCACTGCATGCACACCTTCTCACCTCCCGCGAGATGGT  
GCGCCGCTCGGAGAGTGCCTCCACTACATGTTCCGCCAGGGCTACGTCAAGCTAGCTAGCAAGAT  
CGCCAATATGGAACCTCTTAACCTGGTCTCCTACTTGGGCATGCTGCACGAAACAGGCTCGGTCA  
GCAGGTGCTCCACCACACCTCAAGCATGAGGCGAGACGCGACTACGTCCGGGACACCATTTACCT  
ATACCTGGTCTATACCTGGCAGACCGCCATGGGGGTCTGGCAGCAGTGCCTCGAGGACCGAAACCT  
GCGCGCCTGGAAACGTCTTGGCTCGCGCTCGCCAGAGCCTGTGGACGGGCTTTGATGAGCGCAC  
TATCGCGCAGGACCTCGCCGCTTCTTTTCCCCACCAAGCTCGTAGAGACCTGCAGCGCTCGCT  
CCCCGACTTTGCCAGCCAGAGCATGATGCATGCCTTCCGCTCCTCGTCTCGAGCGCTCCGGCAT

**FIG. 1-7**

SUBSTITUTE SHEET (Rule 26)

8 / 14

CCTGCCCCCGTCTGCAACGCGCTCCCCTCTGACTTTGTGCCCCACCGTCTACCGCGAGTGCCCCGC  
GCCCCCTCTGGGCTCACTGCTACCTCCTGCGCCTCGCCAACTTCCTCATGTACCACTGCGACCTCGC  
CGAGGACACCTCCGGCGAGGGCCTCTTTGAGTGCTACTGCCGCTGCAACCTCTGCGCACCGCACCG  
CTGCCTCGCCACCAACACCGCCCTCCTCAACGAGGTGCAAGCCATCAACACCTTTGAGCTCCAGCG  
GCCCCCAAGCCCCGACGGCACCCCTGCCACCGCCCTTCAAGCTGACCCCCGGTCTCTGGACCTCCGC  
CTTCTCTCGCCACTTTGTCTCCGAGGACTACCACTCGGACCGCATCTCTTCTACGAGGACGTGTC  
CCGCCCCCAGGGTGGAGCCCTCCGCCTGCGTCATCAGCACTCGGCCATTCTCGCGCAATTGCA  
TGACATCAAAAAGGCCAGGGAAGAGTTTTTGTGACCAAAGGCCACGGCGTCTACCTAGACCCCCA  
CACCGGAGAGGAGCTCAACACCGCCGCCCCGTCCACCGCCACCATGCCGCCCCCTCCGGAGGAAGC  
CCATCCGCAGCAGCACCAGCACCAGCAGCAGCCGAGCCACCGCCGCCACCACCGCTCCAGCTA  
CGCAGACCGTGTCCGAAGCGAGCTCCACGCCTACGGCGGTGCGACCGGTTCTCCCGGACCCGT  
CTCTGGCGGATGCTCTGCCAGAGGAACCACTCCCGCGATGCTGCTCGAAGAAGAGGCTCTCAGCA  
GCGAGACCAGCGGCAGCTCCGAAGGCAGTTTGCTCAGTACCCTCGAGGAAGTGGAGGAGGAGG  
AACCGGTCAACCGACGAGGCCATCCAAGCCCTCCTACACCAACAGCAGCAGCAAGAGCATCA  
GCCAGCGCAGGAAGTCCGTCTCCCGAGCGAGGCTCGTAGATGGAATCAGACATCCATCCACCGGA  
GTAGCCAGCCAGGTAGGACACCTCCGCCCCCGGCCGACGCTCCTGGCGCCGCTACCGCCACG  
ACATCCTCTCGGCCCTGGAGTACTGCGCCGAGACGGAGCCTGCGTGCGCCGGTACCTACTCTACC  
ACCACAACATCAACATCCCTTCCAAGATCATCCGTTACTACAAATCCTCTTCCCGTTCCAGCGATC  
TCCAGGAAGGCCGACGAGCGGGCGGCAGCAGAACCGCCACGTCAGCCAGCTGAGAGCTAAGATC  
TTCCCCACGCTGTACGCCATCTTCCAGCAGAGCCGCGGCCGCGCCAGGACGCCCTCAAATCAGGAAC  
CGCACCTGCGCTCCCTCACCAAGAGCTGTCTGTATCACCGCGAGGAGGCCAAGCTGGAACGCACG  
CTCTCGGACGCAAGCTCTCTTCGAGAAGTACTGCGCTCGGCAGCGGCAGACCCGCGGTATTTA  
AGGAGCGGACCCGTGCGTGCGGACACCATGAGCAAAACAAATCCCCACCCCGTACATGTGGTCTTA  
TCAGCCACAATCTGGGCGTGCCGCGGTGCCCTCCGTGATTACTCCACCCGCATGAATTGGCTCAG  
TGCCGGGCTTCCATGATTGGCCAGGTCAATGACATCCGACACACCAGGAACCAGATTCTCATTG  
CCAGGCCCTTATCACCGAGACGCCACGCCCGTCCAAAATCCCCCGTCTGGCCCGCCAGCCTGTT  
GCCTCAGATGACGCAACCGCCACCCACCTGCACCTGCCGCGTAACGAAATTTTGAAGGCAGACT  
GACTGACGCCGGCATGCAATTAGCCGGGGCGGAGCCCTCGCACCCAGAGACTTATATGCCCTGAC  
CCTCCGCGGCAGAGGCATCCAGCTCAACGAGGACCTACCCCTCTCGGCGAGCACTCTCCGGCCGGA  
CGGCATCTTCCAGCTCGGAGGCGGAGGCCGCTCCTCCTTCAACCCACCCGACGCCTACCTGACGCT  
GCAGAACTCCAGCTCCCTTCCCCGCGAGCGGCGGCATCGGCAGCGAGCAATTTGTCCGCGAGTTGCT  
GCCCACGGTCTACATCAACCCCTTCTCCGACCGCCCGGGACCTACCCCGACCACTCATCGCCAA  
CTACAACATCCTAACGACTCTGTAGCAGGCTATGACTGACGGTCCCCAGGGTCAGCAGCGGCTG  
GGGAGCTCCTCGACCAGCACCGCCGCCAGTGCCCTAACCGCTGCTGCTTCGCCAGGGAAGGGATT  
ACCCGGAGTACTTTTGCATCACCCGCGAGCACTTTGAGGCCGAGTGATCCCCGACTCTCTGCAAG  
AAGGCCACGGTCTGCGCTTACGCTCCCCACGCGCTACAGCGACCGCCGCCACCGCGATGGAGACC  
GCACCATCCTCACTTCTGTAAGTACTGCGGCCCTGCTTCTTTCAAAGTTCGCTGTCTCTGCGGCCATC  
CTGCTCCTCACCTCTTCTTCTGACCTTCTGTGTGAGCTGTACAACCGCTCGTAGCGTCAGCCCC  
TACACCTCCCCTCGGTCCAATTTCTGTCCGACATAGAACCAGACTCTGACTCTTACTCGGGCTCT  
GGCTCTGGGGACGATGAAGATTATGAATATGAGCTGGCTACCAACACACCGAACGAAGACATTCTA  
GGCAGCATAGTCATCAACAACCAGATCGGGCCCAAGACCTGGCCCTGGGATACTTTTATGCCGCC  
ATGCAGTTTGTCTTCTTTGCCATCATCATCATCGTCCTCATCTCTACTACCGCCGCTACGTGCTG  
GCCACCGCCCTCATCGTGACGCGCAGATGTGGTCTCCGAGGCCGTCTGCGGAAAACCTTCTCG  
GCCACCGTTGTGGTTACTCCCCAAAACAAGTCAACCCCTGCAACTGCTCTGCGGCTTCGAGGAG  
ATGGTGTCTACTACACCACTCCGTCTTCATGCCCTGGTGGGCTCATCTCTGCTCACCGCCA  
TGGTCCGCTGGCCAACTGGATAGTGATCAGATGCCAGCAGGAACCGCGCCCCGCGCTGCCAC  
CGCCCCACCTATGTGGGACCTGCGCCGAGGACCACATCTACGATGAGCCAACCGTAGGGCAAT  
ACGTACAGATGAAGTAGCTCCCCCTCTTCCCATTTCCCATTTTTCTCTATTCAATAAAGTTGCT  
TACCTGAGTTCATCCACACTCGGTCTGCCAGTGAGTCTATCCATGCGCCGTTTTCCATACTCACA  
TAGCGCAGCCGCGCACGCTCGCCAGGTGACGAACTGTGAAATGTAACATTTGCGCTTCTGTC  
AGCAGCACCCGTTATAGACAGTTCCACCATGGGACCGAAGAAGCAGAAGCGGAGCTACCCGAG  
GACTTCGATCCAGTCTACCCCTATGACGTCCCGCAGCTGCAGATCAATCCACCTTCGTACGCGG  
GACGGATTCAACCAATCCGTGGACGGGGTGTGTCCCTGCACATCGCACCGCCCTCGTTTTTGAC  
AACACCAGGGCCCTCACCCTGGCCTTCGGGGGAGGTCTACAGCTCTCGGGCAAGCAGCTCGTCGTT  
GCCACCGAGGGCTCGGGGCTAACCAACCGGATGGCAAGCTGGTTCTCAAAGTCAAGTCCCCC  
ATCACCTGACCGCCGAGGGCATCTCCCTGTCCCTGGGTCCCGGTCTTTCTAACTCAGAGACCGGC

**FIG. 1-8**

SUBSTITUTE SHEET (Rule 26)

9 / 14

CTCAGTCTGCAAGTCACAGCTCCCCTGCAGTTCCAGGGCAACGCCCTCACTCTTCCCCTCGCCGCC  
GGTCTCCAAAACACCGATGGTGGAAATGGGTGTCAAACCTGGGGAGCGGTCTCACCACGGACAACAGT  
CAGGCGGTGACCGTTAGGTGGGAAATGGACTTCAGCTGAACGGCGAAGGACAACCTACCGTCCCC  
GCCACGGCCCCCTTTAGTCTCAGGGAGCGCAGGCATCTCTTTCAACTACTCCAGCAATGACTTCGTC  
TTAGACAATGACAGTCTCAGTTTGAGGCCAAAGGCCATCTCTGTACCCCTCCGCTGCAGTCCACA  
GAGGACACAATCTCCCTGAATTATTCTAACGACTTTTCTGTGGACAATGGCGCCCTCACCTTGGCT  
CCAACCTTTCAAACCTTACAGCTGTGGACTGGCGCCTCACCCACAGCAAATGTATTCTAACAAAC  
ACCACCACTCCCAACGGCACCTTTTTCTATGCCTGACACGTGTGGGTGGGTAGTTTTGGGTTC  
TTTGCCCTGAAATCATCCATCGACCTTACTAGTATGACCAAAAAGGTCAATTTTATTTTGTATGGG  
GCAGGTGCGCTTCAGTCAGACTCCACTTATAAAGGGAGATTTGGATTTAGATCCAACGACAGCGTA  
ATTGAACCCACAGCCGAGGACTCAGTCCAGCCTGGTTAATGCCAAGCACCTTTATTTATCCACGC  
AACACCTCCGGTCTTCCCTAACATCATTTGTATACATTAATCAGACATATGTGCATGTGGACATC  
AAGGTAAACACACTCTCTACAAACGGATATAGCCTAGAATTTAACTTTCAAAACATGAGCTTCTCC  
GCCCCCTTCTCCACCTCCTACGGGACCTTCTGCTACGTGCCCCGAAGGACAACCTACCGTCCCCGC  
CACGGCCCCCTTAGTCTCAGGGAGCGCAGGCATCTCTTTCAACTACTCCAGCAATGACTTCGTCTT  
AGACAATGACAGTCTCAGTTTGAGGCCAAAGGCCATCTCTGTACCCCTCCGCTGCAGTCCACAGA  
GGACACAATCTCCCTGAATTATTCTAACGACTTTTCTGTGGACAATGGCGCCCTCACCTTGGCTCC  
AACTTTCAAACCTTACAGCTGTGGACTGGCGCCTCACCCACAGCAAATGTATTCTAACAAACAC  
CACCCTCCCAACGGCACCTTTTTCTATGCCTGACACGTGTGGGTGGGTAGTTTTGGGTTCCTT  
TGCCCTGAAATCATCCATCGACCTTACTAGTATGACCAAAAAGGTCAATTTTATTTTGTATGGGGC  
AGGTGCGCTTCAGTCAGACTCCACTTATAAAGGGAGATTTGGATTTAGATCCAACGACAGCGTAAT  
TGAACCCACAGCCGAGGACTCAGTCCAGCCTGGTTAATGCCAAGCACCTTTATTTATCCACGCAA  
CACCTCCGGTTCTTCCCTAACATCATTTGTATACATTAATCAGACATATGTGCATGTGGACATCAA  
GGTAAACACACTCTCTACAAACGGATATAGCCTAGAATTTAACTTTCAAACATGAGCTTCTCCGC  
CCCCCTTCTCCACCTCCTACGGGACCTTCTGCTACGTGCCCCAGAGTGCCTAGAGAACCCTGGCCGT  
CAGCCGGCCTCCCCCTTCCAGGCCACCCGGTACACCACCCGCTCCATGTTTCTGTATGTGTTCTC  
CTCCCGCCGCTTGTGCAGCACCACTCCCGCTGCTCGAGCTGAGGATCCGTGATGGACACAAAGCC  
AGGAAGACACATCCTCAGCTCCGTGGGGGCGTCCAACAACCTGTTTATGTAAAGGAAAATAAAGACT  
CAGAGAAAATCCAAGTTCATATGATTTTTCTTTTATTGATTGGGGGAATTGATTAGGTGGGGTGT  
GCATAATCACAAAATCACATCAGCAGGTACACACCTGAGACATCAGACAGGGGTAAGGACAGCGC  
CTCAGCTTCTGGAACAGACATCAGAAATATTTAATCTGCTGGTAGCTAACACTCCTTCCCAACACC  
ATACACTCCTGGAGGGCCCTCTGCCTCTCCTCCTCCCGCTCCGCGTCCCTCTGCCGGGACCAACC  
TCCCCCTCCGTGAAGTGTGCTTCTCCCCCGCGCTGCGCCCCGATGGCCTCCGCCGCCAGCTTC  
AGCCAGTGCCGCAAGCGCTGGGCGCAGCGCCGAGCCACCGGCTCGCTCAGCTCGTGGCAGCGCCGG  
CACACCAGCACTATGTAATTGGCATAGTCCCCGTACAGTAGATGACCTCCCCCAGTGGAACATG  
CGCAACAGCTTCAGATCAGATCAGTCATACATGATCTTTATGTACATCAGGTGGGCGCCTCGAAACATC  
ACACTGCCACGTCATCAGCGGACTCAGCTGGGCGAGTTACCCGCTCCCTGAACCACCAGAAG  
ATGCGATTGTACTCGCAGCCCCGATGATCTCGCGCATCAGGGAGCGCATCACCACCTGCCCGCGC  
CGGCACTCCAGACTGGACCTTTTACAGACAGTGGAATGAAAGTTCCACAGCGTCGCGCCCCGACAG  
CGTCTCCGGGCTGAAACATATCTGCTCCAGCTCCAACCCCCCACACAGGCTGACTGCAGGAAAAT  
CCATTCTTGATGGGAAAGGATGTAGCGCCAGGGGACCACAATCTCCAAACAGGGAACAAAACATAC  
CGCGGCCCGGCTGTTGCGCACGGCCCCCACCAGGATGCAACGTGCTCACGGAGCAGATACGGGTGGG  
ACAGCGGCCACGCTCTATAGCAAGTCAAGTCCGGAAGTGGCAGCGGGTTGCGCCACCACTGCTACT  
GCTGCCGTGCGCCACCAGCTCCATCGGCTCCTCCATCCTCCTGTTCCATCGGCTGAGGTGCT  
GCCTCCTCCTCCTGCGCTGCTCCATCATGCTCGTCTGCGGTCTCAGGAGTCAAAAATTCA  
TTGGCCACCGCAGCAGAGAGAACATGGAGCGCAGGGGCCAGGTGCCCGGCCGTCGCTCGCTC  
AACTCCCCCAGCAGGTACTCATAGAGATGCTCCTCAAATCCACCGCAAACCAGGCATGCAGAAAC  
TCTTCCGTTTCGAGGACCGCCACGGTAAAGACATAGCCCTCCCGCACCTTACCGCTGCCAGCTGC  
ACGCGCTCATGTGCTGGGAGTACACCCGACCCGGGCCTGGATGTACTCCAGCACCTGATCGCTC  
AGACACCTCACAGAGATGCCAGCCTGAGCCAGCTTCTCATAGAGAGGTGGCTGAATCTTGAGCTTG  
AAGCAGCGAGCGGCTAGGCACTCCCCGCCCCCTTGAACAGGGCGGCGGGTACGCATGGACTTC  
CTCTACATCCGGGGTCTGGCCACCTCACAACTATCTGGCCAATCGCCTGACCACGGGTACCAG  
GTAAGGATGATGTCCGTTGTTGCGAATGAGAATGCTCAGAGGTGACTCGGTAGCGTTATCAATCAC  
GTCCCCAAAGGTCAAAGGTCCCAGTTAGAAGTCAGGTGCTTACAGCCGACAGACACGCCCATAGCA  
ACCAGTGGGAAAAGCCAGCAAGAGATCCGTGGGCACATGCACCGAAGCTCCCGCAGGAATCTCCAC  
CCACTCCGAGGCGTAGACCGTGTAAGCTACACACCCCGCCTCCCGAGTGGGAGCAGAAGCATCTC

**FIG. 1-9**

SUBSTITUTE SHEET (Rule 26)


10 / 14

GCTCAGCCGAAAGAACTTCAGGGTGGCCTGCATATCCTCTTTTACTCACTTGTTAGCAGCTCCACA  
CAGACCAGGGTTGTGTTGGCGGGAATAGGCAGCAGGGGTACGTCCCCAGTGAGGGACACCTGGATG  
GGGGGCAGAGGATTGATGCCAGGAAGCAGCAGGTACTGGGAAACAGAGACCAGATCCCTCCTCTGA  
AAAATCTCGCTCAGTCGGACAAACACAGCAAACCCAGTGGGCACGTAGACTAGCACATTA AAAAAGG  
ATCACGCTGGGCTGTTCTGACGTCAGCACCAGATGTCGGGACGTGCGCAGATGAATGCGGTTCTGA  
TGAATTACCGGAGGCCTCTCACCCGCAGCCAACAGCAGACCGGGCTGCTGATGCGGTCCCGCAGAC  
ATATATGAGTTCAATGTGTGTCTTTTTTCTAAACGTCTAGTGAGTGTGCTCGTCCTGCTCCTGCCA  
ATCAAAATCCGGGCACCAGGGCTGGTGGTTGGACCCGATGAAGAAGCGAGGAGAGGCGGCCTCCTG  
AGTGTGAAGAGTGTCCCGATCCTGCCACGCGAGGTAGGCGAAGTACAGATAGAGCACGGCGAGAAC  
AGTCAGCACCGCGGCCAGCAGCAGTCGGTTCGTGGGCCATGAGAGGGGGCTGATGGGAAGATGGCCG  
GTGACTCCTCTCGCCCCGCTTTCGGTTTCTCCTCGTCTCGCTCTCAGTGTCTCTCTGTGTGACG  
GCCGAGACGAGTGTGAGCGAACACCGCGAGCGGGCCGGTGATATACCCACAGCGGATGTGGCCACG  
CCTGCGGTTCGGTTAATCAGTACCCCATCGTCCGATCGGAATTCCCCCGCCTCCGCGTTAACGATTA  
ACCCGCCCAGAAGTCCCGGGAATTCCCGCCAGCCGGCTCCGCCGCGACCTGCGACTTTGACCCCGC  
CCCTCGGACTTTGACCGTTCCACGCCACGTCATTTCCACGCGACGTCACGTTCCACGCTACG  
TCACACCCCTCTCCACCAATCACCGCCCGCCGCCCAACCCTCTCCGCCAATCACCAGGCCACAA  
AAGGGGCAATAAAAGTGTGCGGTATATTATTGATGATG


**FIG.\_1-10**




12 / 14



**FIG.\_3A**





**FIG.\_3B**





**FIG.\_7**

SUBSTITUTE SHEET (RULE 26)



14 / 14

**FIG.\_6****FIG.\_8**



## SEQUENCE LISTING

<110> Reddy, P. Seshidhar  
Tikoo, Suresh  
Babiuk, Lorne

<120> PORCINE ADENOVIRUS TYPE 3 GENOME

<130> 293102002440

<140> Unassigned

<141> Unassigned

<160> 8

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 34094

<212> DNA

<213> Porcine Adenovirus Type 3

<220>

<400> 1

catcatcaat	aatataccgc	acacttttat	tgcccctttt	gtggcgtggt	gattggcgga	60
gaggggtggg	ggcggcgggc	ggtgattggt	ggagaggggt	gtgacgtagc	gtgggaacgt	120
gacgtcgcgt	gggaaaatga	cgtgtgatga	cgtcccgtgg	gaacgggtca	aagtccaagg	180
ggaaggggtg	gagccctggg	gcggtcctcc	gcggggcggg	gccgagcggc	ggaaattccc	240
gcacaggtgg	agagtaccgc	gggattttgt	gccctctgga	ccggaccttc	gccctccggt	300
gtggcacttc	cgcaccacac	gtccgcggcc	cggatttccc	cacctgacga	cggtagacac	360
actcacctga	gcgggggtgc	cttcgcgctg	agaggctcgc	ggcggccgcc	cgagatgacg	420
tgtgtgggtg	tattttttcc	cctcagtgtg	tatagtcgcg	gcagcgcccg	agagtcacta	480
ctcttgagtc	cgaagggagt	agagttttct	ctcagcgga	cagaccctcg	acatggcgaa	540
cagacttcac	ctggactggg	acggaaaccc	cgaggtggtg	ccggtgctgg	aatgggaccc	600
ggtgatctg	cgcgaccctt	ctccggggga	tgagggcttc	tgtgagccgt	gctgggagag	660
tctggtcgat	ggactgccgg	acgagtggct	ggacagtgtg	gacgaggtgg	aggtgattgt	720
gactgagggg	ggtgagtcag	aggacagtgg	tgggagtgcc	gctggtgact	caggtggctc	780
tcaggggggtc	tttgagatgg	accccccaga	agagggggac	agtaatgagg	aggatatcag	840
cgcggtgggt	gcggaggtgc	tgtctgaact	ggctgatgtg	gtggttgagg	accacttgc	900
gccaccctct	ccgtttgtgt	tggactgccc	cgaggtacct	ggtgtgaact	gccgctcttg	960
tgattaccat	cgctttcact	ccaaggaccc	caatctgaag	tgcagtctgt	gctacatgag	1020
gatgcatgcc	tttgctgtct	atggtgagtg	tttttgaca	tttggtggat	tatgtggaaa	1080
aaaaggaaaa	agtgtttgta	agaaatctca	tgtgtctatt	ccattttttt	gtcttttttag	1140
aagctgtttc	tccagcacct	cacaggtcgg	gttccccggg	acttgagagc	ctgccaggac	1200
gcaagaggaa	gtactgctat	gactcatgca	gcgaacaacc	tttggacctg	tctatgaagc	1260
gcccccgga	ttaatcatta	acctcaataa	acagcatgtg	atgatgactg	attgtctgtg	1320
tctctgccta	tatataccct	tgtggtttgc	aggggaaggga	tgtggtgact	gagctattcc	1380
tcagcatcat	catcgctctg	cttttttcta	ctgcaggcta	tttcttgcta	gctcgctgtc	1440
ccttttcttt	ttctgtgggc	atggactatc	aacttctggc	caagcttact	aacgtgaact	1500
accttaggaa	ggtgatagta	caggggtctc	agaactgccc	ttggtggaaa	aagatttttt	1560
cggacaggtt	tatcaaggta	gtagcagagg	ccaggaggca	gtacgggcaa	gagttgattg	1620
agatttttgt	ggaggggtgag	aggggctttg	gtcctgagtt	cctgcgggaa	gggggactgt	1680
acgaagaggc	cgttctgaaa	gagttggatt	tcagcacctt	gggacgcacc	gtagctagtg	1740
tggctctggt	ctgcttcatt	tttgagaagc	ttcacagca	cagcgggtgg	actgacgagg	1800
gtatttttaag	tcttctggtg	ccgccactat	gttccctgct	ggaggcgcgga	atgatggcgg	1860
agcaggtgcg	gcaggggctg	tgcatacatca	ggatgccgag	cgcgaggcgg	gagatgctgt	1920
tgcccagtgg	gtcatccggc	agtggcagcg	gggccgggat	gcgggaccag	gtggtgccca	1980
agcgcgccgcg	ggagcaggaa	gaggaggagg	aggacgagga	tgggatggaa	gcgagcgggc	2040

gcaggctcga	agggccggat	ctggtttaga	tcgccgccgg	cccgggggag	cggttgagaga	2100
ggggagcggg	gaggagcgcg	gggggtcttc	catggttagc	tatcagcagg	tgctttctga	2160
gtatctggag	agtcctctgg	agatgcatga	gcgtacagc	tttgagcaga	ttaggcccta	2220
tatgcttcag	ccgggggatg	atctggggga	gatgatagcc	cagcacgcca	aggtggagtt	2280
gcagccgggc	acggtgtacg	agctgaggcg	cccgatcacc	atccgcagca	tgtgttacat	2340
catcgggaac	ggggccaaga	tcaagattcg	ggggaattac	acggagtaca	tcaacataga	2400
gcccgtaac	cacatgtgtt	ccattgcggg	catgtggtcg	gtgactatca	cggatgtggt	2460
ttttgatcgg	gagctaccgg	cccgggggtg	tctgatttta	gccaacacgc	acttcacct	2520
gcacggctgc	aacttcctgg	gctttctggg	ctcggttaata	acggcgaacg	ccgggggggt	2580
ggtgcgggga	tgctactttt	tcgcctgcta	caaggcgctg	gaccaccggg	ggcggtctgt	2640
gctgacgggtg	aacgagaaca	cgtttgaaaa	gtgtgtgtac	gcggtggtct	ctgcggggcg	2700
ttgcaggatc	aagtacaact	cctccctgtc	caccttctgc	ttcttgaca	tgagctatac	2760
gggcaagata	gtggggaaca	gcactatgag	cccttacacg	ttcagcgacg	acccctacgt	2820
ggacctgggtg	tgctgccaga	gcgggatggt	gatgccctg	agcacgggtg	acatcgctcc	2880
ctcgtctcgc	ctgcctacc	ctgagttccg	caagaatgtg	ctcctccgca	gcaccatggt	2940
tgtgggcggc	cgctgggca	gcttcagccc	cagccgctgc	tcctacagct	acagctccct	3000
ggtggtggac	gagcagtcct	accgggggtct	gagtggtgacc	tgctgcttcg	atcagacctg	3060
tgagatgtac	aagctgctgc	agtgtacgga	ggcggacgag	atggagacgg	atacctctca	3120
gcagtacgcc	tgctgtgcg	gggacaatca	cccctggccg	caggtgcggc	agatgaaagt	3180
gacagacgcg	ctgcgggcc	cccgtccct	ggtgacgtgc	aactgggggg	agttcagcga	3240
tgacgatgac	tgagatgag	tcacccctc	ccctcctctt	gcaggtacgt	ggccccgcc	3300
agtgggatgg	gctttggatg	ggggagggggt	gttccctata	aaagggggat	gggggtggag	3360
gcatgcagcc	ccacggggaa	gcttgtgtgg	aggatgtctt	ccgaggggtga	gatccggacc	3420
tgcttcattt	cagctcgtct	tcccagctgg	gccggcgtgc	gtcagggagt	ggccgggacg	3480
aatgtgaacg	gcggagtgggt	gggcgcccct	gccagagcg	gggtgctggc	ctactcccgc	3540
ttcgttcagc	agcaacagca	gcagccgggg	acggcggcga	cggggtctgt	gttccggggc	3600
gtgtttccat	cggtgatct	gagcgcggag	gtgggcatga	tgcggcaggc	gctggcggag	3660
ctgcggcagc	agttatggat	gctgcgggag	gtggtggaga	tacagctgcg	ggccacggcc	3720
tcggaggcgg	ccgaggagga	agaggaggag	gagattgtgg	tgacagagga	ggtggcgccc	3780
ggcgctggag	cgaacacccat	ggaagaggag	gaggatgaga	tggtcctgac	gatgactgtg	3840
gtgggggacc	ctgagcctgc	tggagtggaa	gccagccgc	caccaccacc	caccccgag	3900
agcgaccctg	cggtgcctgc	tactaccact	accccgagc	ggctcagcta	cggcgcgagc	3960
aagaggagcg	gtccatgcgc	ggaggacaac	tgacgcggac	tgtgggggga	agaaggggga	4020
ggaggaaaga	agaccatgga	gacgggtggt	tgtcttttct	cagcccaact	ttattgagaa	4080
taataataaa	gcttatggat	gtttggaacg	ataatagcgt	gtccagcggt	ctctgtcttg	4140
cagggtcttg	tgtatcttct	cgaggcaccg	gtagacctgg	tggtggacgt	tgaatacat	4200
gggcatgact	ccctcggcgg	ggtgcaggta	aagccactgg	agggctgggt	gcggggggca	4260
ggtgcagtag	atgatccagt	cataggcggt	ctggttgccg	tggtggttga	aaatgtcctt	4320
gaggagcagg	ctgatggcgg	tgggcagacc	cttggtgtag	gcattgatga	accggttgac	4380
ctgggcgggc	tgcatgaggg	gggacatgat	gtggtacttg	gcctggatct	tgaggttggg	4440
gatgttgccg	ctctggtcgc	ggcgggggtt	catgttgtgg	aggacgacga	ggacggcgta	4500
gccggtgcag	cgggggaagc	gggcgtgcag	cttgaggggg	aaggcgtgga	agaacttggc	4560
gaccccttg	gttccgccga	ggctcctcat	gcactcgtcg	aggacgatgg	cgatgggtcc	4620
gcgggcggcg	gcgcgggcga	agacgttgcg	tgagtcagtg	acatcatagt	tgtgctcctg	4680
catgaggtcc	tggtagctca	tgccgacaaa	gtctggcatg	agggtgccgg	tctgggggat	4740
taggggtgtg	tccggaccgc	tgccggtagt	gcctcgcag	atctgggtct	cccaggcgac	4800
tacctcctgc	ggggggatca	tgtccacctg	cggggtgatg	aagaaaacag	tctccggcgg	4860
gggggagagg	agttgggagg	agatgaggtt	gcggagcagc	tgggacttgc	cggagccggt	4920
gggaccgtag	atgacagcga	tgactggctg	gacctggtag	ttgagggagc	ggcaggtgcc	4980
agccgggggtg	aggaagggca	tgacggcggt	gaggggtgctg	cgcaaggttgc	ggttctcttg	5040
gacgaggtcc	tgacggaggt	gtcggcctcc	cagggagagg	aggtgggaga	gggaggcgaa	5100
ggccttgagg	ggcttgaggc	cctcggcgta	gggcatgtcc	tgacgggcct	ggtggagcac	5160
gcgcagtgcg	tcccagagct	cggttacatg	tcccacggta	tcgtcctcca	gcaggtctgg	5220
ttgtttctcg	ggttggggtt	gctgcgtgag	tacggaaacga	ggcggtgggc	gtcagcgggg	5280
tggaggggtcc	ggtccttcca	gggcgggagg	gcccgcgtga	gggtggtctc	ggtgacgggtg	5340
aagggggcg	tctggggctg	ctcgggtggc	agggctcctc	tgaggctgag	gcggctggtg	5400
ctgaagggtg	cgtctccgag	ctgcgcgtcg	tccaggtagc	actggcggag	gaggtcatag	5460
gagaggtgtt	gggtggcatg	gcccctggcg	cggagcttgc	cggggccgcg	gtgcccga	5520
gcacgcgaaa	cgggtgtcgcg	cagggcgtag	agcttggggg	cggagcaggac	cgtctcggag	5580
ctgtgggcgt	cgtgtcggca	gcgctcgcac	tgggtctcgc	actcgaccag	ccaggtgagc	5640
tgggggttct	ggggatcgaa	gacgaggggg	cccccgttcc	gcttgaggcg	gtgtttacct	5700

ttggtctcca	tgagctcgcg	tccggcgcgg	gtgaggaaga	ggctgtcgg	gtccccgtag	5760
acggagcgca	ggggccggtc	ggcgatgggg	gtgcccggt	cgccggcgta	gaggatgagg	5820
gcccactcgg	agatgaaggc	acgcgcccag	gcgaggacga	agctggcgac	ctgcgagggg	5880
tagcggtcgt	tgggcaactaa	tggcgaggcc	tgctcgagcg	tgtggagaca	gaggtcctcg	5940
tcgtccgcgt	ccaggaagtg	gattggtcgc	cagtggtagt	ccacgtgacc	ggcttgccgg	6000
tcggggggta	taaaaggcgc	ggcccggggt	gcgtggccgt	cagttgcttc	gcaggcctcg	6060
tcaccggagt	ccgcgtctcc	ggcgctcgcg	gctgcggctg	catctgtggt	cccggagtct	6120
tcagggtggg	acgctacgac	aaagtccggg	gtgacctcag	cgctgagggt	gtctgtttct	6180
atgaaggcgg	aggagcggac	ggagaggctg	ccgcgggcga	tggcttcgg	ggtgcgggcg	6240
tccatctggc	tggcgaagac	caccttctta	ttgtcgaggc	gtgtggcgaa	actgccgtag	6300
aggcggttgg	agagaagctt	ggcgatgctg	cggagcggtt	ggtttctgtc	ccggtcgggc	6360
ttttccttgg	cagcgatggt	gagctgcacg	tagtctcggg	cgaggcagcg	ccactcgggg	6420
aagatcggtg	tgcgctcgtc	cggcaggagg	cgcacggccc	agccacggtt	gtggagggtg	6480
accacgtcca	cgtaggtggc	tacctcgccg	cggaggggct	cgttggtcca	gcagaggcgg	6540
ccgcccttgc	gggagcagta	ggggggcagg	acgtccagct	ggtcctcgtc	gggggggtcg	6600
gcgtcgatgg	tgaagagggc	ggcaggagg	tcggggtcga	agtagctgag	gggctcgggg	6660
ccgtcgaggc	ggtcctgcc	gcggcgggcg	gccagggcgc	ggtcgaagg	gttgaggggt	6720
tggccggcgg	ggaaggggtg	ggtgagggcg	ctggcataca	tgccgcagat	gtcatagacg	6780
tagaggggct	cccgcaggag	gccgatgaag	ttggggtagc	agcggccgcc	gcgcaggctc	6840
ttcgcggagc	tagtcataca	gctcgtggga	gggcgcgagg	aggttcggcc	gaggtcgccg	6900
gcctggggcc	ggtctggcgc	gtagaggagc	tgcttgaaaga	tggcgtggga	gttgagctg	6960
atggtggggc	tctggaagac	attgaaggcg	gcgtggggaa	ggccggcctg	cgtgtggacg	7020
aaggcgcgg	aggactcttg	cagcttgccg	accagacggg	cggtgacgac	gacgtcctgg	7080
gcgcagtagc	gcagggtggc	ctggacgatg	tcgtaagcgt	ccccctggct	ctccttcttc	7140
cacaggtcct	tggtgaggag	gtactcctga	tcgctgtccc	agtacttggc	gtgtgggaag	7200
ccgtcctgat	cgcgtaagta	gtcccccg	cggtagaact	cgttcacggc	atcgtagggg	7260
cagtgtccct	tgtccacggc	cagctcgtag	gccgcggcgg	ccttgccgag	gctgggtgct	7320
gtgagggcga	aggtgtcccg	gacatgaac	ttgacgtact	ggtgctgggg	gtcctcgggg	7380
gccatgacgc	cctcctccca	gtccgcgtag	tcgcggcgcg	ggcggaaggc	ggggttgggg	7440
aggttgaagc	tgatgtcatt	gaagaggatg	cgcccggtgc	gcggcatgaa	ggtgcgggtg	7500
accaggaagg	aggggggcac	ctcgcggcgg	tgggcgagca	cctgcgcggc	caggacgatc	7560
tcatcgaaag	ccgagatggt	gtggcccacg	atgtagacct	ccaggaagag	gggcggcccc	7620
cgcaggcggc	ggcgccgcag	ctgggcatag	gccagggggt	cctcggggtc	gtccggcagg	7680
ccggggcccc	gctcctgccc	cagctcggcg	aggtctgggt	tgtggggccag	cagggtgctg	7740
cagaggggtg	ggcctgacgg	ggcctgcagg	gcgtgccgca	gggccttgaa	ggcgcgcccg	7800
atggcgcgct	tctgcgggca	gagcatgtag	aagggtgtgg	ctcgggtctc	cagcgtgca	7860
ggcgggctct	ggacggccac	cacctgcagc	gcggcgctca	gcagctcttc	gtcccccgag	7920
aggtggaaga	ccagcaggaa	gggcacgagc	tgctttccga	agcggccgtg	ccaggtgtag	7980
gtctccaggt	cataggtgag	gaagaggcgg	cgggtgccct	cgggggagcc	gatggggcgg	8040
aaggcgatgg	tctgccacca	gtcggccgct	tggcgctgaa	cgtggtggaa	gtagaagtcc	8100
cggcggcgca	cggagcagg	gtgggcggtc	tggaaagatg	ggccgcagtg	ctcgcaattc	8160
tgggctcctc	ggatgctctt	gatgaggtg	cagcgccctc	gggtgaagag	caggcgagg	8220
gggaagggga	ggcgggcgcg	cgggcccctg	ggcggggggt	cccagcgcac	gtggtgcagg	8280
tgggtgtgct	ggcggtgac	cacctggacg	aagggtggcc	cggcggcgcg	ggccagctcc	8340
accgcggtct	ggggggtagc	ctgcaggagg	tcggggggcg	ggcgaggag	gtgcagctgg	8400
aagaggttgg	ccagggcgct	gtcccagtg	cgggtgtagg	tgatgtctca	gctctccccg	8460
tcctgggtgg	tgcctggag	gcggaggggt	gcgcggcgct	cgagcaggag	ccccgcgctg	8520
ccggcctccg	cggcctcggc	ggcggcggcc	ggtctcaggc	gggcagctgg	gccaggggca	8580
cgggcgcggt	gagctcgggc	agcgggaggt	ggtcgcgcg	cagacgcgag	gcgtgggcga	8640
tgacgcggcg	ggtgatgttc	tggatctgcg	gggtcccgg	gaagaccacg	ggcccgggtg	8700
ctcggaacct	gaaagagagt	tccacggaat	caatgtcggc	atcgtgggtg	gccacctggc	8760
gcaggatctc	ggacacgtcc	ccgctgtttt	cgcggtaggc	gatgtcctgc	atgaactgct	8820
cgagctcgte	ctcgtccagg	tccccgtggc	cggcgcgctc	cacggtggcg	gccaggctga	8880
cgggtgatgcg	gttcgatgat	gccaccagg	cgttctctcc	gttctcgttc	cacacgcgac	8940
tgtagaccag	ctggccgctg	gcgtcccgcg	cgcgcatgac	tacctgggcc	aggttgagcg	9000
ccaccaggcg	gttgaagggc	gctgcaggc	gcaggcggtg	gtgcaggtag	ttgagggtgg	9060
tggcaggtg	ctcgcagagg	aagaagtta	tgaccacg	gcgcagggtc	agctcgttga	9120
tgtcgcccg	gtcctcgagg	cgctgcatga	cccggtagaa	ctcggggg	aagcgaaaaa	9180
actcgtgctg	gcgggcccag	accgtgagct	cctcttccag	ggcgggcgatg	gcctcggcca	9240
ccgcctgccc	cacctcctcc	tctaaggagg	gcggggcgct	gctgggtccc	gccaccgccc	9300
cctcttcttc	ctcttctccc	tccaggggtg	gcattctctc	gtcttcttct	tctgctgctg	9360

ctgcctccgc	ggggacgggg	ggcgacaggcc	ggggacggcg	ccggcgcaag	ggcagccggt	9420
ccacgaagcg	ctcgatgacc	tcgccccgca	tgcggcgcat	ggtctcggtg	acggcgcggc	9480
cgccctcccg	ggggcgagc	tcgaaggcgc	ccccgcgag	cgcggtgccg	ctgcagaggg	9540
gcaggctgag	cgcactgatg	atgcagcgtg	tcaactctct	cgtaggtacc	tcctgctgtt	9600
gcagcgcttc	ggcaaaactcg	cgcacctgct	cttcggaccc	ggcgaagcgt	tcgacgaagg	9660
cgtctagcca	gcaacagtcg	caaggtaagt	tgagcgcggt	gtgcgtcggg	agccggaggt	9720
gccggctgac	gaggaagtga	aagtaggccg	tcttgagctg	ccggatggcg	cgcaggaggg	9780
tgaggtcttt	gcggccggcg	cgctgcaggc	ggatgcggtc	ggccatgccc	caggcctcct	9840
gctggcagcg	gccgatgtcc	ttgagctgct	cctgcagcag	atgtgccacg	ggcacgtccc	9900
ggtcggcgtc	caggtgggtg	cgaccgtagc	cccgacgggg	gcgcagcagc	gccaggtcag	9960
ccaccacgcg	ctcgccagg	atggcctgct	gcctgcgctg	cagggagtct	gagaagtcag	10020
ccaggctccag	gaaccggttg	taggcgcccg	tgttgatggt	gtaggagcag	ttgccacgca	10080
cggaccagtt	gaccacctgg	tagtggggct	ggatgacctc	ggtgtagcgc	agtcgactgt	10140
aggcgcgctg	gtcaaagatg	taatcgttgc	agaggcgag	caggtgctgg	tagccacga	10200
gcaggtgggg	cggaggtag	aggtagagg	gccagtgttc	cgtggccggt	tggcgggggg	10260
agaggttcat	gagcatgagg	cggtagtagc	ggtagatgaa	gcgggacatc	caggcgatgc	10320
cgacggcgga	gacggaggcg	cgggtccact	ggtgggcgcg	gttccaaatg	ttgcgcaccg	10380
ggcggaagag	ctccacggtg	taaatggatt	gccccgtgag	gcgggcgag	tcgagggcg	10440
tctgtcaaaa	agaaccgggt	gtggttgggt	ggtgtgtggt	agcgatctat	ctttctttgt	10500
gatcttggta	gtgaagcctg	ccaggctcca	gcaggggcg	tccgcgctct	ttccttctct	10560
ccctatctgg	aggtgtgtct	ctgttctctt	ttttatttca	tgtagccatg	catcccgttc	10620
tgcggcagat	gaagccgccc	gccggcgccc	tgggcgcgga	gggggcgacg	cgctctcggt	10680
cgccctcgcc	gtcgtgacg	cgcccgcgcg	aggaggggga	gggcctggcg	cggtgtcg	10740
gcgcggcggc	ccccgagcgg	caccacgggg	tgcagctcaa	gcgagaggcc	atggaggcct	10800
atgtgccgag	gcagaatgcg	ttccgcgagc	gaccggggga	ggagggggag	gagatgaggg	10860
acctgcgggt	ccgcgcgggg	cgggagatgc	agctggaccg	ggagcgagtg	ctccagccc	10920
aggactttga	ggggcgcggtg	gaggagcgcg	ggggagtga	cgcggcgcg	gcccacatga	10980
gcgcggccag	cctggcccag	gcctacgagc	agacggtagc	cgaggaggtc	aacttccaaa	11040
agaccttcaa	caacaacgtg	cgcacctgg	tgagccggga	cgaggtgacc	atgggactga	11100
tgcacctgtg	ggactttgtg	gaggccttcc	tgcagcacc	ccggtcccgc	gcgctgaccg	11160
cgcagctgct	gctgatcgcg	cagcactgcc	gggacgaggg	catggtgaag	gaggcgctgc	11220
tgagcctggg	cgcgcccag	agccgctggc	tggtagacct	ggtgaacctg	ctccagacca	11280
ttgtggtgca	ggagcggtcc	atgagcctga	gcgagaaggt	ggcgccatc	aactactcgg	11340
tggcgacct	ggccaagcac	tacgcgcgca	agagctccac	cttctacatg	cgcgcggtgg	11400
tgaagctgct	ggtgctggcc	gacaacctgg	gcatgtaccg	caacaagcgg	ctggagcgcg	11460
tggtcagcac	ctcgcgcgcg	cgcgagctca	atgacaagga	agctcatgtt	tggcctccgc	11520
cggcgctgg	ccggggagg	cgaggaggac	ctggaggagg	aggaggacct	ggaggaggcg	11580
gaggaggagg	agctggaaa	aggaggagtt	cgggtccccg	ggaccgcggc	cggtgaggtg	11640
gcagtcctcg	ctgactgcga	gcgatgaggg	tgatgtgtac	tgatggcaac	catccccctt	11700
tttaacaaca	acagcagcat	ggcggcgagc	tctgaagctg	ggcgggcggc	ggcggggggt	11760
agcgcgccct	cctggcgccc	cgagcgggcg	acgcggtg	aggcgctgcc	ctccctggac	11820
gagccttggg	agcaggctct	gcggcgcatc	atggcgctga	cgcccgacgg	gtctcgggcg	11880
ttcgcgagcc	agccctggc	caaccgcatc	ggggccatcc	tggaggcggt	ggtgcctccg	11940
cgacgaacc	cgacgcacga	gaaggtgctg	accgtggtga	acgcgctgct	ggagacctcg	12000
gccatccgcc	cggacgaggc	cggcatggtg	tacgatgcgc	tgctggagcg	ggtctcccg	12060
tacaacagcg	gcaacgtgca	gaccaacctg	gaccggctgt	cccaggacgt	gcggcaggtg	12120
atcgcccagc	gcgagcgctc	gagcgccaac	aacctgggca	gcctggccgc	gctgaatgcc	12180
ttcatcgctc	cgctgcccgc	aacggtggag	cggggccagg	agagctacct	ggggttccct	12240
agcgcgctc	ggctgctggt	gagcgaggtg	ccgcagacgg	aggtgttccg	ctcggggccc	12300
cacaccttcc	tgcaggcggc	gcggaacggt	tccaagacgg	tgaacctcaa	ccaggccatg	12360
gagaacctgc	ggccctgtg	ggggctgcag	gcccccgctg	gggagcgcg	gcacgtgtcc	12420
tccttctgta	cgcccaacac	ccggctgctg	ctgctcctgg	tggctccctt	cgcgaggag	12480
atgaacgtca	gccggagctc	ctacattggg	cacctgctga	cactctaccg	cgagacgctg	12540
gccaacttgc	atgtggacga	gcgcacgtac	caggagatca	ccagcgctcag	ccgggcgttg	12600
ggcgacgagg	acgacgcggc	gcggctgcag	gccacctca	acttcttcc	gaccaacctg	12660
cagcgcgcg	tgccggcggc	gtatgccctg	accgcgag	aggagcgcat	cctgcgctac	12720
gtgcagcagg	ccgtgagcct	gtacctgatg	caggacgggg	cgacggccac	gggcgccttg	12780
gacgaggcca	gccgcaacct	ggagcccagc	ttctacgcgg	cgcaccggga	cttcatcaac	12840
cgcctgatgg	actacttcca	tcgcgcggcc	gcggtggcgc	ccaactactt	tatgaatgcc	12900
gtcctgaacc	cccgtggct	gccctcgag	ggcttcttca	ccggcggtga	tgacttccc	12960
gagcaggacg	agggggagga	gcggccctgg	gacgccttgg	acagcgacga	ggagggccgc	13020

ctcatgctgc	ggtccgcagc	ctcctcagag	ccctcctcct	ccttcacccc	cctgccccctg	13080
accgaggagc	cgccctcgcg	gccctccacc	ccggccctct	cgcgcgtecc	gtccccgggca	13140
tcctccctgc	tctctctggc	ctctctggga	aagcgggagg	gaggggactc	gctcgcttac	13200
tcgcccggca	cgccaccta	tggtctctcg	tgggctcgc	gccgctccag	cctggccagc	13260
ggcgccgaca	gcctggagt	ggacgcgctg	ctggccctc	ccaaggatgt	gaacgagcac	13320
ccaggcgccg	ccgcggccg	ccgcgcgcgc	gcctcccgct	cctccctgga	ggaggacatc	13380
gacgccatca	gcagccggct	gttcacctgg	cgacgcgcgc	cccaggagat	gggcctgccc	13440
gtggccagct	tctcccgccg	ccaccagccg	cgccccgggg	ccctcgaaga	cgacgaggag	13500
gaggaagact	ggcgccagga	ccggttcttt	cgcttcgaag	cgcccagga	aaaccccttc	13560
cgccacatcg	cccccaagg	gctgtaatgc	aaaaaagcaa	aataaaaaaac	ccctcccggt	13620
ccaactcacc	acggccatgg	ttgtccttgt	gtgcccgtea	gatgaggagg	atgatgccag	13680
cagcgccgcc	gcagggagcg	tcgctctcgc	cgctctacga	gagtgtggtg	gggtcttcgc	13740
tcacggagcc	tctttatgtg	ccgcgcgggt	acctgggccc	caccgagggg	cggaacagca	13800
tcctgtattc	acagctcccg	ccgctctacg	ataccacaaa	gatctatctg	atcgataaca	13860
agtcggcgga	tatcgccagt	ctgaactacc	aaaacaacca	cagtgaacttt	ctcaccagcg	13920
tggtgcagaa	cagcgacttc	acgcccattg	aggcgagcac	gcagaccatc	aacctggatg	13980
agcgctcgcg	ctggggcggg	gagtttaaga	gcattctgac	caccaacatc	cccaacgtga	14040
cccagtacat	gttcagcaac	agcttcgggg	tgcgccctgat	gagcgcgcg	gataaagaga	14100
caaatgcccc	cacctacgag	tggttcaccc	tgacctgccc	cgagggaac	ttctcggaca	14160
tcgcggtcat	cgacctgatg	aacaacgcga	tcgtgcgaga	ctacctggcg	gtggggcggc	14220
agcagggggt	caaggaggag	gacatcgggg	tgaagatcga	cacgcgcaac	ttcgcctgg	14280
gctatgaccc	ggagaccaag	ctggctcatgc	ccggcagcta	caccaacatg	gcctttcacc	14340
ccgacgtggt	gctggcaccg	ggctgcgcca	tcgacttcac	cttctccgc	ctaaàcaacc	14400
tgctgggcat	ccgcaagcgc	tacccctacc	aggagggtt	catgctgacc	tacgaggacc	14460
tggggggggg	caacatcccc	gcgctgctgg	acctcaccac	ctatgatcag	gagaactcca	14520
gcaccatcaa	gccccgaag	caggacagca	agggtcgag	ctaccacgtg	ggcgaggacc	14580
ccgagggcgg	ggacaccttc	acctactacc	gcagctggta	cctggccctac	aactacgggg	14640
accggccac	gggcaccgcc	tcccagacgc	tgctggtctc	ccgggacgta	acctgcggag	14700
tgagacaggt	ctactggagc	ctgccggacc	tgatgcagga	cccggtgacc	ttccggccca	14760
gccagacgcc	gagcaactac	ccggtggtag	ccacggagct	actgccgctg	cgctcccggg	14820
ccttctacaa	cacccaggcc	gtgtactccc	agctcctgca	gcaggccacc	aacaacaccc	14880
tggtctttta	ccgcttcccc	gagaaccaga	tcctcctgcg	cccgccagag	tccaccatca	14940
cctccatcag	cgagaacgtg	ccctcgctga	cggaccacgg	cacgctgccg	ctgcgttaaca	15000
gcatccccgg	ggtgcagcgg	gtaaccgtca	ccgagcgcg	gcgcgcgctg	tgtccctatg	15060
tgtaacaagag	tctcggggtg	gtgaccccga	gggtgctcag	cagccgaacc	ttctaaccga	15120
cagccctacc	cgtcacaggg	gagacagaga	aaagacagcc	agccccgcca	tggccatcct	15180
cgtctcgccc	agcaacaact	ttggctgggg	actgggcctg	cgctccatgt	acgggggcg	15240
ccgcgcgctg	tccccggatc	accccgatg	cgctccgacg	cactaccggg	ccaactgggc	15300
cagtctgaag	ggacgcgctg	cccccagcac	catagcgaca	acggatgacc	ctgtggccga	15360
cgtggtcaac	gcgatcgccg	gcgccacccc	ccgcccgcgc	cgccatcgte	gacgtcgag	15420
ggcgcgcgcg	gtctcctccg	tgcccgctac	cggggacccg	gtggccgatg	tggtcaacgc	15480
ggtggaggcg	gtatcccggc	gcgcgcgcgc	gcggcgccgt	tcttcgcgca	tgacagaccac	15540
gggggacccc	gtggcggtatg	tggtggcggc	ggtggaagcg	gtggcgcgcc	ggaggcgag	15600
cacccggcgg	cggcgcaggc	gctccgcgc	ggccatcctg	ggggtgcgcc	gcagccgccc	15660
cctccgcaaa	cgcacctcgt	cctgagattt	ttgtgttttg	ttttttctgc	ctcccggtgg	15720
tgaacaagtc	catccatcca	tccaacatcc	gtggctgctg	tgtctttgtc	ttttctttgc	15780
gttgcgcccc	agttgagccg	gcaccgacgc	gctcgcccat	ggccatctcg	cgccgcgtga	15840
aaaaggagct	gctgcaggcg	ttggcgcccc	aggtgtacgg	ggcgccctaag	aaggaggaga	15900
aggacgtcaa	agaggagtcc	aaagctgacc	ttaaaccgct	gaagaagcgg	cgcaaggcca	15960
agcggggggt	gagcgacagc	gacgaggtgc	tggtgctggg	cacgcgcccc	aggcgccgct	16020
ggacggggcg	gcgcgtgcgc	gcccacctac	cgcccggtgc	cagcctcgcc	tacgtcccgg	16080
gtcttcggag	gtcgagcgcc	accaagcgct	ctgcggacga	gttgatgcg	gacacggaca	16140
tcctgcagca	ggcgctccag	cgctgaacg	aatttgctta	tggcaagaga	gcccggcgcc	16200
agcggcgggc	ccgccccctc	ccgacccccg	cgtcccgcgg	ccggaccacc	aagcgctctt	16260
atgacgaggt	cgtggcagac	agtacatcc	tgcagcaact	tggatccggg	gaccgctcca	16320
atgagttctc	ctatggcaag	cggctcgctg	tggggagtc	aggagacacc	gtcccgtctg	16380
tgggcgctccc	gctggaggaa	ggcaggaaacc	acacacccag	cctgcagccg	ctcaccgagc	16440
ccatgcccct	ggtgtcccct	cgacagggcg	tcaagcgccg	ggcgccccgc	gacgagccca	16500
ccgcctcact	ggtccccacc	gtgcaggtcc	tgccccccaa	gcgtcgtctg	caggaggtgg	16560
tggtggagcc	gcccgtcca	gcacccacgc	cgccctcagc	cccgcggcg	tccagccggc	16620
gcatcattct	ggctccgcgc	cgggcggggc	ggccccaggc	cgctcgtggcg	ccgcagctca	16680

gcgcggccgc	ggcgctggag	cggcgggcgg	ccgcgcgtgcc	cctgccaccg	gacacggagg	16740
acgacctggt	ggagatggca	gaggctgtcg	ccgcgcccga	ggtgctgccc	agcctccccg	16800
tctccatcat	gccgcccacc	gccacggagg	tgcccttgcc	cgtacagacc	ccactgccgc	16860
ccgtggcggt	ggccaagagc	tccctgacct	ccggcctccg	cgcgctgatg	ggcaccgagc	16920
gggtgccggt	tccagtcctg	gaggcgcccc	tggtggccat	gcccgtgctc	cgggccacca	16980
ccgcccgtgc	cgagcccccg	cgcgcgtgc	cccgcagggc	cgtgcgggac	atcccggcca	17040
ggcagccccg	cacggtatcc	ctgcccgtgc	tcacggagcc	cggcccggcc	accgcggtcg	17100
cctccgtgcg	cgcggcagcc	caagtcctgc	aggcgccccc	cgcgcgaccg	gccaccgtct	17160
ccgtgggggt	gggcaccgag	ccggtggtgc	agtccatcac	ggtcaagcgg	tcaaagcgcc	17220
tgaccaagca	ccatcggggt	gcagaccatc	gacgtcaccg	tgcccaccgt	ccgcactgtc	17280
agcgtgggca	ccaacacgcc	ccggtgagg	agcgctccgg	tgggcgcca	gaccgtccc	17340
gagaccgct	ccagggggt	gcaggtggct	ttccaaccag	cgtgctagcc	caccgcacac	17400
ccaggcaggt	gcggtgacg	gcggtggtgc	ccccaccccc	gcgcgccccg	gtggttccgg	17460
tgccccggcg	cccgcggcgg	ttccggtgcc	tccccagcc	cctccagccc	cgcgcgcgcc	17520
gcgtgcgcct	cgcgccccca	gagcgctcg	gcgtgcgcgc	cgtaccccgg	tgccggtggc	17580
agcgccgccc	gcccgcagcg	gcggtccccc	gccctcggt	gccgaggcgg	cccatcgctc	17640
tgccccgggt	gcgctatcat	cccagtcagg	ccatggctcc	caccgccccaa	cgcgtcatct	17700
ggcggtgatt	tatttttgga	gacctgactg	tggtgtgttc	cttaaatttt	ttatctcct	17760
cctcctctgc	tgaagccaga	cgatgctgac	ctaccggttg	cggctgcccg	tgccgagcg	17820
gagaccgaga	ctccgcggtg	ggttccgcgt	ggcgctccgg	cgcagcgccg	gcaggcgccg	17880
gtaccgccgg	gggcccgatga	ggggtggcat	cctgcggcgg	ctggtgcccc	tcacgcgcgc	17940
atccatctgg	gcccaccccg	gcacgcctc	ggtggcgatg	agtgtagac	aacgcaatta	18000
acggcgctgc	tgtgtatgtg	tgtcttccat	gtgccttcc	tccttcgttc	ccaacggaac	18060
agcagcaccg	tctccatgga	ggacctaaag	ttttccgcgt	tggtccacg	ctttggcacg	18120
cggccggtca	tgggcacttg	gagcgaaatc	ggcacgagtc	agatgaacgg	cggcgcgctc	18180
agctggagca	atatctggag	cgggctgaag	agctttggtg	gttctctggc	ctccacggcc	18240
aacaaggcct	ggaacagcgg	gacggtgacg	agcgtgcgca	acaagttgaa	ggatgccgac	18300
gtgcagggga	agataggtga	ggtcattgcc	tcgggggtcc	acggtgccct	ggacgtggcc	18360
aaccaggccg	tctcccacgc	cgtggaccgc	cgtgcaaca	gcagcagctg	cggcagcagc	18420
agctcctccg	ccagcagcag	caacagatgg	gcctcgtgga	accctcctat	gagatggaga	18480
cagacgagct	gcctcctccc	cccaggacc	tcttgccctc	tcctcctcct	ccgcgcctg	18540
cctcgcccac	tccgcgcgc	caatcccgcg	ggacgtcccg	ccaagcggcc	gccgcgcgcc	18600
aggagatcat	catccgctcc	gacgagcccc	ctccctatga	agagctgtat	cccgaacagg	18660
ccgggacccc	gccaccttg	gagctgcctc	ccgagaccaa	actgcccggc	gtggcccaca	18720
ataagatgcg	ccccccgcgg	ccgctcacca	ccaccacctc	ctccgctgcc	gccgcgcgcc	18780
ccgccccggc	ccccgcggct	cctgtgcgtc	ggcgccggc	cgcggctccg	gccgcggctc	18840
cggcgagttc	caaaggcccc	ccaggtgggg	gtccgcgcgc	gcgggtggca	aaacaaactc	18900
aacaccattg	tgggactggg	tgtccgcaca	tgcaagcgcc	gtcgttggtg	ctgagagaga	18960
cagcatggag	aaacaacaat	gtctggattc	aaataaagac	acgcctatct	ttccacgggtg	19020
ctccgcgctg	tggtattttc	aacgggctgt	ttccttttgc	atctctgtgc	catcgcccca	19080
cggggaattc	cgcaggatgg	cgacgcgctc	gagtgcccg	cagtggtcct	atatgcacat	19140
ctccgggcag	gcgcgctccg	agtacctgtc	tcgggggtcg	gtgcagttct	cccaggcgac	19200
ggagacctac	tttaacctga	acaacaagtt	taggaacccc	accgtcgcgc	ccaccacga	19260
tgtgacgacg	gagcgctcgc	agcggctgca	gctgcgcttc	gtccccgtgg	acaaggagga	19320
cactcagtac	acatacaaga	cccgttcca	gctggcggtg	ggcgacaacc	gcgtgttgga	19380
catggcgagc	accttctttg	acatccgggg	aacgctggac	cggggaccct	ccttcaaacc	19440
gtactcgggc	accgcgtaca	acatcatggc	tcccaagagc	gtcccaaca	actgtcaata	19500
tctagaccct	aaaggtgaaa	ctgaggtggg	caaaagttaat	accattgctc	aagcaagttt	19560
tgtgggtcct	attgatgaaa	ccacgggaga	cattaaaatt	acagaagaag	aagacgaaga	19620
gaccaccatc	gatcctttgt	atgagcccca	accccagctt	ggtccaagct	cgtggtcaga	19680
caatatacct	tctgcgacta	gcggagctgg	aagagttctc	aaacagacca	caccgcgtca	19740
accttggtac	ggttcttatg	cctctccgac	aaatattcac	ggtgggcaaa	cgaaggatga	19800
caaggttaca	ccattgtact	ttacaaacaa	tcccgccacc	gaagccgaag	cactcgaaga	19860
aatggatta	aagccaaatg	tcacctata	ctcagaggat	gttgacctaa	aagcaccaga	19920
tactcatctg	gtctatgctg	tgaatcaaac	ccaggaattc	gtcfaatatg	gacttgga	19980
acaggccgct	ccaacagggg	ccaattacat	cggcttcagg	gacaacttta	tcgggtggtt	20040
gtactacaac	agcaatggca	accagggcac	gctagccggt	caggcctctc	agctcaacgc	20100
ggtggtcgac	ctgcaggaca	ggaatcaccg	aactagctac	cagctcttcc	tcgatagcct	20160
ctatgacagg	tcgaggtact	ttagcctgtg	gaaccaggcc	atcgattctt	atgacaagga	20220
tgtgcgtgtg	ctggaaaaca	atggcggtga	ggacgagatg	cccaactttt	gctttcccat	20280
cggcgccatc	gagaccaaca	tgacatttac	acagctcaaa	aagagtgaga	atggtggctc	20340

aagagccaca	acctggacaa	aggagaatgg	ggatgatggc	ggaaacggag	cggagcacta	20400
cctgggcatc	ggcaacctca	acgccatgga	gatcaatctc	acggccaacc	tctggcgag	20460
cttctctac	agcaacgtgg	cgctgtacct	gcctgacaag	tacaagtttt	ccccgccaa	20520
cgtccccatc	gacccaaca	cgcaactcta	tgactacatc	aacaagcgcc	tgccctcaa	20580
caacctcatt	gatacctttg	tcaacatcgg	ggcgcgctgg	tcccggatg	tcatggacaa	20640
cgtcaacccc	ttcaaccacc	accgcaacta	cggcctgcgc	taccgctccc	agctcctggg	20700
caacggccgc	tactgcaagt	tccacatcca	ggtgccgcaa	aagtcttttg	ccctcaagag	20760
cctgctgctc	ctgccggggg	cgacctacac	ctacgagtg	tccttccgca	aggacgtcaa	20820
catgatcctc	cagtcacgc	tgggcaacga	cctccgcgcg	gacggggcca	aaatcaacat	20880
cgagagcgtc	aacctctacg	ccagcttctt	tcccatggcc	cacaacaccg	cctccaccct	20940
ggaggccatg	ctgcgcaacg	acaccaacaa	ccaaaccttt	attgacttcc	tctctccgc	21000
caacatgctc	taccatcc	cgccaacgt	caccaacctg	cccatctcca	ttcccagccg	21060
caactgggcc	gccttccgcg	gctggagctt	cacgcggtg	aagcacaacg	agacccccgc	21120
cctgggctcg	cccttcgacc	cctactttac	ctactcgggc	tccatcccct	acctggacgg	21180
gaccttctac	ctgggccaca	ccttccgcgc	catcagcatc	cagttcgact	cctccgtggc	21240
ctggccgggc	aatgaccgcc	tgctcactcc	caacgagttc	gaggtcaagc	gcaccgtgga	21300
cggggagggc	tacacggtgg	cccagaccaa	catgacaaa	gactggttcc	tggtgcagat	21360
gctcgccac	tacaacatcg	gctaccaggg	ataccacctg	ccagagggt	accgcgaccg	21420
cactactcc	tctctgcgca	actttgagcc	catgtgcgc	caggtgcccg	actacgtcaa	21480
ccacaaagat	gagtaacctg	aggtgcccac	caccaaccag	ttcaacagca	gcggctttgt	21540
atccgcggcc	ttcacgcgcg	gcatgcgcga	ggggcaccca	taccccgcca	actggcccta	21600
cccgtctatc	ggcgaagacg	ccgtgcagac	cgtgaccag	cgcaagttcc	tctgcgaccg	21660
cacgtcttgg	cgcctcccct	tctcctccaa	cttcatgtcc	atgggcaccc	tcaccgacct	21720
gggccagaac	ctcctctacg	ccaactcggc	ccacgcctc	gacatgacct	tcgaggtcga	21780
cgccatggat	gaacccaccc	tcttgtatgt	tctgttcgag	gtctttgacg	tctgcggcgt	21840
gcaccagccg	caccgaggcg	tcctcgaggc	cgctacactg	cgcacgcct	tctccgcgg	21900
gaacgccacc	acctaaaggc	gagccgcgca	ggcatgggca	gcaccgagga	cgagctccga	21960
gccatggcgc	gcgacctcca	gctgccccgc	ttcttgggca	cctttgacaa	gtccttcccg	22020
ggcttcttgc	aagagtccca	gcgtgctgc	gccatcgta	acacggccgc	ccgccacacc	22080
ggaggccgcc	actggctggc	cgtcgccctg	gagccgcct	cgcgacactt	ctacttcttt	22140
gaccccttcg	gcttctccga	ccgggagctc	gcccagggtc	atgactttga	gtaccagcgc	22200
ctgctgcgca	agagcgccat	ccagagcacc	ccggaccgct	gcctcacgct	cgtcaagagc	22260
acccagagcg	tgcagggacc	gcacagcgcc	gcctgcggac	tcttctgcct	cctcttctc	22320
gcgcctttg	cccgctacct	cgacagcccc	atggcctaca	atcccgctcat	ggacctggtg	22380
gaggcggtgg	acaacgagcg	gctcttcgac	gccgacgtcc	agcccatctt	ccgcgccaac	22440
caggaggcct	gctacgcgtt	cctcgctcgc	cactccgcct	acttccgcgc	ccaccgccac	22500
gccatcatgg	aacagacaca	cctgcacaaa	gcgtcogata	tgcaataaag	gctttttatt	22560
gtaagtcaaa	aaggcctctt	ttatcctccg	tcgcctgggg	gtgtatgtag	atggggggac	22620
taggtgaacc	cggacccgcc	gtcggtccc	ctccatcccc	tcttctctca	aaacaggctc	22680
tcctcgtcgt	cctccgttcc	cacggggaag	atggtgttct	gcacctggaa	ctggggcccc	22740
cacttgaact	cgggcaccgt	cagtggaggc	cgcgtctgca	tcagggcggc	ccacatctgt	22800
ttggtcagct	gcagggccag	catcacatcg	ggggcgctga	tcttgaaatc	acaattcttc	22860
tgggggttgc	cgcgcgaccc	gcggtacacc	gggttgtagc	actggaacac	cagcaccgcg	22920
gggtgggtca	cgttgccag	aatcttgggg	tcttccacca	gctgggggtt	cagcgccgcc	22980
gacccgctca	gcgcgaagg	ggtgatcttg	caggtctgcc	ggcccagcag	gggcacctgg	23040
cggcagcccc	agccgcagtc	gcacaccagc	ggcatcagca	ggtgcgtctc	cgcggtgccc	23100
atccgggggt	agcaggcctt	ctggaaagcc	ttgagctgct	cgaaggcctg	ctgcgccttg	23160
gagccctccg	agtagaagag	gccgcaggac	cgcgcagaga	aggtgttggg	ggccgacccc	23220
acgtcgtggc	tgcaacacat	ggccccgtcg	ttgcgcagct	gcaccacgtt	gcggccccag	23280
cggttggtgg	tgatcttggc	gcgctcgggg	gtctcgcgca	gggcgcgctg	cccgttctcg	23340
ctggtgagat	ccatctccac	cagctgctcc	ttgttgatca	tgggcagccc	gtgcaggcag	23400
tgcagcccct	ccgagccgct	gcggtgctgc	cagatcacgc	acccgcaggg	gttccactcg	23460
ggcgtcttca	gacccgcgcg	cttcaccaca	aagtccagca	ggaagcgggc	catcactgtc	23520
agcaggctct	tttgcggtgct	gaaggtcagc	tggcagctga	tcttgcgctc	gttcagccag	23580
gcttgggccc	cgcgcgggaa	gcactccagg	gtgctgccgt	ccggcagcag	cgtcaggccc	23640
ttgatctcca	ccttcagggg	gaccagcatc	tgacagcca	gatccatggc	ccgctgccac	23700
ttctgctcct	ctgcagccag	ctgcagcagc	ggccgggcca	cgcccggtct	cggggtcacc	23760
gggcgcgggg	ggcgggcccc	ctcctcttcc	tcccatctt	cgcccttctc	cctcgcgggc	23820
cgcgcgctcg	ccgctgcgct	ctcttcagcc	tcttctcct	cctcctcgct	gaccaggggc	23880
ttggcacgcg	cgcgcttccg	ccgctcctgc	acgggcggag	aggccgcgcg	cttgcgccct	23940
ccccgcgcgc	ggctgggggt	cgcgacagga	gcgtcgcca	caatcagcac	ccctcttcc	24000



ccgctgtcat	agtccagacac	gtccgaatag	cggcgactca	ttttgcttcc	cctagatgga	24060
agaccagcac	agcgcagcca	gtgagctggg	gtcctccgcg	gccccgaccc	ttccgcgcgc	24120
accaccgccg	ccacctccgc	ccacgtcacc	gccacettca	ctgcagcagc	ggcagcagga	24180
gcccaccgaa	accgatgacg	cggaggacac	ctgctcctcg	tcctcctcgt	cctccgcctc	24240
cagcgagtgc	ttcgtctcgc	cgttggaaga	cacgagctcc	gaggactcgg	cggacacggg	24300
gtccccctcc	gagccccgcc	gggacgagga	ggagcaggag	gaggactcgc	ccgaccgcta	24360
catggacgcg	gacgtgctgc	agcgccacct	gctgcgccag	agtaccatcc	tgcgccaggt	24420
cctgcaggag	gccgcccccg	gcgcagccgc	ggaggccgcc	gaggcgccct	cggggcgga	24480
gctcagccgc	cgcttggaa	cggccctctt	ctcccccgcc	acgccgcgcg	ggcgccagga	24540
gaacggaacc	tgcgccccgg	acccccgcct	caacttctac	ccggtcttca	tgctgcccga	24600
ggccctggcc	acctacctcc	tcttcttcca	caaccaaag	atccccgtca	gctgcgcgcg	24660
caaccgcccc	cgagccgacg	gcactggcg	gctgccag	gggacccct	tacctgacta	24720
tccaaccacc	cagcaggttt	acaagatctt	tgaggccctg	ggggacgagg	agccggcctg	24780
cgccaaccag	gacctgaaag	agcgcgacag	cgtgttagtc	gagctcaagc	tggacaaccc	24840
ccgcctggcg	gtggtcaagc	agtgcacgc	cgtcaccac	ttcgccctacc	cggccctggc	24900
gctgccaccc	aaggtcatga	gcacgctcat	gcagaccctg	ctggtgcgcc	gcgcgagccc	24960
actccccgac	gagggcgaga	cgcctctcga	ggacctcctg	gtggtcagcg	acgagcagct	25020
ggcccgcctg	atgcacacct	cggaccccaa	ggtcctggag	gagcggcgca	agaccgtcac	25080
cgccgcctgc	atggtcacgg	tgcagctcca	ctgcactgac	accttctcca	cctccgcgga	25140
gatggtgcgc	cgctcggag	agtgcctcca	ctacatgttc	cgccagggct	acgtcaagct	25200
agctagcaag	atcgccaata	tggaaactctc	taacctggtc	tcctacttgg	gcatgctgca	25260
cgaaaacagg	ctcggtcagc	acgtgctcca	ccacaccctc	aagcatgagg	cgagacgcga	25320
ctacgtccgg	gacaccattt	acctatacct	ggtctatacc	tggcagaccg	ccatgggggt	25380
ctggcagcag	tgcctcgagg	accgaaacct	gcgcgcctcg	gaaacgtctc	tggtcgcgcg	25440
tcgccagagc	ctgtggacgg	gctttgatga	gcgcactatc	gcgcaggacc	tcgccgcgtt	25500
ccttttcccc	accaagctcg	tagagaccct	gcagcgctcg	ctccccgact	ttgccagcca	25560
gagcatgatg	catgcttcc	gctccttctg	cctcgagcgc	tcgggcctcc	tgcccgcctg	25620
ctgcaacgcg	ctccccctctg	actttgtgcc	caccgtctac	cgcgagtgcg	cgccgcccct	25680
ctgggctcac	tgctacctcc	tgcgcctcgc	caacttcttc	atgtaccact	gcgacctcgc	25740
cgaggacacc	tccggcgagg	gcctctttga	gtgctactgc	cgctgcaacc	tctgcgcacc	25800
gcaccgcgtg	ctcgccacca	acaccgccct	cctcaacgag	gtgcaagcca	tcaacacctt	25860
tgagctccag	cggcccccca	agccccgacg	caccctgcca	ccgcccttca	agctgacccc	25920
cggctctctg	acctccgcct	tcctccgcca	ctttgtctcc	gaggactacc	actcggaccg	25980
catcctcttc	taccaggacg	tgtcccgccc	ccccagggtg	gagccctccg	cctgcgtcat	26040
cacgcactcg	gcattctcgc	cgcaattgca	tgacatcaaa	aaggccaggg	aagagttttt	26100
gctgacaaa	ggccacggcg	tctacctaga	ccccacacc	ggagaggagc	tcaacaccgc	26160
cgccccgtcc	accgcccacc	atgccgcccc	tccggaggaa	gccccatccg	agcagcacca	26220
gcaccagcag	cagccgagcc	accgcccgcg	ccaccaccgc	tccagctacg	cagaccgtgt	26280
ccgaagcgag	ctccacgcct	acggcggtgc	gaccgggttc	tcccgcgacc	ctgtctctgg	26340
cggatgctct	gccagaggaa	cccactcccg	cgatgctgct	cgaagaagag	gctctcagca	26400
cgagagcagc	cggcagctcc	gaaggcagtt	tgtcagtagc	cctcgaggaa	ctggaggagg	26460
aggaggaacc	ggtcacaccg	acgaggccat	ccaagccctc	ctacaccaac	agcagcagca	26520
gcaagagcat	cagccagcgc	aggaactccg	tcgtccccag	cgaggctcgt	agatggaatc	26580
agacatccat	ccaccggagt	agccagccag	gtaggacacc	tccgcccctg	gcccgcgcac	26640
gctcctggcg	ccgctaccgc	cacgacatcc	tctcgcccct	ggagtactgc	gccggagacg	26700
gagcctgcgt	gcgcgcgtac	ctactctacc	accacaacat	caacatccct	tccaagatca	26760
tccgttacta	caaatcctct	tcccgttcca	gcgatctcca	ggaaggccgc	agcagcggcg	26820
gcagcagaac	cagcccacgt	cagccagctg	agagctaaga	tcttccccac	gctgtacgcc	26880
atcttccagc	agagccgcg	cggccaggac	gccctcaaaa	tcaggaaaccg	caccctgcgc	26940
tcctcacca	agagctgtct	gtatcacccg	gaggaggcca	agctggaacg	cacgctctcg	27000
gacgcagaag	ctctcttcga	gaagtactgc	gctcggcagc	ggcagaccgc	ccggtattta	27060
aggagcggac	cctgcgtgcg	gacacaccat	gagcaaacaa	atccccaccc	cgtacatgtg	27120
gtcttatcag	ccacaatctg	ggcgtgccgc	cgggtgcctcc	gtcgattact	ccaccgcgat	27180
gaattggctc	agtgcggggc	cttccatgat	tggccaggtc	aatgacatcc	gacacaccag	27240
gaaccagatt	ctcattcgcc	aggcccttat	caccgagacg	ccacgccccg	tccaaaatcc	27300
cccgtcctgg	cccgcagacc	tggtgcctca	gatgacgcga	ccgcccaccc	acctgcacct	27360
gccgcgtaac	gaaattttgg	aaggcagact	gactgacgcc	ggcatgcaat	tagccggggg	27420
cggagccctc	gcacccagag	acttatatgc	cctgaccctc	cgcggcagag	gcatccagct	27480
caacgaggac	ctacccctct	cggcgagcac	tctccggccg	gacggcatct	tccagctcgg	27540
aggcggaggc	cgctcctcct	tcaaccccac	cgacgcctac	ctgacgctgc	agaactccag	27600
ctcccttccc	cgcagcggcg	gcatcggcag	cgagcaattt	gtccgcgagt	tcgtgcccac	27660



ggtctacatc	aacccttct	cgggaccgcc	cgggacctac	cccgaccagt	tcatcgccaa	27720
ctacaacatc	ctaacggact	ctgtagcagg	ctatgactga	cgggtccccag	ggtcagcagc	27780
ggctgcggga	gctcctcgac	cagcaccgcc	gccagtggcc	taaccgctgc	tgcttcgcca	27840
gggaaggga	tcaccggag	tacttttgca	tcacccgcga	gcactttgag	gccgagtga	27900
tccccgactc	tctgcaagaa	ggccacggtc	tgcgtttcag	cctccccacg	cgctacagcg	27960
accgcgcca	ccgcatgga	gaccgcacca	tcctcacttc	gtactactgc	ggcctgctt	28020
ctttcaaagt	tcgctgtctc	tgcggccatc	ctgctcctca	ccctcttctt	ctcgaccttc	28080
tgtgtgagct	gtacaaccgc	tcgtagcgtc	agccctaca	cctccctcgc	cgccaattt	28140
ctgtccgaca	tagaaccaga	ctctgactct	tactcgggct	ctggctctgg	ggacgatgaa	28200
gattatgaat	atgagctggc	taccaacaca	ccgaacgaag	acattctagg	cagcatagtc	28260
atcaacaacc	agatcggggc	caagaccctg	gccctgggat	acttttatgc	cgccatgcag	28320
tttgtcttct	ttgccatcat	catcatcgtc	ctcatcctct	actaccgccc	ctacgtgctg	28380
gccaccggcc	tcctcgtgca	gcgcagatg	tggctctccg	aggccgtcct	gcggaacc	28440
ttctcgcca	ccgttggtgt	tactccccca	aaacaagtca	ccccctgcaa	ctgctcctgc	28500
cgcttcgagg	agatggtgtt	ctactacacc	acctcctct	tcattgccctg	gtgggcctca	28560
tcctcctgct	caccgccatg	gtccgcctgg	ccaactggat	agtggatcag	atgccagca	28620
ggaaccggcg	cccgcgcgtg	ccaccgcccc	tcacctatgt	gggacctgc	gccgaggacc	28680
acatctacga	tgagccaacc	gtagggcaat	acgtacagat	gaagtagctc	cccccttctt	28740
ccattccccc	atttttctct	attcaataaa	gttgcttacc	tgagttcatc	cacactcggg	28800
ctgcagtg	agtcctcca	tgcgcgcttt	tcctactca	catagcgag	ccgcgacgc	28860
ctcgccaggt	gcgaaactg	tcgaaatgta	acatttcg	cttctgtcag	cagcaccgcc	28920
ttatagacca	gttcaccat	gggaccgaag	aagcagaagc	gcgagctacc	cgaggacttc	28980
gatccagtct	acccctatga	cgtcccgag	ctgcagatca	atccacctt	cgtagcggg	29040
gacggattca	accaatccgt	ggacggggtg	ctgtccctgc	acatcgacc	gcccctcggt	29100
tttgacaaca	ccagggccct	caccctggcc	ttcgggggag	gtctacagct	ctcgggcaag	29160
cagctcgctg	ttgccaccga	gggctcgggg	ctaaccacca	acccggatgg	caagctggtt	29220
ctcaagtca	agtcccccat	caccctgacc	gcccgaaggc	tctccctgtc	cctgggtccc	29280
ggtctttcta	atcagagac	cggcctcagt	ctgcaagtca	cagctccct	gcagtccag	29340
ggcaacggcc	tcactcttcc	cctcgccgcc	ggtctccaaa	acaccgatgg	tggaatgggt	29400
gtcaaaactg	ggagcggctt	caccacggac	aacagtcagg	cggtagccgt	tcaggtggga	29460
aatggacttc	agctgaacgg	cgaaggacaa	ctcacgctcc	ccgccacggc	cccttagtc	29520
tcaggagcg	caggcatctc	tttcaactac	tccagcaatg	acttcgtctt	agacaatgac	29580
agtctcagtt	tgaggccaaa	ggccatctct	gtcacccctc	cgctgcagtc	cacagaggac	29640
acaactctcc	tgaattatc	taacgacttt	tctgtggaca	atggcgccct	caccttggt	29700
ccaactttca	aaccctacac	gctgtggact	ggcgccctac	ccacagcaaa	tgtcttcta	29760
acaaacacca	ccactcccaa	cggcaccttt	ttcctatgcc	tgacacgtgt	gggtgggtta	29820
gttttggtt	cctttgccct	gaaatcatcc	atcgacctta	ctagtatgac	caaaaagggtc	29880
aattttat	ttgatggggc	aggctcggtt	cagtcagact	ccacttataa	aggagattt	29940
ggatttagat	ccaacgacag	cgtaattgaa	cccacagccg	caggactcag	tccagcctgg	30000
ttaatgccaa	gcacctttat	ttatccacgc	aacacctccg	gttcttccct	aacatcattt	30060
gtatacata	atcacagata	tgtgcattgt	gacatcaagg	taaacacact	ctctacaaac	30120
ggatatagcc	tagaatttaa	ctttcaaaac	atgagcttct	ccgccccctt	ctccacctcc	30180
tacgggacct	tctgtacgt	gccccgaagg	acaactcacc	gtccccgcca	cggccccctt	30240
agtctcagg	agcgcaggca	tctctttcaa	ctactccagc	aatgacttcg	tcttagacaa	30300
tgacagtctc	agtttgaggc	caaaggccat	ctctgtcacc	cctccgctgc	agtcacaga	30360
ggacacaatc	tccctgaatt	attctaacga	cttttctgtg	gacaatggcg	ccctcacctt	30420
ggctccaact	ttcaaaccct	acacgctgtg	gactggcgcc	tcaccacacag	caaatgtcat	30480
tctaacaac	accaccactc	ccaacggcac	ctttttccta	tgctgacac	gtgtgggtgg	30540
gttagttttg	ggttcctttg	ccctgaaatc	atccatcgac	cttactagta	tgacaaaaaa	30600
ggtcaatttt	atttttgatg	gggcaggctg	gcttcagtc	gactccactt	ataaaggagg	30660
atgttgattt	agatccaacg	acagcgtaat	tgaaccaca	gccgcaggac	tcagtccagc	30720
ctggttaatg	ccaagcacct	ttattttatc	acgcaacacc	tccggttctt	ccctaacatc	30780
atgtgtatc	attaatcaga	catatgtgca	tgtggacatc	aaggtaaaca	cactctctac	30840
aaacggatat	agcctagaat	ttaactttca	aaacatgagc	ttctccgccc	ccttctccac	30900
ctcctacggg	accttctgct	acgtgcccc	gagtgcctag	agaaccctgg	ccgtcagccg	30960
gcctccccct	tcccaggcca	cccggtagac	cacccgctcc	atgtttctgt	atgtgtctc	31020
ctcccgccg	ttgtgcagca	ccacctcccg	ctgctcgagc	tgaggatccg	tgatggcac	31080
aaagccagg	agacacatcc	tcagctccgt	gggggcgtcc	aacaactgtt	tatgtaaagg	31140
aaaataaaga	ctcagagaaa	atccaagttc	atatgatttt	tcttttattg	attgggggaa	31200
ttgattcagg	tggggtgtgc	ataatcacaa	aatcacatc	agcaggtaca	cacctgagac	31260
atcagacagg	ggtaaggaca	gcgcctcagc	ttctggaaca	gacatcagaa	atatttaatc	31320

tgctggtagc	taacactcct	tcccaacacc	atacactcct	ggagggccct	ctgcctctcc	31380
tcctcccgtc	ccgcgtccct	ctgccgggac	caccactccc	cctccgtgaa	ctgctgcttc	31440
ctcccccgcc	gctgcgcccc	gatggcctcc	gccgccagct	tcagccagtg	ccgcaagcgc	31500
tgggcgcgagc	gccgaagccac	cggctcgcctc	agctcgtggc	agcgccggca	caccagcact	31560
atgtaattgg	catagtcccc	gtcacagtag	atgacctccc	cccagtgga	catgcgcaac	31620
agcttcagat	cacagtcata	catgatcttt	atgtacatca	ggtgggcgcc	tcgaaacatc	31680
acactgcccc	cgtacatcac	gcgactcacg	ctgggcaggt	tcaccgcctc	cctgaaccac	31740
cagaagatgc	gattgtactc	gcagccccgg	atgatctcgc	gcatcaggga	gcgcatcacc	31800
acctgccccg	cgcggcactc	cagactggac	cttttcagac	agtggcaatg	aaagtccac	31860
agcgtcgcg	ccgcacagcg	tctccgggct	gaaacatatc	tgctccagct	ccaaccccc	31920
acacaggctg	tactgcagga	aaatccattc	ttgatgggaa	aggatgtagc	gccaggggac	31980
cacaatctcc	aaacagggaa	caaaacatac	cgcgccccgg	ctggtgcgca	cgccccccac	32040
cggatgcaac	gtgctcacgg	agcagatacg	ggtgggacag	cgccccacgt	ctcatagcaa	32100
gtcaagtccg	gaagtggcac	ggggttcgcc	accactgcta	ctgctgccgc	tgcgccacca	32160
gtcccatcgg	ctcctccatc	ctcctcctgt	tcgatcggct	gaggtgctgc	ctcctcctcc	32220
tcctgcgct	gctccatcat	gctcgtctgc	ggtcatcagg	agtcaaaaaa	ttcattggcc	32280
accgcacgca	gagagaacat	ggagcgcagg	ggcccagggtg	cccggcccgt	gcgctcgctc	32340
aactccccca	gcaggtactc	atagagatgc	tcctccaaat	ccaccgcaaa	ccaggcatgc	32400
agaaactctt	ccgttcgagg	accgcccacg	gtaaagacat	agccctcccc	caccttcacc	32460
gctgccagct	gcacgcgctc	atgtcgtctg	gagtacaccc	ggaccggggc	ctggatgtac	32520
tccagcacct	gatcgctcag	acacctcaca	gagatgccag	cctgagccag	cttctcatag	32580
agaggtggct	gaatcttgag	cttgaagcag	cgagcggcta	ggcactcccc	gcccccttgg	32640
aacaggggcg	cgggttcagc	catggacttc	ctctacatcc	ggggtcctgg	ccacctcaca	32700
aactatctgg	ccaatcgctc	gaccacgggt	caccaggtaa	ggatgatgtc	cgttgttgcg	32760
aatgagaatg	ctcagagggtg	actcggtagc	gttatcaatc	acgtcccaaa	aggtccaaag	32820
gtcccagtta	gaagttaggt	gcttcagacc	gcagacacgc	ccatagcaac	cagtgggaaa	32880
agccagcaag	agatccgtgg	gcacatgcac	cgaagctccc	gcaggaatct	ccaccactc	32940
cgaggcgtag	accgtgtaag	ctacacaccc	cgccctccga	gtgggagcag	aagcattctc	33000
gctcagccga	aagaacttca	gggtggcctg	catatcctct	tttactcact	tgtagcagc	33060
tcacacagca	ccagggttgt	gttggcggga	ataggcagca	ggggtacgtc	cccagtgagg	33120
gacacctgga	tggggggcag	aggattgatg	ccaggaagca	gcaggtagctg	ggaaacagag	33180
accagatccc	tcctctgaaa	aatctcgctc	agtcggacaa	acacagcaaa	cccagtgggc	33240
acgtagacta	gcacattaaa	aaggatcacg	ctgggctgtt	ctgacgtcag	caccagatgt	33300
cgggacgtgc	gcagatgaat	gcggttctga	tgaattaccg	gaggcctctc	acccgcagcc	33360
aacagcagac	cgggtgctgt	atgcggtccc	gcagacatat	atgagttcaa	tgtgtgtctt	33420
ttttctaacc	gtctagttag	tgtgctcgct	ctgctcctgc	caatcaaaat	ccgggcacca	33480
gggctggtgg	ttggaccgga	tgaagaagcg	aggagaggcg	gcctcctgag	tgtgaagagt	33540
gtcccgatcc	tgccacgcga	ggtaggcgaa	gtacagatag	agcacggcga	gaacagtcag	33600
caccgcggcc	agcagcagtc	ggctcgtggc	catgagaggg	ggctgatggg	aagatggccg	33660
gtgactcctc	tcgccccgct	ttcggtttct	cctcgtctcg	ctctcagtgt	ctctctctgt	33720
gtcagcgccg	agacgagtgt	gagcgaacac	cgcgagcggg	ccggtgatat	acccacagcg	33780
gatgtggcca	cgccctgcgt	cggttaatca	gtacccatc	gtccgatcgg	aattcccccg	33840
cctccgcgtt	aacgattaac	ccgccagaa	gtcccgggaa	ttcccgcag	ccggtccgc	33900
cgcgacctgc	gactttgacc	ccgccctcg	gactttgacc	gttcccacgc	cacgtcattt	33960
tcccacgcga	cgtcacgttc	ccacgctacg	tcacacccct	ctccaccaat	caccgcccgc	34020
cgcccccaac	cctctccgcc	aatcaccacg	ccacaaaagg	ggcaataaaa	gtgtgcggta	34080
tattattgat	gatg					34094

&lt;210&gt; 2

&lt;211&gt; 44

&lt;212&gt; DNA

&lt;213&gt; Porcine Adenovirus Type 3

&lt;400&gt; 2

gcggatcctt aattaacatc atcaataata taccgcacac tttt

44

&lt;210&gt; 3

&lt;211&gt; 32

&lt;212&gt; DNA

<213> Porcine Adenovirus Type 3

<400> 3  
cacctgcaga tacacccaca cacgtcatct cg 32

<210> 4  
<211> 32  
<212> DNA  
<213> Porcine Adenovirus Type 3

<400> 4  
cacctgcagc ctcctgagtg tgaagagtgt cc 32

<210> 5  
<211> 20  
<212> DNA  
<213> Porcine Adenovirus Type 3

<400> 5  
gactgacgcc ggcatgcaat 20

<210> 6  
<211> 27  
<212> DNA  
<213> Porcine Adenovirus Type 3

<400> 6  
cggatcctga cgctacgagc ggttgta 27

<210> 7  
<211> 27  
<212> DNA  
<213> Porcine Adenovirus Type 3

<400> 7  
cggatccata cgtagagatg aagtagc 27

<210> 8  
<211> 20  
<212> DNA  
<213> Porcine Adenovirus Type 3

<400> 8  
tctgactgaa gccgacctgc 20